0001425450-18-000115.txt : 20181031 0001425450-18-000115.hdr.sgml : 20181031 20181031165320 ACCESSION NUMBER: 0001425450-18-000115 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181031 DATE AS OF CHANGE: 20181031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORTHOPEDIATRICS CORP CENTRAL INDEX KEY: 0001425450 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261761833 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38242 FILM NUMBER: 181150973 BUSINESS ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 BUSINESS PHONE: 574-268-6379 MAIL ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 10-Q 1 kids-20180930.htm 10-Q Document
ORTHOPEDIATRICS CORPNon-accelerated Filer10-Q2018Q3FALSE128114500001425450--12-312018-09-301311430.000250.0002550,000,00050,000,00012,807,52012,621,78112,807,52012,621,781P6M2530573535752—————————P6Mthree yearsP3YP10YP10YP10YP10Y———P10Y——————101,8651,5379,5574,087—1,484—4,3641,8653,0219,5578,451—100014254502018-01-012018-09-30xbrli:shares00014254502018-10-29iso4217:USD00014254502018-09-3000014254502017-12-310001425450country:US2018-09-300001425450country:US2017-12-310001425450us-gaap:NonUsMember2018-09-300001425450us-gaap:NonUsMember2017-12-31iso4217:USDxbrli:shares00014254502018-07-012018-09-3000014254502017-07-012017-09-3000014254502017-01-012017-09-300001425450us-gaap:CommonStockMember2017-12-310001425450us-gaap:AdditionalPaidInCapitalMember2017-12-310001425450us-gaap:RetainedEarningsMember2017-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001425450us-gaap:RetainedEarningsMember2018-01-012018-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-09-300001425450us-gaap:CommonStockMember2018-01-012018-09-300001425450us-gaap:AdditionalPaidInCapitalMember2018-01-012018-09-300001425450us-gaap:CommonStockMember2018-09-300001425450us-gaap:AdditionalPaidInCapitalMember2018-09-300001425450us-gaap:RetainedEarningsMember2018-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-09-300001425450country:US2018-01-012018-09-300001425450country:US2017-01-012017-09-300001425450us-gaap:NonUsMember2018-01-012018-09-300001425450us-gaap:NonUsMember2017-01-012017-09-3000014254502016-12-3100014254502017-09-300001425450us-gaap:IPOMemberus-gaap:CommonStockMember2017-10-122017-10-120001425450us-gaap:IPOMemberus-gaap:CommonStockMember2017-10-120001425450us-gaap:IPOMemberus-gaap:SeriesBPreferredStockMember2017-10-122017-10-120001425450us-gaap:NotesPayableOtherPayablesMember2017-12-310001425450us-gaap:RevolvingCreditFacilityMember2017-12-310001425450us-gaap:MinimumMember2018-01-012018-09-300001425450us-gaap:MaximumMember2018-01-012018-09-300001425450kids:A2007EquityIncentivePlanMember2018-09-300001425450kids:New2017EquityIncentivePlanMember2018-09-300001425450us-gaap:EmployeeStockOptionMember2018-01-012018-09-300001425450us-gaap:RestrictedStockMember2018-01-012018-09-300001425450kids:A2007EquityIncentivePlanMember2018-01-012018-09-300001425450us-gaap:BuildingAndBuildingImprovementsMemberus-gaap:MinimumMember2018-01-012018-06-300001425450us-gaap:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2018-01-012018-06-300001425450us-gaap:FurnitureAndFixturesMemberus-gaap:MinimumMember2018-01-012018-06-300001425450us-gaap:FurnitureAndFixturesMemberus-gaap:MaximumMember2018-01-012018-06-300001425450us-gaap:MinimumMemberus-gaap:ComputerEquipmentMember2018-01-012018-06-300001425450us-gaap:MaximumMemberus-gaap:ComputerEquipmentMember2018-01-012018-06-300001425450us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2018-01-012018-06-300001425450us-gaap:MinimumMemberus-gaap:OfficeEquipmentMember2018-01-012018-06-300001425450us-gaap:MaximumMemberus-gaap:OfficeEquipmentMember2018-01-012018-06-300001425450us-gaap:TechnologyEquipmentMember2018-01-012018-06-300001425450kids:SampleInventoryMember2018-01-012018-06-3000014254502018-04-012018-06-3000014254502017-04-012017-06-3000014254502017-01-012017-06-300001425450us-gaap:NotesPayableOtherPayablesMember2018-09-300001425450us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2018-09-300001425450us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2017-12-310001425450us-gaap:MortgagesMember2018-09-300001425450us-gaap:MortgagesMember2017-12-31xbrli:pure0001425450us-gaap:NotesPayableOtherPayablesMember2014-05-310001425450us-gaap:NotesPayableOtherPayablesMember2015-11-300001425450us-gaap:NotesPayableOtherPayablesMember2017-04-300001425450us-gaap:NotesPayableOtherPayablesMember2017-10-012017-10-310001425450us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2017-12-312017-12-310001425450us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2017-12-310001425450us-gaap:MortgagesMember2013-08-012013-08-310001425450us-gaap:MortgagesMember2013-08-310001425450us-gaap:NotesPayableOtherPayablesMember2018-07-012018-09-300001425450us-gaap:NotesPayableOtherPayablesMember2017-07-012017-09-300001425450us-gaap:NotesPayableOtherPayablesMember2018-01-012018-09-300001425450us-gaap:NotesPayableOtherPayablesMember2017-01-012017-09-300001425450us-gaap:NotesPayableOtherPayablesMember2017-04-302017-04-300001425450us-gaap:RoyaltyAgreementTermsMemberkids:CaseWesternReserveUniversityMember2007-12-012007-12-010001425450us-gaap:RoyaltyAgreementTermsMemberkids:CaseWesternReserveUniversityMember2017-08-022017-08-020001425450kids:CaseWesternReserveUniversityMember2018-07-012018-09-300001425450kids:CaseWesternReserveUniversityMember2017-07-012017-09-300001425450kids:CaseWesternReserveUniversityMember2018-09-300001425450kids:CaseWesternReserveUniversityMember2017-12-3100014254502017-01-012017-12-310001425450us-gaap:RestrictedStockMember2017-12-310001425450us-gaap:RestrictedStockMember2017-01-012017-12-310001425450us-gaap:RestrictedStockMember2018-09-300001425450us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember2018-07-012018-09-300001425450us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember2017-07-012017-09-300001425450us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember2018-01-012018-09-300001425450us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember2017-01-012017-09-300001425450us-gaap:MinimumMember2018-09-300001425450us-gaap:MaximumMember2018-09-3000014254502018-01-012018-06-300001425450us-gaap:EmployeeStockOptionMember2018-01-012018-06-300001425450us-gaap:EmployeeStockOptionMember2017-04-012017-06-300001425450us-gaap:EmployeeStockOptionMember2017-01-012017-06-300001425450us-gaap:RedeemableConvertiblePreferredStockMember2017-10-120001425450us-gaap:RedeemableConvertiblePreferredStockMember2017-09-300001425450us-gaap:RedeemableConvertiblePreferredStockMember2018-09-3000014254502018-06-300001425450us-gaap:SeriesAPreferredStockMemberus-gaap:RedeemableConvertiblePreferredStockMember2018-01-012018-06-300001425450us-gaap:SeriesAPreferredStockMemberus-gaap:RedeemableConvertiblePreferredStockMember2017-01-012017-06-300001425450us-gaap:RedeemableConvertiblePreferredStockMemberus-gaap:SeriesBPreferredStockMember2018-01-012018-06-300001425450us-gaap:RedeemableConvertiblePreferredStockMemberus-gaap:SeriesBPreferredStockMember2017-01-012017-06-300001425450us-gaap:RestrictedStockMember2018-01-012018-06-300001425450us-gaap:RestrictedStockMember2017-01-012017-06-300001425450us-gaap:EmployeeStockOptionMember2018-01-012018-06-300001425450us-gaap:EmployeeStockOptionMember2017-01-012017-06-300001425450us-gaap:WarrantMember2018-01-012018-06-300001425450us-gaap:WarrantMember2017-01-012017-06-30kids:segment0001425450country:US2018-07-012018-09-300001425450country:US2017-07-012017-09-300001425450us-gaap:NonUsMember2018-07-012018-09-300001425450us-gaap:NonUsMember2017-07-012017-09-300001425450kids:TraumaandDeformityMember2018-07-012018-09-300001425450kids:TraumaandDeformityMember2017-07-012017-09-300001425450kids:TraumaandDeformityMember2018-01-012018-09-300001425450kids:TraumaandDeformityMember2017-01-012017-09-300001425450kids:SpineMember2018-07-012018-09-300001425450kids:SpineMember2017-07-012017-09-300001425450kids:SpineMember2018-01-012018-09-300001425450kids:SpineMember2017-01-012017-09-300001425450kids:SportsMedicineandOtherMember2018-07-012018-09-300001425450kids:SportsMedicineandOtherMember2017-07-012017-09-300001425450kids:SportsMedicineandOtherMember2018-01-012018-09-300001425450kids:SportsMedicineandOtherMember2017-01-012017-09-30kids:supplier0001425450us-gaap:AffiliatedEntityMember2018-01-012018-09-300001425450kids:FMIHansaMedicalProductsMemberus-gaap:AffiliatedEntityMember2018-07-012018-09-300001425450kids:FMIHansaMedicalProductsMemberus-gaap:AffiliatedEntityMember2017-07-012017-09-300001425450kids:FMIHansaMedicalProductsMemberus-gaap:AffiliatedEntityMember2018-01-012018-09-300001425450kids:FMIHansaMedicalProductsMemberus-gaap:AffiliatedEntityMember2017-01-012017-09-3000014254502018-01-012018-01-010001425450us-gaap:MaximumMember2018-01-012018-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018 

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-38242
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
26-1761833
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)

2850 Frontier Drive
Warsaw, IN 46582
(Address of principal executive offices, including zip code)
(574) 268-6379
(Registrant’s telephone number, including area code)
________________________________________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
x
Smaller reporting company
x
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨    No x
As of October 29, 2018, there were 12,811,450 outstanding shares of common stock, $0.00025 par value per share, of OrthoPediatrics Corp.


OrthoPediatrics Corp.
Form 10-Q
For the Quarterly Period Ended September 30, 2018 

TABLE OF CONTENTS
Page No. 
PART I. FINANCIAL INFORMATION 
Item 1
Item 2
Item 3
Item 4
PART II. OTHER INFORMATION 
Item 1 
Item 1A 
Item 6 






NOTE REGARDING FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to:

• our ability to achieve or sustain profitability in the future;

• our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

• our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

• our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability.

• our ability to comply with extensive government regulation and oversight both in the United States and abroad;

• our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and

• our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others;

We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 15, 2018 and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.
3

PART I. FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
September 30, December 31,  
20182017
(Unaudited) 
ASSETS 
Current assets: 
Cash $24,463 $42,582 
Accounts receivable - trade, less allowance for doubtful accounts of $131 and $143, respectively 9,456 5,603 
Inventories, net 26,646 19,498 
Inventories held by international distributors, net 234 1,047 
Prepaid expenses and other current assets 1,045 831 
Total current assets 61,844 69,561 
Property and equipment, net 12,774 10,391 
Other assets: 
Amortizable intangible assets, net 2,000 2,089 
Other intangible assets 260 260 
Total other assets 2,260 2,349 
Total assets $76,878 $82,301 
LIABILITIES AND STOCKHOLDERS' EQUITY 
Current liabilities: 
Accounts payable - trade $5,903 $5,495 
Accrued compensation and benefits 3,302 2,905 
Current portion of long-term debt with affiliate 117 113 
Other current liabilities 1,594 954 
Total current liabilities 10,916 9,467 
Long-term liabilities: 
Long-term debt with affiliate, net of current portion 21,330 21,418 
Revolving credit facility with affiliate 3,947 3,921 
Total long-term liabilities 25,277 25,339 
Total liabilities 36,193 34,806 
Commitments and contingencies (Note 11) 
Stockholders' equity: 
Common stock, $0.00025 par value; 50,000,000 shares authorized; 12,807,520 shares and 12,621,781 shares issued and outstanding as of September 30, 2018 and December 31, 2017 2 2 
Additional paid-in capital 153,649 150,424 
Accumulated deficit (112,623)(103,066)
Accumulated other comprehensive (loss) income (343)135 
Total stockholders' equity 40,685 47,495 
Total liabilities and stockholders' equity $76,878 $82,301 
See notes to condensed consolidated financial statements.
4

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Net revenue $15,820 $12,375 $42,991 $33,939 
Cost of revenue 3,843 2,884 10,825 8,321 
Gross profit 11,977 9,491 32,166 25,618 
Operating expenses: 
Sales and marketing 7,150 5,633 20,005 15,122 
General and administrative 4,877 3,487 16,393 10,282 
Research and development 1,122 1,127 3,455 2,482 
Total operating expenses 13,149 10,247 39,853 27,886 
Operating loss (1,172)(756)(7,687)(2,268)
Other expenses: 
Interest expense, net 608 761 1,722 1,857 
Other expense (income) 85 20 148 (38)
Total other expenses 693 781 1,870 1,819 
Net loss $(1,865)$(1,537)$(9,557)$(4,087)
Net loss attributable to common stockholders $(1,865)$(3,021)$(9,557)$(8,451)
Weighted average common stock - basic and diluted 12,624,858 1,773,385 12,417,972 1,754,576 
Net loss per share attributable to common stockholders - basic and diluted $(0.15)$(1.70)$(0.77)$(4.82)
See notes to condensed consolidated financial statements.
5

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In Thousands)
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Net loss $(1,865)$(1,537)$(9,557)$(4,087)
Other comprehensive (loss) income: 
Foreign currency translation adjustment (100)121 (478)193 
Other comprehensive (loss) income (100)121 (478)193 
Comprehensive loss $(1,965)$(1,416)$(10,035)$(3,894)
See notes to condensed consolidated financial statements.
6

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Accumulated 
Additional Other Total 
Common Stock Paid-in Accumulated Comprehensive Stockholders' 
Shares Value Capital Deficit Income (loss) Equity 
Balance at January 1, 201812,621,781 $2 $150,424 $(103,066)$135 $47,495 
Net loss — — — (9,557)— (9,557)
Other comprehensive loss — — — — (478)(478)
Stock option exercise 11,533 — 326 — — 326 
Restricted stock 174,206 — 2,899 — — 2,899 
Balance at September 30, 201812,807,520 $2 $153,649 $(112,623)$(343)$40,685 
See notes to condensed consolidated financial statements.
7

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)

Nine Months Ended
September 30, 
20182017
OPERATING ACTIVITIES 
Net loss $(9,557)$(4,087)
Adjustments to reconcile net loss to net cash used in operating activities: 
Depreciation and amortization 2,177 1,748 
Stock-based compensation 2,899 1,081 
Changes in certain current assets and liabilities: 
Accounts receivable - trade (4,077)(1,588)
Inventories (6,087)(3,276)
Inventories held by international distributors 813 345 
Prepaid expenses and other current assets (214)(382)
Accounts payable - trade 408 1,559 
Accrued expenses and other liabilities 798 513 
Other (15)193 
Net cash used in operating activities (12,855)(3,894)
INVESTING ACTIVITIES 
Purchases of licenses (195)(1,337)
Purchases of property and equipment (5,311)(3,949)
Net cash used in investing activities (5,506)(5,286)
FINANCING ACTIVITIES 
Proceeds from issuance of debt with affiliate — 10,139 
Payments on mortgage notes (84)(80)
Proceeds from exercise of stock options 326 — 
Payments of deferred offering costs — (250)
Net cash provided by financing activities 242 9,809 
NET (DECREASE) INCREASE IN CASH (18,119)629 
Cash, beginning of year 42,582 1,609 
Cash, end of period $24,463 $2,238 
SUPPLEMENTAL DISCLOSURES 
Cash paid for interest $1,722 $1,856 
Accretion of redeemable convertible preferred stock $— $4,364 
Transfer of instruments from property and equipment to inventory $1,061 $1,196 
See notes to condensed consolidated financial statements.
8

ORTHOPEDIATRICS CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In Thousands, Except Share and Per Share data)
NOTE 1 – BUSINESS

OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform | Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. In September 2018, we further expanded operations in Canada selling direct to local hospitals.

On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold 4,600,000 shares of common stock at a public offering price of $13.00 per share for aggregate gross proceeds of $59,800. We received approximately $46,900 in net proceeds after deducting $4,200 of underwriting discounts and commissions, paying approximately $2,700 of offering costs and paying approximately $6,000 of Series B dividends.

Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.


NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD and OrthoPediatrics NZ Limited (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017, the condensed consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statement of stockholders’ equity for the nine months ended September 30, 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2017 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and
9

Exchange Commission ("SEC") on March 15, 2018. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2017 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $112,623 and $103,066 as of September 30, 2018 and December 31, 2017, respectively. Effective December 31, 2017, we entered into an amended loan agreement with Squadron to consolidate a majority of our term note into a $20,000 term loan, reestablished a $15,000 revolving credit facility, changed the interest rate and extended the loan period through January 31, 2023. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance at September 30, 2018, expected cash flows from operations for the next twelve months subsequent to the issuance of the condensed consolidated financial statements and the availability under the revolving credit facility are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months subsequent to the issuance of the condensed consolidated financial statements.

Use of Estimates

Preparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.  

Foreign Currency Transactions

We currently bill our international distributors in United States ("U.S.") dollars, resulting in minimal foreign exchange transaction expense.

Beginning in the second quarter of 2017, we began selling direct within the United Kingdom, Ireland, Australia and New Zealand and billing using the local currency for each country. In September 2018, we began selling direct in Canada. The financial statements of our foreign subsidiaries are accounted for and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the condensed consolidated statements of comprehensive loss.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent
10

sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as, discounted cash flows, and are based on the best information available, including our own data.   

We do not have any assets or liabilities that are measured on a recurring basis under the presented fair value hierarchy.

Revenue from Contracts with Customers
The Company adopted ASC 606, "Revenue From Contracts With Customers (ASC 606)", on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have any impact on the Company’s consolidated historical financial statements. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of "ASC 605, Revenue Recognition (ASC 605)." In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.
 
Revenue Recognition – International

Outside of the United States, we primarily sell our products through independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on our history of collections and returns from international customers, we have concluded that collectability is not reasonably assured at the time of delivery for certain customers who have not evidenced a consistent pattern of timely payment. Accordingly, we do not recognize international revenue and associated cost of revenue at the time title transfers for these customers for whom collectibility has not been deemed probable based on the customer’s history and ability to pay, but rather when cash has been received. Until such payment, cost of revenue is recorded as inventories held by international distributors, net of adjustment for estimated unreturnable inventory, on our condensed consolidated balance sheets.
11

For international independent stocking distributors for whom we have determined collectability is probable, based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment.
In early 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Additionally, in September 2018 we began selling in Canada utilizing the subject agency model. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract.. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.

Cash and Cash Equivalents

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheet for cash are valued at cost, which approximates fair value.

Accounts Receivable

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods and are purchased from third parties.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.

12

In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.

Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand and Canada are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements 25 to 30 years 
Furniture and fixtures 5 to 7 years 
Computer equipment 3 to 5 years 
Business software 3 years 
Office and other equipment 5 to 7 years 
Instruments 5 years 
Sample inventory 2 years 

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses. Amortization is calculated on a straight-line basis over the estimated useful life of the patents and licenses. Amortization for patents and licenses commences at the time of patent approval and market launch, respectively. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.

Other Intangible Assets

We have indefinite lived tradename assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is
13

measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.

Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.  

Research and development costs were $1,122 and $1,127 for the three months ended September 30, 2018 and 2017, respectively, and $3,455 and $2,482 for the nine months ended September 30, 2018 and 2017, respectively.

Stock-Based Compensation

Prior to our IPO, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,789,647 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

14

Restricted stock may not be transferred prior to the expiration of the restricted period. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally last until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We estimate the fair value of stock options and restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the vesting period for stock options and the restriction period for restricted stock.

Calculating the fair value of stock-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock options. Use of the valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options and the risk free rate of return for a period that approximates the expected term of our stock options. Because we were a privately-held company with a limited operating history, we utilized the historical stock price volatility from a representative group of comparable industry competitors to estimate expected stock price volatility.

Prior to the IPO, in determining the fair value of our common stock at the grant date, which is the basis for the fair value of stock based awards, we used the market approach, which was based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. In using the market approach, we consider both the guideline public company method and the precedent transaction method. Given the absence of a public trading market for our common stock prior to our IPO, we exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: the preferences and dividends of our redeemable convertible preferred stock relative to those of our common stock; our operating results and financial conditions, including our level of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. Prior to our IPO, for restricted stock awards we applied a discount for lack of marketability to the fair value of common stock to estimate the impact of valuing a minority interest in our Company as a closely held, non-public company with no liquid market for its shares. Following the IPO, we value restricted stock awards using the market value on the grant date.  

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.

15

We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 and our disclosure obligations regarding executive compensation may be reduced. We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering, or December 31, 2022. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

Following the recent SEC amendment raising the financial thresholds for a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we qualify as a smaller reporting company effective with the filing of this quarterly report. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” on the recognition of revenue for all contracts with customers designed to improve comparability and enhance financial statement disclosures. The underlying principle of this comprehensive model is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the payment to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These standards became effective for us on January 1, 2018. We elected to apply the modified retrospective approach, and we have not identified any accounting changes that would materially impact the amount of reported revenues and did not record any adjustments on January 1, 2018, related to this new guidance.

In February 2016, the FASB issued ASU 2016-02 “Leases,” which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new standard requires lessees to
16

recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB issued ASU No. 2018-11 "Leases (Topic 842): Targeted Improvements," which provides an alternative modified retrospective transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is reocognized on the date of adoption.  The new standard will be effective starting in the first quarter of 2019. Early adoption is permitted. We are currently evaluating the impact of this standard, but we do not believe this guidance will have a material effect on our financial position, results of operations or cash flows.

In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments" which provides guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted ASU 2016-15 effective January 1, 2018. The adoption did not have any impact on our consolidated financial position, results of operations and cash flows.

In March 2018, the FASB issued ASU 2018-05 "Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118”), to state the income tax accounting implications of the Tax Cuts and Jobs Act (“New Tax Act”)" which clarifies the measurement period time frame, changes in subsequent reporting periods and reporting requirements as a result of the New Tax Act of 2017. In accordance with SAB No. 118, a company must reflect the income tax effects of those aspects of the New Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the New Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the New Tax Act. SAB No. 118 provides a measurement period that should not extend beyond one year and it begins in the period that includes the enactment date which was December 22, 2017. We have not completed the accounting for the income tax effects of certain elements of the New Tax Act. When additional guidance and regulations enable us to finalize certain tax positions, we will reflect the impact of this ASU 2018-05 on the tax provision and deferred tax calculation as of December 31, 2018.


NOTE 3 - DEBT AND CREDIT ARRANGEMENTS

Long-term debt consisted of the following:
September 30, December 31, 
20182017
Note payable to Squadron $20,000 $20,000 
Revolving credit facility with Squadron 3,947 3,921 
Mortgage payable to affiliate 1,447 1,531 
Total debt 25,394 25,452 
Less: current maturities 117 113 
Long-term debt, net of current maturities $25,277 $25,339 

In May 2014, we entered into the Second Amended and Restated Loan and Security Agreement with Squadron in connection with a restructuring of our debt and equity. The terms of this agreement required monthly interest only payments computed at 10% per annum with all principal and unpaid interest due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement. The note payable was secured by substantially all of our assets. In November 2015, this agreement was amended to provide a revolving loan commitment of an additional $7,000. The revolving loan commitment was structured under the same terms and conditions with interest payable monthly computed at 10% per
17

annum and principal due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement.

In April 2017, we entered into the Third Amended and Restated Loan and Security Agreement with Squadron to provide an additional $16,000 revolving loan commitment and extend the maturity date on the note payable and revolving credit facility to May 31, 2019 with an automatic extension to May 31, 2020 if we meet certain revenue goals. The agreement was structured similarly to previous amendments with interest payable monthly computed at 11.0% per annum and included a $1,000 extension fee payable in three installments on the anniversary date of the agreement. The extension fee was recorded in full upon closing as a deferred financing cost within long-term debt with affiliate, net of current portion, and was to be recognized ratably over the term of the agreement as deferred financing charges within interest expense on the consolidated statements of operations assuming an IPO did not happen.

Effective December 31, 2017, we entered into a Fourth Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Squadron. Pursuant to the Loan Agreement, we have consolidated a majority of the term loan amounts into a $20,000 term note and reestablished a $15,000 revolving credit facility. Also, $667 of the extension fee was cancelled as of the completion of our IPO in October 2017. Both facilities include interest only payments and will have an interest rate equal to the greater of (a) three month LIBOR plus 8.61%, or (b) 10.0%. The Loan Agreement also extended the maturity date to January 31, 2023. Borrowings under the Loan Agreement are secured by substantially all of our assets and are unconditionally guaranteed by each of our subsidiaries.

The fair value of our note payable to Squadron was estimated based on prices for the same or similar issues and the current interest rates offered for the debt of the same remaining maturities, which are considered level 2 inputs in accordance with ASC Topic 820, “Fair Value Measurements and Disclosures.” At September 30, 2018, the fair value approximated the carrying value.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At December 31, 2017, the mortgage balance was $1,531 of which current principal due of $113 was included in current portion of long-term debt. At September 30, 2018, the mortgage balance was $1,447 of which current principal due of $117 was included in current portion of long-term debt.

Interest expense relating to notes payable to Squadron and Tawani was $608 and $761 for the three months ended September 30, 2018 and 2017, respectively, and $1,722 and $1,857 for the nine months ended September 30, 2018 and 2017, respectively.


NOTE 4 - STRATEGIC ARRANGEMENTS

Effective December 1, 2007, we entered into a ten-year agreement with Case Western Reserve University (“CASE”) to assist in certain aspects of our research and development. Effective August 2, 2017, we entered into an Amended and Restated License Agreement to account for additional licensed product and extend the agreement for another ten years. The main focus of this research and development involves leveraging our exclusive rights to the Hamann-Todd Collection of the Cleveland National History Museum, the world's largest pediatric osteological collection, to assist in the design of implants which match pediatric bone curvature and structure.

In exchange for services, CASE receives certain royalties and up-front fees. The royalties and certain fees are contingent upon our obtaining FDA approval and the launch of our products into the marketplace. CASE receives a minimum annual royalty of $10 or a royalty of 3% of net sales on products, whichever is
18

greater. Additionally, for each new product developed, CASE will receive milestone payments of $5 for FDA approval to sell our products within the United States and $10 for general product launch. Additionally, CASE receives a royalty of 3% of net sales on products fully developed and being sold in the marketplace.

The royalty expense recognized related to the CASE agreement is recorded as a component of cost of revenue and was $37 and $38 for the three months ended September 30, 2018 and 2017, respectively, and $108 and $111 for the nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018 and December 31, 2017, $37 and $37, respectively, was due to CASE.


NOTE 5 - INCOME TAXES

For the three and nine month periods ended September 30, 2018 and 2017, we calculated the provision of income taxes by applying an estimate of the annual effective tax rate for the full fiscal year to the ordinary loss for the reporting period resulting in a zero tax provision consistent with prior periods.

The deferred tax assets were fully offset by a valuation allowance at September 30, 2018 and December 31, 2017, and no income tax benefit has been recognized in our condensed consolidated statements of operations for any of the periods presented. At December 31, 2017, we had available federal and state tax loss carryforwards of $70,335 and tax credits for federal and state tax purposes of $335 which begin to expire in 2028. Any losses incurred in 2018 and beyond do not expire. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $16,200 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062, which is increased by $2,302 over the first five years as a result of an unrealized built in gain. The Section 382 ownership change analysis will be re–evaluated prior to release of the year-ending December 31, 2018 financial statements to account for equity ownership changes that occur during 2018.

Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2017 and through September 30, 2018. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth.


NOTE 6 - STOCKHOLDERS’ EQUITY

Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.

Our stock option activity and related information are summarized as follows:
Weighted-Average Contractual Terms 
Options Exercise Price (in Years) 
Outstanding at January 1, 2018176,959 $29.42 2.0
Exercised (11,533)29.29 
Forfeited or expired (50,652)27.61 
Outstanding at September 30, 2018114,774 $30.33 2.1

19

Options generally include a time-based vesting schedule permitting the options to vest ratably over no years. At September 30, 2018 and December 31, 2017, all options were fully vested.

There was no stock-based compensation expense on stock options for the three and nine month periods ended September 30, 2018 and 2017, respectively.

Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-Average 
Remaining 
Restricted Contractual Terms 
Stock (in Years) 
Outstanding at January 1, 2018548,005 0.3
Granted175,541 
Forfeited(1,335)
Vested(547,670)
Outstanding at September 30, 2018174,541 2.4
Restricted stock exercisable at September 30, 2018— 

At September 30, 2018, there was $2,951 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 2.4 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $267 and $354 for the three months ended September 30, 2018 and 2017, respectively, and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively. Due to our limited operating history and lack of marketability before the IPO, a discount of 15% was applied when estimating the stock-based compensation expense on restricted stock granted in 2017.

Total stock-based compensation expense is included as a component of general and administrative expenses in our condensed consolidated statement of operations and was $267 and $354 for the three months ended September 30, 2018 and 2017, respectively, and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively.

Warrants

Our warrant activity and related information are summarized as follows:
Weighted-Average 
Warrants Exercise Price 
Outstanding at January 1, 201844,101 $27.03 
Forfeited or expired (25,535)26.55 
Outstanding at September 30, 201818,566 $27.69 

For all periods presented, the warrants were issued at exercise prices ranging from $26.27 to $30.97 per share. The warrants generally have a ten-year term. At September 30, 2018, no warrants had been exercised. At inception, no fair value was assigned to the warrants.


20

NOTE 7 – NET LOSS PER SHARE

The following is a reconciliation of basic and diluted net loss per share attributable to common stockholders: 
Three Months Ended Nine Months Ended 
September 30, September 30, 
2018201720182017
Net loss $(1,865)$(1,537)$(9,557)$(4,087)
Accretion of cumulative dividends of redeemable preferred stock to redemption value — (1,484)— (4,364)
Net loss attributable to common stockholders - basic and diluted $(1,865)$(3,021)$(9,557)$(8,451)
Weighted average number of shares - basic and diluted 12,624,858 1,773,385 12,417,972 1,754,576 
Net loss per share attributable to common stockholders - basic and diluted $(0.15)$(1.70)$(0.77)$(4.82)

Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 

Prior to the completion of our IPO on October 12, 2017, we had authorized 7,000,000 shares of redeemable convertible preferred stock, of which 3,649,475 were outstanding as of September 30, 2017, designated in series, with the rights and preferences of each series determined by the Board of Directors. Upon completion of our IPO, all of our previously outstanding shares of Series A and B Preferred Stock were converted into common stock on a 1:1 conversion ratio. As of September 30, 2018 and December 31, 2017, there are no redeemable convertible preferred shares outstanding. Series A and B preferred stock include rights to participate in dividends and distributions to common stockholders on an if-converted basis, and accordingly are also considered participating securities.  During periods of undistributed losses however, no effect is given to our participating securities since they are not contractually obligated to share in the losses.

We have incurred a net loss for all periods presented, such that diluted net loss per common stock is the same as basic net loss per common stock. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented (shares for the redeemable convertible preferred shares for the nine months ended September 30, 2017 were determined based on the applicable conversion ratio of 1:1):
As of September 30, 
20182017
Redeemable convertible preferred stock - Series A — 670,000 
Redeemable convertible preferred stock - Series B — 2,979,475 
Restricted stock 174,541 704,770 
Stock options 114,774 177,763 
Warrants 18,566 44,101 
307,881 4,576,109 




21

NOTE 8 – BUSINESS SEGMENT

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We disaggregate revenue from contracts with customers by operating segment. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three and nine months ended September 30, 2018 or 2017. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2018 and December 31, 2017.

Product sales by source were as follows:  
Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by geographic location: 2018201720182017
U.S. $12,421 $9,556 $32,532 $26,085 
International 3,399 2,819 10,459 7,854 
Total $15,820 $12,375 $42,991 $33,939 

Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by category: 2018201720182017
Trauma and deformity $10,562 $8,730 $29,545 $24,339 
Scoliosis 5,027 3,299 12,609 8,652 
Sports medicine/other 231 346 837 948 
Total $15,820 $12,375 $42,991 $33,939 

No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2018 and 2017.


NOTE 9 - RELATED PARTY TRANSACTIONS
In addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 3), we currently use FMI Hansa Medical Products, LLC (“FMI”) and Structure Medical, LLC (“Structure Medical”) as two of our suppliers. Each of these entities is affiliated with Squadron. In 2017, FMI merged with and into Structure Medical. We do not have long-term contracts with either supplier. We made aggregate payments to Structure and FMI of $738 and $757 for the three months ended September 30, 2018 and 2017, respectively, and $3,004 and $1,862 for the nine months ended September 30, 2018 and 2017, respectively.


22

NOTE 10 - EMPLOYEE BENEFIT PLAN

We have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. Effective January 1, 2018, we have elected to match our employees' 401(k) contributions up to 3% of employees' salary.


NOTE 11 – COMMITMENTS AND CONTINGENCIES

We are involved with various legal actions arising in the ordinary course of our activities. We accrue for those cases where the potential liability is estimable and probable. From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. On January 20, 2017, K2M, Inc. filed suit against us in the United States District Court for the District of Delaware (K2M, Inc. v. OrthoPediatrics Corp. et al., Case No. 1:17-cv-0061) seeking unspecified damages for alleged infringement of U.S. Patent No. 9,532,816. The complaint was amended on August 21, 2017 to add, among other things, a claim of patent infringement regarding U.S. Patent No. 9,655,664. These patents relate to certain instruments used in our RESPONSE spine systems, which represent a portion of our total scoliosis portfolio. We have denied these claims and responded with counterclaims seeking declaratory relief that the patents in question are both invalid and not infringed. The parties attended a court-ordered mediation on October 24, 2017, which did not resolve the dispute, but as we move forward with this matter we welcome constructive discussions on a negotiated settlement. Nevertheless, we view our case as particularly strong and will continue to vigorously defend this matter. On January 8 and 22, 2018, we filed our first and second petitions for inter partes review ("IPR") with the United States Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB") to challenge the patentability of U.S. Patent No. 9,532,816 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-00429 and IPR2018-00521). On June 28, 2018, the PTAB instituted the subject IPRs and set a trial date of February 20, 2019 for both IPRs. Additionally, the parties have agreed to stay the above-referenced district court proceedings pending the outcome of the subject IPR proceedings. The Court ordered the stay on July 10, 2018. Moreover, on August 21, 2018, we filed three petitions with PTAB to challenge the patentability of the above-referenced U.S. Patent No. 9,655,664 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-01546, IPR2018-01547, and IPR2018-01548). Although we believe that the K2M lawsuit is without merit and we will vigorously defend the claims asserted against us, intellectual property litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have a material adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

As of September 30, 2018, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. Additionally, we have minimum royalty commitments of $500 annually through 2026.

We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2018, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.


23

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto contained elsewhere in this quarterly report, as well as the information under "Note Regarding Forward-Looking Statements."

Overview

We are the only medical device company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $2.5 billion opportunity globally, including over $1.1 billion in the United States.

We sell implants and instruments to our customers for use by pediatric orthopedic surgeons to treat orthopedic conditions in children. We provide our implants in sets that consist of a range of implant sizes and include the instruments necessary to perform the surgical procedure. In the United States, our customers typically expect us to have full sets of implants and instruments on site at each hospital but do not purchase the implants until they are used in surgery. Accordingly, we must make an up-front investment in inventory of consigned implants and instruments before we can generate revenue from a particular hospital and we maintain substantial levels of inventory at any given time.

We currently market 25 surgical systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity, (ii) scoliosis and (iii) sports medicine/other. We rely on a broad network of third parties to manufacture the components of our products, which we then inspect and package. We believe our innovative products promote improved surgical accuracy, increase consistency of outcomes and enhance surgeon confidence in achieving high standards of care. In the future, we expect to expand our product offering within these categories, as well as to address additional categories of the pediatric orthopedic market.

The majority of our revenue has been generated in the United States, where we sell our products through a network of 33 independent sales agencies employing more than 130 sales representatives specifically focused on pediatrics, 86 of whom were full-time equivalents devoted to our sales activities. These independent sales agents are trained by us, distribute our products and are compensated through sales-based commissions and performance bonuses. We do not sell our products through or participate in physician-owned distributorships, or PODs.

We market and sell our products internationally in 38 countries, primarily through independent stocking distributors. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of their surgeon customers. In April 2017, we began to supplement our use of independent distributors with direct sales programs in the United Kingdom, Ireland, Australia and New Zealand and further expanded to Canada in September 2018. In these markets, we work through sales agencies that are paid a commission, similar to our U.S. sales model. We expect these arrangements to generate an increase in revenue and gross margin.

We believe there are significant opportunities for us to strengthen our position in U.S. and international markets by increasing investments in consigned implant and instrument sets, strengthening our global sales and distribution infrastructure and expanding our product offering.


24

Emerging Growth Company and Smaller Reporting Company Status

The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and reflect the financial position, results of operations, and cash flows of OrthoPediatrics Corp (the "Company," “we,” "our" or "us"). We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. The JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Summary of Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017

The following table sets forth our results of operations for the three and nine months ended September 30, 2018 and 2017:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2018 2017 
Increase (Decrease)
%
2018 2017 
Increase
%
Net revenue
$15,820 $12,375 $3,445 28 %$42,991 $33,939 $9,052 27 %
Cost of revenue
3,843 2,884 959 33 %10,825 8,321 2,504 30 %
Sales and marketing expenses
7,150 5,633 1,517 27 %20,005 15,122 4,883 32 %
General and administrative expenses
4,877 3,487 1,390 40 %16,393 10,282 6,111 59 %
Research and development expenses
1,122 1,127 (5)—%3,455 2,482 973 39 %
Other expenses
693 781 (88)(11)%1,870 1,819 51 3 %
Net loss
$(1,865)$(1,537)$328 21 %$(9,557)$(4,087)$5,470 134 %

Net Revenue

The following tables set forth our net revenue by geography and product category for the three and nine months ended September 30, 2018 and 2017:
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by geographic location: 2018 2017 2018 2017 
U.S. $12,421 $9,556 $32,532 $26,085 
International 3,399 2,819 10,459 7,854 
Total $15,820 $12,375 $42,991 $33,939 
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by category: 2018 2017 2018 2017 
Trauma and deformity $10,562 $8,730 $29,545 $24,339 
Scoliosis 5,027 3,299 12,609 8,652 
Sports medicine/other 231 346 837 948 
Total $15,820 $12,375 $42,991 $33,939 

25

Net revenue increased $3.4 million, or 28%, from $12.4 million for the three months ended September 30, 2017 to $15.8 million for the three months ended September 30, 2018. The increase was due to trauma and deformity sales growth of $1.8 million, or 21%, primarily driven by sales of our PediNail and PediPlate products and scoliosis sales growth of $1.7 million, or 52%, primarily driven by sales of our RESPONSE and FIREFLY® Pedicle Screw Navigation Guides products, offset by a reduction in sports medicine/other sales of $0.1 million, or 33%. Nearly all the change in each category was due to an increase in the unit volume sold and not a result of price changes.

Net revenue increased $9.1 million, or 27%, from $33.9 million for the nine months ended September 30, 2017 to $43.0 million for the nine months ended September 30, 2018. The increase was due to trauma and deformity sales growth of $5.2 million, or 21%, primarily driven by sales of our PediNail, PediLoc, PediFrag and Locking Proximal Femur products, scoliosis sales growth of $4.0 million, or 46%, primarily driven by sales of our RESPONSE, FIREFLY® Pedicle Screw Navigation Guides and BandLoc products, offset by a reduction in sports medicine/other sales of $0.1 million, or 12%. Nearly all the increase in each category was due to an increase in the unit volume sold and not a result of price changes.

Cost of Revenue and Gross Margin

Cost of revenue increased $1.0 million, or 33%, from $2.9 million for the three months ended September 30, 2017 to $3.8 million for the three months ended September 30, 2018. The increase was due primarily to increased revenue volume as well as international sales, including sets. Gross margin was 77% for the three months ended September 30, 2017 and 76% for the three months ended September 30, 2018. The decrease was due primarily to a higher percentage of international sales, including sets.

Cost of revenue increased $2.5 million, or 30%, from $8.3 million for the nine months ended September 30, 2017 to $10.8 million for the nine months ended September 30, 2018. The increase was due primarily to increased revenue volume as well as international sales, including sets. Gross margin was 75% for the nine months ended September 30, 2017 and 75% for the nine months ended September 30, 2018.

Sales and Marketing Expenses

Sales and marketing expenses increased $1.5 million, or 27%, from $5.6 million for the three months ended September 30, 2017 to $7.2 million for the three months ended September 30, 2018. Sales and marketing expenses increased $4.9 million, or 32%, from $15.1 million for the nine months ended September 30, 2017 to $20.0 million for the nine months ended September 30, 2018. The increase was due primarily to increased sales commission expenses, driven by the increase in unit volume sold, the addition of commission expense for United Kingdom, Australia and New Zealand as well as marketing expenses.

General and Administrative Expenses

General and administrative expenses increased $1.4 million, or 40%, from $3.5 million for the three months ended September 30, 2017 to $4.9 million for the three months ended September 30, 2018. General and administrative expenses increased $6.1 million, or 59%, from $10.3 million for the nine months ended September 30, 2017 to $16.4 million for the nine months ended September 30, 2018. The increase was due primarily to additional stock compensation expense associated with the accelerated vesting of our restricted stock following our IPO, increased legal expense and the addition of personnel and resources to support the growth of our business. Depreciation and amortization expenses increased $0.1 million, or 16%, from $0.7 million for the three months ended September 30, 2017 to $0.8 million for the three months ended September 30, 2018 and increased $0.4 million, or 21%, for the nine months ended September 30, 2017 from $1.7 million for the nine months ended September 30, 2017 to $2.1
26

million for the nine months ended September 30, 2018. The increase was primarily due to increased investments in consigned surgical instrument sets and amortization on intangible licenses.

Research and Development Expenses

Research and development expenses remained flat at $1.1 million for the three months ended September 30, 2017 and 2018. Research and development expenses increased $1.0 million, or 39%, from $2.5 million for the nine months endedSeptember 30, 2017 to $3.5 million for the nine months ended September 30, 2018. The increase was driven by incremental product development including the addition of personnel and the growth of our business.

Other Expenses

Other expenses were $0.7 million and $0.8 million for the three months ended September 30, 2018 and 2017, respectively, and other expenses were $1.9 million and $1.8 million for the nine months ended September 30, 2018 and 2017, respectively. Other expenses consist primarily of interest expense on our long-term debt.

Liquidity and Capital Resources

We have incurred operating losses since inception which resulted in negative cash flows from operating activities of $12.9 million and $3.9 million for the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, we had an accumulated deficit of $112.6 million. We anticipate that our losses will continue in the near term as we continue to expand our product portfolio and invest in additional consigned implant and instrument sets to support our expansion into existing and new markets. Since inception, we have funded our operations primarily with proceeds from the sales of our common and preferred stock, convertible securities and debt, as well as through sales of our products. At September 30, 2018, we had cash and cash equivalents of $24.5 million.

We believe our existing cash and cash equivalents and amounts available under our revolving credit facility cash receipts from sales of our products will be sufficient to meet our anticipated cash requirements for more than the next twelve months.

Cash Flows

The following table sets forth our cash flows from operating, investing and financing activities for the periods indicated:
For the Nine Months Ended September 30, 
20182017
Net cash used in operating activities
$(12,855)$(3,894)
Net cash used in investing activities
(5,506)(5,286)
Net cash provided by financing activities 242 9,809 
Net (decrease) increase in cash and cash equivalents $(18,119)$629 

Cash Used in Operating Activities

Net cash used in operating activities was $12.9 million and $3.9 million for the nine months ended September 30, 2018 and 2017, respectively. The primary use of this cash was to fund our operations related to the development and commercialization of our products in each of these years. Net cash used for working capital was $8.4 million and $2.6 million for the nine months ended September 30, 2018 and 2017, respectively. During the nine months ended September 30, 2018, the primary driver of working capital cash usage was the increase in inventory of $6.1 million and accounts receivable of $4.1 million.

27

Cash Used in Investing Activities

Net cash used in investing activities was $5.5 million and $5.3 million for the nine months ended September 30, 2018 and 2017, respectively. Net cash used in investing activities consisted primarily of purchases of instrument sets, which were consigned in the United States, United Kingdom, Australia and New Zealand, of $5.3 million and $3.9 million for the nine months ended September 30, 2018 and 2017, respectively. We also purchased an additional $0.2 million and $1.3 million in new product licenses during the nine months ended September 30, 2018 and 2017, respectively.

Cash Provided By Financing Activities

Net cash provided by financing activities was $0.2 million and $9.8 million for the nine months ended September 30, 2018 and 2017, respectively. Net cash provided by financing activities consisted primarily of the payment of $84 thousand and $80 thousand in mortgage payments in the nine months ended September 30, 2018 and 2017, respectively. During the nine months ended September 30, 2018, these payments were offset by $0.3 million of proceeds received from the exercise of stock options. During the nine months ended September 30, 2017, these payments were offset by net borrowings of $10.1 million on our revolving credit facility with an affiliate.

Indebtedness

Loan Agreement

Effective December 31, 2017, we entered into a Fourth Amended and Restated Loan and Security Agreement (the "Loan Agreement" with Squadron Capital LLC (the "Lender"). Under the terms of the Loan Agreement, the Lender has provided to us a term loan in the principal amount of $20.0 million and a revolving loan in an aggregate principal amount that will not exceed $15.0 million. Interest on the term loan and revolving loan will accrue at the greater of (a) three month LIBOR plus 8.61% or (b) 10.0% (the "Applicable Rate") and will be payable monthly by us. The Loan Agreement expires in January 2023.

The Loan Agreement amends and restates the Third Amended and Restated Loan and Security Agreement between the Lender and us, dated April 26, 2017, the Amended and Restated Term Note A, dated April 26, 2017 and the Term Note B, dated as of April 26, 2017, by (a) consolidating the prior term note amounts into a $20.0 million term note and reestablishing a $15.0 million revolving loan, (b) changing the interest rate on the term note and the revolving loan to the Applicable Rate (compared to the previous rate of 10.0% for the term note and 11.0% for the revolving credit facility), and (c) extending the loan period through January 31, 2023, except as accelerated pursuant to the Loan Agreement (compared to the previous maturity of May 31, 2019 or 2020 depending on revenue).

At September 30, 2018, we had approximately $23.9 million in outstanding indebtedness under the Loan Agreement. Borrowings under the Loan Agreement are secured by substantially all of our assets and are unconditionally guaranteed by each of our subsidiaries.

There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions as further detailed in the Loan Agreement.

The Loan Agreement includes events of default, the occurrence and continuation of any of which provides Squadron with the right to exercise remedies against us and the collateral securing the loans, including cash. These events of default include, among other things, the failure to pay amounts due
28

under the credit facilities, insolvency, the occurrence of a material adverse event, which includes a material adverse change in our business, operations or properties (financial or otherwise) or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against us in an amount greater than $250,000. The occurrence of a material adverse change could result in the acceleration of payment of the debt.

We are obligated to make monthly interest-only payments on the term loan facilities until the earlier of: (i) a transaction pursuant to which any person acquires (a) shares of our capital stock possessing the voting power to elect a majority of our board of directors or (b) all or substantially all of our assets on a consolidated basis; or (ii) January 31, 2023, at which point the term loan credit facilities, plus all accrued, unpaid interest thereon, will become due.

We may prepay the term loan facility in whole or in part without premium or penalty upon ten days’ prior written notice to Squadron.

Mortgage Note

In August 2013, pursuant to the purchase of our office and warehouse space, we entered into a mortgage note payable to Tawani Enterprises Inc., the owner of which is a member of Squadron’s Managing Committee. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $15,543, with interest compounded at 5% until maturity in August 2028, at which time a final payment of remaining principal and interest will become due. The mortgage is secured by the related real estate and building. The mortgage balance was $1.4 million and $1.5 million at September 30, 2018 and December 31, 2017, respectively.

Pediatric Orthopedic Business Seasonality

Our revenue is typically higher in the summer months and holiday periods, driven by higher sales of our trauma and deformity and scoliosis products, which is influenced by the higher incidence of pediatric surgeries during these periods due to recovery time provided by breaks in the school year. Additionally, our scoliosis patients tend to have additional health challenges that make scheduling their procedures variable in nature.

29

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses during the reporting periods. We monitor and analyze these items for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.

For further information regarding our critical accounting policies, see “Note 2 - Significant Accounting Policies” of notes to condensed consolidated financial statements and our critical accounting policies within the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K filed with the SEC on March 15, 2018. There have been no material changes, other than the adoption of Accounting Standards Codification 606 "Revenue from Contracts with Customers" during the three and nine months ended September 30, 2018.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "smaller reporting company," we are not required to provide the information required by this item.

ITEM 4.  CONTROLS AND PROCEDURES

a. Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) at the end of the period covered by this quarterly report.

Based on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives, and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

b. Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
30

PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. On January 20, 2017, K2M, Inc. filed suit against us in the United States District Court for the District of Delaware (K2M, Inc. v. OrthoPediatrics Corp. et al., Case No. 1:17-cv-0061) seeking unspecified damages for alleged infringement of U.S. Patent No. 9,532,816. The complaint was amended on August 21, 2017 to add, among other things, a claim of patent infringement regarding U.S. Patent No. 9,655,664. These patents relate to certain instruments used in our RESPONSE spine systems, which represent a portion of our total scoliosis portfolio. We have denied these claims and responded with counterclaims seeking declaratory relief that the patents in question are both invalid and not infringed. The parties attended a court-ordered mediation on October 24, 2017, which did not resolve the dispute, but as we move forward with this matter we welcome constructive discussions on a negotiated settlement. Nevertheless, we view our case as particularly strong and will continue to vigorously defend this matter. On January 8 and 22, 2018, we filed our first and second petitions for inter partes review ("IPR") with the United States Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB") to challenge the patentability of U.S. Patent No. 9,532,816 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-00429 and IPR2018-00521). On June 28, 2018, the PTAB instituted the subject IPRs and set a trial date of February 20, 2019 for both IPRs. Additionally, the parties have agreed to stay the above-referenced district court proceedings pending the outcome of the subject IPR proceedings. The Court ordered the stay on July 10, 2018. Moreover, on August 21, 2018, we filed three petitions with PTAB to challenge the patentability of the above-referenced U.S. Patent No. 9,655,664 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-01546, IPR2018-01547, and IPR2018-01548). Although we believe that the K2M lawsuit is without merit and we will vigorously defend the claims asserted against us, intellectual property litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have a material adverse effect on our business, operating results and financial condition. See “Risk Factors — Risks Related to Intellectual Property — Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products or impact our stock price” within our Annual Report on Form 10-K filed with the SEC on March 15, 2018.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, operating results or financial condition.

ITEM 1A.  RISK FACTORS

In addition to the other information set forth in this quarterly report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 15, 2018. In connection with our status as a “smaller reporting company,” we are including a revised risk factor below, which updates and supersedes the corresponding risk factor relating to certain reduced disclosure requirements discussed in our Annual Report on Form 10-K (under “– Risks Related to Ownership of Our Common Stock”), and should be read in conjunction with the other “Risk Factors” discussed in such Annual Report.

We are an “emerging growth company” and a “smaller reporting company” and the reduced disclosure requirements applicable to us could make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act. We may remain an emerging growth company until as late as December 31, 2022, though we may cease to be an emerging growth company earlier under certain circumstances, including (i) if the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of any June 30, in which case we would cease to be an emerging
31

growth company as of the following December 31, or (ii) if our gross revenue exceeds $1.07 billion in any fiscal year. “Emerging growth companies” may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

In addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

We are also a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us. Some investors may find our common stock less attractive because we rely on these exemptions, there may be a less active trading market for our common stock and our stock price may be more volatile.

ITEM 6.  EXHIBITS

The exhibits filed as part of this quarterly report are set forth on the Exhibit Index, which is
incorporated herein by reference.



32

EXHIBIT INDEX
Exhibit
Number
Description 
+ 
+ 
+ 
+ 
101.INS ++ XBRL Instance Document 
101.SCH ++ XBRL Taxonomy Extension Schema Document 
101.CAL ++ XBRL Taxonomy Extension Calculation Linkbase Document 
101.DEF ++ XBRL Taxonomy Extension Definition Linkbase Document 
101.LAB ++ XBRL Taxonomy Extension Label Linkbase Document 
101.PRE ++ XBRL Taxonomy Extension Presentation Linkbase Document 

+ Exhibits that are filed with this Report (other than through incorporation by reference to other disclosures or exhibits).

++ Furnished and not filed herewith.

33

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ORTHOPEDIATRICS CORP.
October 31, 2018
By:
/s/ Mark C. Throdahl
Mark C. Throdahl
President and Chief Executive Officer

October 31, 2018
By:
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer

34
 EX-31.1 2 exhibit311-ceocertific.htm Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark C. Throdahl, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


/s/ Mark C. Throdahl
Mark C. Throdahl
President and Chief Executive Officer
(Principal Executive Officer)

Date:  October 31, 2018


 EX-31.2 3 exhibit312-cfocertific.htm Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Fred L. Hite, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer
(Principal Financial Officer)

Date:  October 31, 2018


 EX-32.1 4 exhibit321-ceocertific.htm Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mark C. Throdahl, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.

/s/ Mark C. Throdahl
Mark C. Throdahl
President and Chief Executive Officer
(Principal Executive Officer)

Date:  October 31, 2018


 EX-32.2 5 exhbit322-cfocertifica.htm Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Fred L. Hite, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.

/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer
(Principal Financial Officer)

Date:  October 31, 2018


 EX-101.SCH 6 kids-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - BUSINESS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2110103 - Disclosure - DEBT AND CREDIT ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - STRATEGIC ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - STRATEGIC ARRANGEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2319303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2324304 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - NET LOSS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2128108 - Disclosure - BUSINESS SEGMENT link:presentationLink link:calculationLink link:definitionLink 2329305 - Disclosure - BUSINESS SEGMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - BUSINESS SEGMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2135110 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2137111 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 kids-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 kids-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 kids-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Stock Common Stock [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Range [Domain] Range [Domain] Revenue Recognition - United States and International Revenue from Contract with Customer [Policy Text Block] Revenue from Contract with Customer Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Geographical [Domain] Geographical [Domain] Accounts payable - trade Accounts Payable, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Accounting Policies [Abstract] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Payments on mortgage notes Repayments of Long-term Debt Current Fiscal Year End Date Current Fiscal Year End Date Restricted stock Restricted Stock [Member] Accretion of redeemable convertible preferred stock Temporary Equity, Accretion to Redemption Value Computer equipment Computer Equipment [Member] Equity Award [Domain] Equity Award [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Operating expenses: Operating Expenses [Abstract] Royalty Agreement Terms Royalty Agreement Terms [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Net proceeds on sale of stock Sale of Stock, Consideration Received on Transaction Stock-based compensation expense, discount rate SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountRate Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Inventories, net Inventory, Policy [Policy Text Block] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Impairment charges, finite-lived Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Additional Paid-in Capital Additional Paid-in Capital [Member] Royalty payable Accrued Royalties, Current Proceeds from issuance of debt with affiliate Proceeds from Issuance of Long-term Debt Payments to related party Related Party Transaction, Purchases from Related Party Milestone payments for FDA approval to sell our products within the United States ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementAbilitytoSellMilestonePayment Options granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Common stock, shares outstanding Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Schedule of Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] STOCKHOLDERS' EQUITY Disclosure of Compensation Related Costs, Share-based Payments [Text Block] General and Administrative Expense General and Administrative Expense [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract] Research and Development [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Public offering price (usd per share) Sale of Stock, Price Per Share Schedule of product sales by geographic location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Temporary Equity [Line Items] Temporary Equity [Line Items] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Property and equipment, net Property, Plant and Equipment, Net Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Outstanding at period start (in shares) Outstanding at period end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Royalty agreement percentage ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementPercent Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Interest expense, net Interest Income (Expense), Net Stock Option Stock options Employee Stock Option [Member] Sales and marketing Selling and Marketing Expense Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Operating loss Operating Income (Loss) Statement [Table] Statement [Table] Commitments and Contingencies Disclosure [Abstract] Unrecognized compensation expense, weighted average period of recognition (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Gross proceeds on sale of stock SaleofStockConsiderationReceivedonTransactionGross Inventories Increase (Decrease) in Inventories Changes in certain current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Estimated limitation on losses generated prior to ownership change date OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation Outstanding at period start (in shares) Outstanding at period end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Increase of estimated annual limitation of first five years OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease DEBT AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Warrants Warrant [Member] Mortgage payable to affiliate Mortgages [Member] Accrued compensation and benefits Employee-related Liabilities, Current Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Term of warrants (in years) ClassofWarrantorRightTerm Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] "Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements EmergingGrowthCompanyReportingRequirementsPolicyPolicyTextBlock Net loss attributable to common stockholders - diluted Net Income (Loss) Available to Common Stockholders, Diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Commitments and contingencies (Note 11) Commitments and Contingencies OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Three month LIBOR London Interbank Offered Rate (LIBOR) [Member] Statement of Stockholders' Equity [Abstract] Research and development Research and development costs Research and Development Expense Other expense (income) Other Nonoperating Income (Expense) Total liabilities Liabilities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Structure Medical StructureMedicalLLCMember U.S. UNITED STATES Series B Preferred Stock Redeemable convertible preferred stock - Series B Series B Preferred Stock [Member] Sample inventory SampleInventoryMember Cost of Revenue Cost of Goods and Services Sold, Policy [Policy Text Block] Cost of Goods and Services Sold, Policy Amortizable intangible assets, net Finite-Lived Intangible Assets, Net Document Period End Date Document Period End Date FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-term liabilities: Liabilities, Noncurrent [Abstract] Stock-based compensation expense Allocated Share-based Compensation Expense Loss carryforwards Operating Loss Carryforwards Revolving Credit Facility Revolving Credit Facility [Member] Project [Axis] Project [Axis] Common stock, $0.00025 par value; 50,000,000 shares authorized; 12,807,520 shares and 12,621,781 shares issued and outstanding as of September 30, 2018 and December 31, 2017 Common Stock, Value, Issued Redeemable convertible preferred stock - Series A Series A Preferred Stock [Member] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Assets [Abstract] Assets [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Range [Axis] Range [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Other intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Cash Cash, beginning of year Cash, end of period Cash and Cash Equivalents, at Carrying Value Accounts payable - trade Increase (Decrease) in Accounts Payable Basis of Presentation and Unaudited Interim Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Accretion of cumulative dividends of redeemable preferred stock to redemption value Temporary Equity, Accretion to Redemption Value, Adjustment Royalty agreement period ResearchandDevelopmentArrangementContracttoPerformforOthersTerm Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Conversion ratio Convertible Preferred Stock, Shares Issued upon Conversion Cost of revenue Cost of Goods and Services Sold Document Fiscal Year Focus Document Fiscal Year Focus Long-term debt with affiliate, net of current portion Notes and Loans, Noncurrent 2017 Plan New2017EquityIncentivePlanMember Total assets Assets Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] IPO IPO [Member] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Project [Domain] Project [Domain] Plan Name [Domain] Plan Name [Domain] Cash paid for interest Interest Paid, Net Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Note payable to Squadron Notes Payable, Other Payables [Member] Schedule of product sales by category Schedule of Segment Reporting Information, by Segment [Table Text Block] Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Document Fiscal Period Focus Document Fiscal Period Focus 2007 Plan A2007EquityIncentivePlanMember Document Type Document Type Accumulated Deficit Retained Earnings [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income Statement [Abstract] Stock issued during period, shares, new issues (in shares) Stock Issued During Period, Shares, New Issues Sales and Marketing Expenses SalesAndMarketingExpensePolicyPolicyTextBlock Number of operating segments Number of Operating Segments Tax provision Income Tax Expense (Benefit) Use of Estimates Use of Estimates, Policy [Policy Text Block] Milestone payment for general product launch ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementProductLaunchMilestonePayment BUSINESS SEGMENT Segment Reporting Disclosure [Text Block] Inventories Inventory, Net Total current assets Assets, Current NET (DECREASE) INCREASE IN CASH Cash and Cash Equivalents, Period Increase (Decrease) Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Revolving credit facility with affiliate Long-term Line of Credit, Noncurrent Total current liabilities Liabilities, Current Employer contribution as a percentage of employees' salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Building and building improvements Building and Building Improvements [Member] General and administrative General and Administrative Expense Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Reconciliation of basic and diluted net loss per share attributable to common stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Related Party [Axis] Related Party [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Total liabilities and stockholders' equity Liabilities and Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Royalty expense Royalty Expense Schedule of stock option activity Share-based Compensation, Stock Options, Activity [Table Text Block] Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Accounts receivable - trade, less allowance for doubtful accounts of $131 and $143, respectively Accounts Receivable, Net, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Minimum annual royalty payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment Revolving credit facility with Squadron Line of Credit [Member] Class of Stock [Line Items] Class of Stock [Line Items] Debt Disclosure [Abstract] BUSINESS Nature of Operations [Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity Components [Axis] Equity Components [Axis] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Variable Rate [Axis] Variable Rate [Axis] Award Type [Axis] Award Type [Axis] EMPLOYEE BENEFIT PLAN Pension and Other Postretirement Benefits Disclosure [Text Block] Total other assets Intangible Assets, Net (Excluding Goodwill) Counterparty Name [Domain] Counterparty Name [Domain] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net loss attributable to common stockholders Net loss attributable to common stockholders - basic Net Income (Loss) Available to Common Stockholders, Basic Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Forfeited or expired, weighted average exercise price (in dollars per share) Class of Warrant or Right, Forfeited or Expired, Weighted Average Exercise Price of Warrants or Rights Class of Warrant or Right, Forfeited or Expired, Weighted Average Exercise Price Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Offering costs PaymentsofStockIssuanceCostsOfferingCosts Beginning weighted-average exercise price (in dollars per share) Ending weighted-average exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Common stock, shares issued Common Stock, Shares, Issued Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Class of Warrant or Right Outstanding [Roll Forward] Class of Warrant or Right Outstanding [Roll Forward] Class of Warrant or Right Outstanding Total operating expenses Operating Expenses Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Restricted Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Current portion of long-term debt with affiliate Less: current maturities Long-term Debt, Current Maturities Property and equipment, depreciable lives Property, Plant and Equipment [Table Text Block] Outstanding at period start, Weighted-Average Exercise Price (in dollars per share) Outstanding at period end, Weighted-Average Exercise Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Related Party Transaction [Line Items] Related Party Transaction [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Contractual Terms (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Other comprehensive (loss) income Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Deferred financing cost Debt Issuance Costs, Noncurrent, Net Redeemable Convertible Preferred Stock Redeemable convertible preferred stock - Series A and Series B Redeemable Convertible Preferred Stock [Member] Stock-based compensation Share-based Compensation Instruments Technology Equipment [Member] Net loss Net loss Net Income (Loss) Attributable to Parent FMI FMIHansaMedicalProductsMember Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Other comprehensive (loss) income: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Forfeited or expired, Weighted-Average Exercise Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Geographical [Axis] Geographical [Axis] Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Number of related party suppliers NumberOfRelatedPartyEntitiesSuppliers Tax credit carryforward Tax Credit Carryforward, Amount Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Sports medicine/other SportsMedicineandOtherMember STRATEGIC ARRANGEMENTS Research, Development, and Computer Software Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Depreciable lives Property, Plant and Equipment, Useful Life Entity Filer Category Entity Filer Category Purchases of licenses Payments to Acquire Intangible Assets Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Redeemable convertible preferred stock, authorized (in shares) Temporary Equity, Shares Authorized Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Additional revolving loan commitment LineofCreditFacilityIncreaseInMaximumBorrowingCapacity Counterparty Name [Axis] Counterparty Name [Axis] Income Tax Disclosure [Abstract] Long-term debt Long-term debt Mortgage balance Long-term Debt Impairment charges, indefinite-lived Impairment of Intangible Assets, Finite-lived Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Affiliated Entity Affiliated Entity [Member] Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Products and Services [Axis] Products and Services [Axis] Number of warrants exercised (in shares) ClassofWarrantorRightExercised Sale of Stock [Domain] Sale of Stock [Domain] Schedule of restricted stock activity Nonvested Restricted Stock Shares Activity [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement [Line Items] Statement [Line Items] Dividend payments Payments of Dividends Number of reportable segments Number of Reportable Segments Entity Registrant Name Entity Registrant Name Total other expenses Nonoperating Income (Expense) Business software Software and Software Development Costs [Member] Furniture and fixtures Furniture and Fixtures [Member] SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Schedule of antidilutive securities excluded from computation of net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Current liabilities: Liabilities, Current [Abstract] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Amendment Flag Amendment Flag Stock option exercise (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Extension fee payable period Debt Instrument, Extension Fee, Term Other assets: Other Assets, Noncurrent [Abstract] Scoliosis SpineMember Accounts receivable - trade Increase (Decrease) in Accounts and Notes Receivable Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Sale of Stock [Axis] Sale of Stock [Axis] Estimated annual limitation of losses OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit Credit Facility [Domain] Credit Facility [Domain] Office and other equipment Office Equipment [Member] INCOME TAXES Income Tax Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Restricted stock exercisable (in shares) SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisableNumber Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Segment Reporting [Abstract] Payments of deferred offering costs Payments of Stock Issuance Costs Interest expense Interest Expense Statement of Cash Flows [Abstract] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Amortizable Intangible Assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Transfer of instruments from property and equipment to inventory TransferOfPropertyAndEquipmentToInventory Redeemable convertible preferred stock, outstanding (in shares) Temporary Equity, Shares Outstanding Weighted average common shares - basic and diluted (in shares) Weighted average number of shares - basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Class of Stock [Axis] Class of Stock [Axis] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Revolving credit facility Line of Credit Facility, Maximum Borrowing Capacity Debt instrument, extension fee cancelled DebtInstrumentExtensionFeeCancelled Advertising Costs Advertising Costs, Policy [Policy Text Block] Trauma and deformity TraumaandDeformityMember Related Party [Domain] Related Party [Domain] Common stock, shares authorized Common Stock, Shares Authorized Earnings Per Share [Abstract] Shares available for award (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Products and Services [Domain] Products and Services [Domain] Exercised, Weighted-Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Minimum Minimum [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Retirement Benefits [Abstract] Schedule of long-term debt instruments Schedule of Long-term Debt Instruments [Table Text Block] Current assets: Assets, Current [Abstract] Variable Rate [Domain] Variable Rate [Domain] Credit Facility [Axis] Credit Facility [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Other Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Stock option exercise Stock Issued During Period, Value, Stock Options Exercised CASE CaseWesternReserveUniversityMember Total long-term liabilities Total long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities Statement of Comprehensive Income [Abstract] Revenues Revenues Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] International Non-US [Member] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Gross profit Gross Profit Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent NET LOSS PER SHARE Earnings Per Share [Text Block] Underwriting discounts and commissions on sale of stock PaymentsofStockIssuanceCostsUnderwritingDiscountsandCommissions Other expenses: Other Nonoperating Income (Expense) [Abstract] Class of Stock [Domain] Class of Stock [Domain] SUPPLEMENTAL DISCLOSURES Supplemental Cash Flow Elements [Abstract] Forfeited or expired (in shares) Class of Warrant or Right, Forfeited or Expired Class of Warrant or Right, Forfeited or Expired Plan Name [Axis] Plan Name [Axis] Restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Monthly interest and principal installments Debt Instrument, Periodic Payment Outstanding at January 1, 2018 (in shares) Outstanding at September 30. 2018 (in shares) Class of Warrant or Right, Outstanding Document And Entity Information [Abstract] Document And Entity Information [Abstract] Weighted-Average Remaining Contractual Terms (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Other current liabilities Other Liabilities, Current Equity Component [Domain] Equity Component [Domain] Maximum Maximum [Member] Related Party Transactions [Abstract] EX-101.PRE 10 kids-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 kids-20180930_htm.xml IDEA: XBRL DOCUMENT 0001425450 2018-01-01 2018-09-30 0001425450 us-gaap:NonUsMember 2017-12-31 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember 2018-09-30 0001425450 2018-06-30 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-06-30 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-06-30 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-06-30 0001425450 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001425450 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0001425450 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001425450 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001425450 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001425450 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001425450 country:US 2018-07-01 2018-09-30 0001425450 country:US 2017-07-01 2017-09-30 0001425450 us-gaap:NonUsMember 2018-07-01 2018-09-30 0001425450 us-gaap:NonUsMember 2017-07-01 2017-09-30 0001425450 kids:TraumaandDeformityMember 2018-07-01 2018-09-30 0001425450 kids:TraumaandDeformityMember 2017-07-01 2017-09-30 0001425450 kids:TraumaandDeformityMember 2018-01-01 2018-09-30 0001425450 2018-07-01 2018-09-30 0001425450 kids:TraumaandDeformityMember 2017-01-01 2017-09-30 0001425450 kids:SpineMember 2018-07-01 2018-09-30 0001425450 kids:SpineMember 2017-07-01 2017-09-30 0001425450 kids:SpineMember 2018-01-01 2018-09-30 0001425450 kids:SpineMember 2017-01-01 2017-09-30 0001425450 kids:SportsMedicineandOtherMember 2018-07-01 2018-09-30 0001425450 kids:SportsMedicineandOtherMember 2017-07-01 2017-09-30 0001425450 kids:SportsMedicineandOtherMember 2018-01-01 2018-09-30 0001425450 kids:SportsMedicineandOtherMember 2017-01-01 2017-09-30 0001425450 2017-07-01 2017-09-30 0001425450 us-gaap:AffiliatedEntityMember 2018-01-01 2018-09-30 0001425450 kids:FMIHansaMedicalProductsMember us-gaap:AffiliatedEntityMember 2018-07-01 2018-09-30 0001425450 kids:FMIHansaMedicalProductsMember us-gaap:AffiliatedEntityMember 2017-07-01 2017-09-30 0001425450 kids:FMIHansaMedicalProductsMember us-gaap:AffiliatedEntityMember 2018-01-01 2018-09-30 0001425450 kids:FMIHansaMedicalProductsMember us-gaap:AffiliatedEntityMember 2017-01-01 2017-09-30 0001425450 2018-01-01 2018-01-01 0001425450 us-gaap:MaximumMember 2018-01-01 2018-06-30 0001425450 2017-01-01 2017-09-30 0001425450 us-gaap:CommonStockMember 2017-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001425450 us-gaap:RetainedEarningsMember 2017-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001425450 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001425450 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001425450 us-gaap:CommonStockMember 2018-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001425450 us-gaap:RetainedEarningsMember 2018-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001425450 country:US 2018-01-01 2018-09-30 0001425450 country:US 2017-01-01 2017-09-30 0001425450 us-gaap:NonUsMember 2018-01-01 2018-09-30 0001425450 2018-10-29 0001425450 us-gaap:NonUsMember 2017-01-01 2017-09-30 0001425450 2016-12-31 0001425450 2017-09-30 0001425450 us-gaap:CommonStockMember us-gaap:IPOMember 2017-10-12 2017-10-12 0001425450 us-gaap:CommonStockMember us-gaap:IPOMember 2017-10-12 0001425450 us-gaap:SeriesBPreferredStockMember us-gaap:IPOMember 2017-10-12 2017-10-12 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001425450 us-gaap:MinimumMember 2018-01-01 2018-09-30 0001425450 us-gaap:MaximumMember 2018-01-01 2018-09-30 0001425450 kids:A2007EquityIncentivePlanMember 2018-09-30 0001425450 kids:New2017EquityIncentivePlanMember 2018-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001425450 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001425450 kids:A2007EquityIncentivePlanMember 2018-01-01 2018-09-30 0001425450 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2018-01-01 2018-06-30 0001425450 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2018-01-01 2018-06-30 0001425450 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2018-01-01 2018-06-30 0001425450 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2018-01-01 2018-06-30 0001425450 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2018-01-01 2018-06-30 0001425450 2018-09-30 0001425450 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2018-01-01 2018-06-30 0001425450 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-06-30 0001425450 us-gaap:OfficeEquipmentMember us-gaap:MinimumMember 2018-01-01 2018-06-30 0001425450 us-gaap:OfficeEquipmentMember us-gaap:MaximumMember 2018-01-01 2018-06-30 0001425450 us-gaap:TechnologyEquipmentMember 2018-01-01 2018-06-30 0001425450 kids:SampleInventoryMember 2018-01-01 2018-06-30 0001425450 2018-04-01 2018-06-30 0001425450 2017-04-01 2017-06-30 0001425450 2017-01-01 2017-06-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2018-09-30 0001425450 2017-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-30 0001425450 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-12-31 0001425450 us-gaap:MortgagesMember 2018-09-30 0001425450 us-gaap:MortgagesMember 2017-12-31 0001425450 us-gaap:NotesPayableOtherPayablesMember 2014-05-31 0001425450 us-gaap:NotesPayableOtherPayablesMember 2015-11-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-04-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-10-01 2017-10-31 0001425450 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-12-31 2017-12-31 0001425450 country:US 2018-09-30 0001425450 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-12-31 0001425450 us-gaap:MortgagesMember 2013-08-01 2013-08-31 0001425450 us-gaap:MortgagesMember 2013-08-31 0001425450 us-gaap:NotesPayableOtherPayablesMember 2018-07-01 2018-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-07-01 2017-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2018-01-01 2018-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2017-04-30 2017-04-30 0001425450 kids:CaseWesternReserveUniversityMember us-gaap:RoyaltyAgreementTermsMember 2007-12-01 2007-12-01 0001425450 kids:CaseWesternReserveUniversityMember us-gaap:RoyaltyAgreementTermsMember 2017-08-02 2017-08-02 0001425450 country:US 2017-12-31 0001425450 kids:CaseWesternReserveUniversityMember 2018-07-01 2018-09-30 0001425450 kids:CaseWesternReserveUniversityMember 2017-07-01 2017-09-30 0001425450 kids:CaseWesternReserveUniversityMember 2018-09-30 0001425450 kids:CaseWesternReserveUniversityMember 2017-12-31 0001425450 2017-01-01 2017-12-31 0001425450 us-gaap:RestrictedStockMember 2017-12-31 0001425450 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001425450 us-gaap:RestrictedStockMember 2018-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0001425450 us-gaap:NonUsMember 2018-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001425450 us-gaap:MinimumMember 2018-09-30 0001425450 us-gaap:MaximumMember 2018-09-30 0001425450 2018-01-01 2018-06-30 0001425450 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001425450 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001425450 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember 2017-10-12 0001425450 us-gaap:RedeemableConvertiblePreferredStockMember 2017-09-30 iso4217:USD shares kids:segment kids:supplier shares iso4217:USD pure ORTHOPEDIATRICS CORP Non-accelerated Filer 10-Q 2018 Q3 false 12811450 0001425450 --12-31 2018-09-30 131000 143000 0.00025 0.00025 50000000 50000000 12807520 12621781 12807520 12621781 P6M P25Y P30Y P5Y P7Y P3Y P5Y P3Y P5Y P7Y P5Y P2Y 0 0 0 0 0 0 0 0 0 P6M P3Y P3Y P10Y P10Y P10Y P10Y 0 0 0 P10Y 0 0 0 0 0 0 P10Y -1865000 -1537000 -9557000 -4087000 0 1484000 0 4364000 -1865000 -3021000 -9557000 -8451000 0 1 24463000 42582000 9456000 5603000 26646000 19498000 234000 1047000 1045000 831000 61844000 69561000 12774000 10391000 2000000 2089000 260000 260000 2260000 2349000 76878000 82301000 5903000 5495000 3302000 2905000 117000 113000 1594000 954000 10916000 9467000 21330000 21418000 3947000 3921000 25277000 25339000 36193000 34806000 2000 2000 153649000 150424000 -112623000 -103066000 -343000 135000 40685000 47495000 76878000 82301000 15820000 12375000 42991000 33939000 3843000 2884000 10825000 8321000 11977000 9491000 32166000 25618000 7150000 5633000 20005000 15122000 4877000 3487000 16393000 10282000 1122000 1127000 3455000 2482000 13149000 10247000 39853000 27886000 -1172000 -756000 -7687000 -2268000 -608000 -761000 -1722000 -1857000 -85000 -20000 -148000 38000 -693000 -781000 -1870000 -1819000 -1865000 -1537000 -9557000 -4087000 -1865000 -3021000 -9557000 -8451000 12624858 1773385 12417972 1754576 -0.15 -1.70 -0.77 -4.82 -1865000 -1537000 -9557000 -4087000 -100000 121000 -478000 193000 -100000 121000 -478000 193000 -1965000 -1416000 -10035000 -3894000 12621781 2000 150424000 -103066000 135000 47495000 -9557000 -9557000 -478000 -478000 11533 326000 326000 174206 2899000 2899000 12807520 2000 153649000 -112623000 -343000 40685000 -9557000 -4087000 2177000 1748000 2899000 1081000 4077000 1588000 6087000 3276000 -813000 -345000 214000 382000 408000 1559000 798000 513000 15000 -193000 -12855000 -3894000 195000 1337000 5311000 3949000 -5506000 -5286000 0 10139000 84000 80000 326000 0 0 250000 242000 9809000 -18119000 629000 42582000 1609000 24463000 2238000 1722000 1856000 0 4364000 1061000 1196000 BUSINESS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform | Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. In September 2018, we further expanded operations in Canada selling direct to local hospitals. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold 4,600,000 shares of common stock at a public offering price of $13.00 per share for aggregate gross proceeds of $59,800. We received approximately $46,900 in net proceeds after deducting $4,200 of underwriting discounts and commissions, paying approximately $2,700 of offering costs and paying approximately $6,000 of Series B dividends. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut. 4600000 13.00 59800000 46900000 4200000 2700000 6000000 SIGNIFICANT ACCOUNTING POLICIES<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD and OrthoPediatrics NZ Limited (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017, the condensed consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statement of stockholders’ equity for the nine months ended September 30, 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2017 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> Exchange Commission ("SEC") on March 15, 2018. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2017 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div><div style="padding-left:1pt;padding-right:1pt;"><span><br/></span></div><div style="padding-left:1pt;padding-right:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $112,623 and $103,066 as of September 30, 2018 and December 31, 2017, respectively. Effective December 31, 2017, we entered into an amended loan agreement with Squadron to consolidate a majority of our term note into a $20,000 term loan, reestablished a $15,000 revolving credit facility, changed the interest rate and extended the loan period through January 31, 2023. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance at September 30, 2018, expected cash flows from operations for the next twelve months subsequent to the issuance of the condensed consolidated financial statements and the availability under the revolving credit facility are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months subsequent to the issuance of the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Preparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We currently bill our international distributors in United States ("U.S.") dollars, resulting in minimal foreign exchange transaction expense. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Beginning in the second quarter of 2017, we began selling direct within the United Kingdom, Ireland, Australia and New Zealand and billing using the local currency for each country. In September 2018, we began selling direct in Canada. The financial statements of our foreign subsidiaries are accounted for and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the condensed consolidated statements of comprehensive loss. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels:</span></div><div><span><br/></span></div><div style="text-indent:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt;"><span><br/></span></div><div style="padding-left:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt;"><span><br/></span></div><div style="padding-left:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as, discounted cash flows, and are based on the best information available, including our own data.    </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We do not have any assets or liabilities that are measured on a recurring basis under the presented fair value hierarchy. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue from Contracts with Customers</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The Company adopted ASC 606, "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Revenue From Contracts With Customers </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">(ASC 606)", on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have any impact on the Company’s consolidated historical financial statements. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of "ASC 605, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Revenue Recognition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> (ASC 605)." In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Outside of the United States, we primarily sell our products through independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on our history of collections and returns from international customers, we have concluded that collectability is not reasonably assured at the time of delivery for certain customers who have not evidenced a consistent pattern of timely payment. Accordingly, we do not recognize international revenue and associated cost of revenue at the time title transfers for these customers for whom collectibility has not been deemed probable based on the customer’s history and ability to pay, but rather when cash has been received. Until such payment, cost of revenue is recorded as inventories held by international distributors, net of adjustment for estimated unreturnable inventory, on our condensed consolidated balance sheets. </span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">For international independent stocking distributors for whom we have determined collectability is probable, based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In early 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Additionally, in September 2018 we began selling in Canada utilizing the subject agency model. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract.. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheet for cash are valued at cost, which approximates fair value. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventories, net </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods and are purchased from third parties. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand and Canada are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Depreciable lives are generally as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Building and building improvements </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25 to 30 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 to 5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Business software </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Office and other equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Sample inventory </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2 years </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Amortizable intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">include fees necessary to secure various patents and licenses. Amortization is calculated on a straight-line basis over the estimated useful life of the patents and licenses. Amortization for patents and licenses commences at the time of patent approval and market launch, respectively. Intangible assets are amortized over a 3 to 20 year period. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Amortizable intangible assets are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We have indefinite lived tradename assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Revenue</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales and Marketing Expenses</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Advertising Costs </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Research and development costs were $1,122 and $1,127 for the three months ended September 30, 2018 and 2017, respectively, and $3,455 and $2,482 for the nine months ended September 30, 2018 and 2017, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Prior to our IPO, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,789,647 shares for award. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Restricted stock may not be transferred prior to the expiration of the restricted period. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally last until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzNmZhN2Q3MjdhZDQ1ODViNTY5ZjljNDg3NjYwOWU1L3NlYzplMzZmYTdkNzI3YWQ0NTg1YjU2OWY5YzQ4NzY2MDllNV8xOTIvZnJhZzo0NmI5OGJlZDJhYmU0YzJjOTJlODBhYjQ3YzJjOGE1YS90ZXh0cmVnaW9uOjQ2Yjk4YmVkMmFiZTRjMmM5MmU4MGFiNDdjMmM4YTVhXzE5NjI3_10b9fa93-d410-41e2-996e-5d9a599c5391">six</span> months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We estimate the fair value of stock options and restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the vesting period for stock options and the restriction period for restricted stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Calculating the fair value of stock-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock options. Use of the valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options and the risk free rate of return for a period that approximates the expected term of our stock options. Because we were a privately-held company with a limited operating history, we utilized the historical stock price volatility from a representative group of comparable industry competitors to estimate expected stock price volatility. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Prior to the IPO, in determining the fair value of our common stock at the grant date, which is the basis for the fair value of stock based awards, we used the market approach, which was based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. In using the market approach, we consider both the guideline public company method and the precedent transaction method. Given the absence of a public trading market for our common stock prior to our IPO, we exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: the preferences and dividends of our redeemable convertible preferred stock relative to those of our common stock; our operating results and financial conditions, including our level of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. Prior to our IPO, for restricted stock awards we applied a discount for lack of marketability to the fair value of common stock to estimate the impact of valuing a minority interest in our Company as a closely held, non-public company with no liquid market for its shares. Following the IPO, we value restricted stock awards using the market value on the grant date.   </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 and our disclosure obligations regarding executive compensation may be reduced. We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering, or December 31, 2022. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Following the recent SEC amendment raising the financial thresholds for a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we qualify as a smaller reporting company effective with the filing of this quarterly report. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” on the recognition of revenue for all contracts with customers designed to improve comparability and enhance financial statement disclosures. The underlying principle of this comprehensive model is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the payment to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These standards became effective for us on January 1, 2018. We elected to apply the modified retrospective approach, and we have not identified any accounting changes that would materially impact the amount of reported revenues and did not record any adjustments on January 1, 2018, related to this new guidance. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In February 2016, the FASB issued ASU 2016-02 “</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Leases,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">” which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new standard requires lessees to</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB issued ASU No. 2018-11 "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842): Targeted Improvements,"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> which provides an alternative modified retrospective transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is reocognized on the date of adoption.  The new standard will be effective starting in the first quarter of 2019. Early adoption is permitted. We are currently evaluating the impact of this standard, but we do not believe this guidance will have a material effect on our financial position, results of operations or cash flows. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In August 2016, the FASB issued ASU No. 2016-15 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">“Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> which provides guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted ASU 2016-15 effective January 1, 2018. The adoption did not have any impact on our consolidated financial position, results of operations and cash flows. </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In March 2018, the FASB issued ASU 2018-05 "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118”), to state the income tax accounting implications of the Tax Cuts and Jobs Act (“New Tax Act”)"</span> which clarifies the measurement period time frame, changes in subsequent reporting periods and reporting requirements as a result of the New Tax Act of 2017. In accordance with SAB No. 118, a company must reflect the income tax effects of those aspects of the New Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the New Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the New Tax Act. SAB No. 118 provides a measurement period that should not extend beyond one year and it begins in the period that includes the enactment date which was December 22, 2017. We have not completed the accounting for the income tax effects of certain elements of the New Tax Act. When additional guidance and regulations enable us to finalize certain tax positions, we will reflect the impact of this ASU 2018-05 on the tax provision and deferred tax calculation as of December 31, 2018. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD and OrthoPediatrics NZ Limited (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017, the condensed consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statement of stockholders’ equity for the nine months ended September 30, 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2017 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> Exchange Commission ("SEC") on March 15, 2018. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2017 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div>The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. -112623000 -103066000 20000000 15000000 Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We currently bill our international distributors in United States ("U.S.") dollars, resulting in minimal foreign exchange transaction expense. </span></div>Beginning in the second quarter of 2017, we began selling direct within the United Kingdom, Ireland, Australia and New Zealand and billing using the local currency for each country. In September 2018, we began selling direct in Canada. The financial statements of our foreign subsidiaries are accounted for and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the condensed consolidated statements of comprehensive loss. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels:</span></div><div><span><br/></span></div><div style="text-indent:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt;"><span><br/></span></div><div style="padding-left:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt;"><span><br/></span></div><div style="padding-left:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as, discounted cash flows, and are based on the best information available, including our own data.    </span></div>We do not have any assets or liabilities that are measured on a recurring basis under the presented fair value hierarchy. <div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue from Contracts with Customers</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The Company adopted ASC 606, "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Revenue From Contracts With Customers </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">(ASC 606)", on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have any impact on the Company’s consolidated historical financial statements. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of "ASC 605, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Revenue Recognition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> (ASC 605)." In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Outside of the United States, we primarily sell our products through independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on our history of collections and returns from international customers, we have concluded that collectability is not reasonably assured at the time of delivery for certain customers who have not evidenced a consistent pattern of timely payment. Accordingly, we do not recognize international revenue and associated cost of revenue at the time title transfers for these customers for whom collectibility has not been deemed probable based on the customer’s history and ability to pay, but rather when cash has been received. Until such payment, cost of revenue is recorded as inventories held by international distributors, net of adjustment for estimated unreturnable inventory, on our condensed consolidated balance sheets. </span></div>For international independent stocking distributors for whom we have determined collectability is probable, based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. In early 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Additionally, in September 2018 we began selling in Canada utilizing the subject agency model. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract.. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts. Cash and Cash EquivalentsWe maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheet for cash are valued at cost, which approximates fair value. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div>The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventories, net </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods and are purchased from third parties. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div>In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand and Canada are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Depreciable lives are generally as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Building and building improvements </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25 to 30 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 to 5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Business software </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Office and other equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Sample inventory </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2 years </span></td></tr></table></div> Sample inventory is carried at cost less accumulated depreciation. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Depreciable lives are generally as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Building and building improvements </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25 to 30 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 to 5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Business software </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Office and other equipment </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 to 7 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Instruments </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Sample inventory </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2 years </span></td></tr></table></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Amortizable intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">include fees necessary to secure various patents and licenses. Amortization is calculated on a straight-line basis over the estimated useful life of the patents and licenses. Amortization for patents and licenses commences at the time of patent approval and market launch, respectively. Intangible assets are amortized over a 3 to 20 year period. </span></div>Amortizable intangible assets are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. P3Y P20Y 0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We have indefinite lived tradename assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is</span></div> measured by the amount by which the carrying amount exceeds the fair market value of the assets. 0 Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense. 1122000 1127000 3455000 2482000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Prior to our IPO, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,789,647 shares for award. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Restricted stock may not be transferred prior to the expiration of the restricted period. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally last until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzNmZhN2Q3MjdhZDQ1ODViNTY5ZjljNDg3NjYwOWU1L3NlYzplMzZmYTdkNzI3YWQ0NTg1YjU2OWY5YzQ4NzY2MDllNV8xOTIvZnJhZzo0NmI5OGJlZDJhYmU0YzJjOTJlODBhYjQ3YzJjOGE1YS90ZXh0cmVnaW9uOjQ2Yjk4YmVkMmFiZTRjMmM5MmU4MGFiNDdjMmM4YTVhXzE5NjI3_10b9fa93-d410-41e2-996e-5d9a599c5391">six</span> months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We estimate the fair value of stock options and restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the vesting period for stock options and the restriction period for restricted stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Calculating the fair value of stock-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock options. Use of the valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options and the risk free rate of return for a period that approximates the expected term of our stock options. Because we were a privately-held company with a limited operating history, we utilized the historical stock price volatility from a representative group of comparable industry competitors to estimate expected stock price volatility. </span></div>Prior to the IPO, in determining the fair value of our common stock at the grant date, which is the basis for the fair value of stock based awards, we used the market approach, which was based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. In using the market approach, we consider both the guideline public company method and the precedent transaction method. Given the absence of a public trading market for our common stock prior to our IPO, we exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: the preferences and dividends of our redeemable convertible preferred stock relative to those of our common stock; our operating results and financial conditions, including our level of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. Prior to our IPO, for restricted stock awards we applied a discount for lack of marketability to the fair value of common stock to estimate the impact of valuing a minority interest in our Company as a closely held, non-public company with no liquid market for its shares. Following the IPO, we value restricted stock awards using the market value on the grant date. 1585000 1789647 P3Y 0 P6Y Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance. </span></div>We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 and our disclosure obligations regarding executive compensation may be reduced. We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering, or December 31, 2022. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Following the recent SEC amendment raising the financial thresholds for a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we qualify as a smaller reporting company effective with the filing of this quarterly report. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us. </span></div>Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” on the recognition of revenue for all contracts with customers designed to improve comparability and enhance financial statement disclosures. The underlying principle of this comprehensive model is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the payment to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These standards became effective for us on January 1, 2018. We elected to apply the modified retrospective approach, and we have not identified any accounting changes that would materially impact the amount of reported revenues and did not record any adjustments on January 1, 2018, related to this new guidance. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In February 2016, the FASB issued ASU 2016-02 “</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Leases,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">” which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new standard requires lessees to</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB issued ASU No. 2018-11 "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842): Targeted Improvements,"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> which provides an alternative modified retrospective transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is reocognized on the date of adoption.  The new standard will be effective starting in the first quarter of 2019. Early adoption is permitted. We are currently evaluating the impact of this standard, but we do not believe this guidance will have a material effect on our financial position, results of operations or cash flows. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In August 2016, the FASB issued ASU No. 2016-15 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">“Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> which provides guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted ASU 2016-15 effective January 1, 2018. The adoption did not have any impact on our consolidated financial position, results of operations and cash flows. </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In March 2018, the FASB issued ASU 2018-05 "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118”), to state the income tax accounting implications of the Tax Cuts and Jobs Act (“New Tax Act”)"</span> which clarifies the measurement period time frame, changes in subsequent reporting periods and reporting requirements as a result of the New Tax Act of 2017. In accordance with SAB No. 118, a company must reflect the income tax effects of those aspects of the New Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the New Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the New Tax Act. SAB No. 118 provides a measurement period that should not extend beyond one year and it begins in the period that includes the enactment date which was December 22, 2017. We have not completed the accounting for the income tax effects of certain elements of the New Tax Act. When additional guidance and regulations enable us to finalize certain tax positions, we will reflect the impact of this ASU 2018-05 on the tax provision and deferred tax calculation as of December 31, 2018. DEBT AND CREDIT ARRANGEMENTS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Long-term debt consisted of the following: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"/><td style="width:57.069021%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.064205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.064205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Note payable to Squadron </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving credit facility with Squadron </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,947 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,921 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage payable to affiliate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,447 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,394 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,452 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current maturities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">117 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">113 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of current maturities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,277 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,339 </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In May 2014, we entered into the Second Amended and Restated Loan and Security Agreement with Squadron in connection with a restructuring of our debt and equity. The terms of this agreement required monthly interest only payments computed at 10% per annum with all principal and unpaid interest due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement. The note payable was secured by substantially all of our assets. In November 2015, this agreement was amended to provide a revolving loan commitment of an additional $7,000. The revolving loan commitment was structured under the same terms and conditions with interest payable monthly computed at 10% per</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> annum and principal due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In April 2017, we entered into the Third Amended and Restated Loan and Security Agreement with Squadron to provide an additional $16,000 revolving loan commitment and extend the maturity date on the note payable and revolving credit facility to May 31, 2019 with an automatic extension to May 31, 2020 if we meet certain revenue goals. The agreement was structured similarly to previous amendments with interest payable monthly computed at 11.0% per annum and included a $1,000 extension fee payable in three installments on the anniversary date of the agreement. The extension fee was recorded in full upon closing as a deferred financing cost within long-term debt with affiliate, net of current portion, and was to be recognized ratably over the term of the agreement as deferred financing charges within interest expense on the consolidated statements of operations assuming an IPO did not happen.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Effective December 31, 2017, we entered into a Fourth Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Squadron. Pursuant to the Loan Agreement, we have consolidated a majority of the term loan amounts into a $20,000 term note and reestablished a $15,000 revolving credit facility. Also, $667 of the extension fee was cancelled as of the completion of our IPO in October 2017. Both facilities include interest only payments and will have an interest rate equal to the greater of (a) three month LIBOR plus 8.61%, or (b) 10.0%. The Loan Agreement also extended the maturity date to January 31, 2023. Borrowings under the Loan Agreement are secured by substantially all of our assets and are unconditionally guaranteed by each of our subsidiaries. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The fair value of our note payable to Squadron was estimated based on prices for the same or similar issues and the current interest rates offered for the debt of the same remaining maturities, which are considered level 2 inputs in accordance with ASC Topic 820, “</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">.” At September 30, 2018, the fair value approximated the carrying value. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At December 31, 2017, the mortgage balance was $1,531 of which current principal due of $113 was included in current portion of long-term debt. At September 30, 2018, the mortgage balance was $1,447 of which current principal due of $117 was included in current portion of long-term debt.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Interest expense relating to notes payable to Squadron and Tawani was $608 and $761 for the three months ended September 30, 2018 and 2017, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span>and $1,722 and $1,857 for the nine months ended September 30, 2018 and 2017, respectively. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Long-term debt consisted of the following: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"/><td style="width:57.069021%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.064205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.064205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Note payable to Squadron </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving credit facility with Squadron </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,947 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,921 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage payable to affiliate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,447 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,394 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,452 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current maturities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">117 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">113 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of current maturities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,277 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">25,339 </span></td></tr></table></div> 20000000 20000000 3947000 3921000 1447000 1531000 25394000 25452000 117000 113000 25277000 25339000 0.10 7000000 0.10 16000000 0.110 1000000 20000000 15000000 667000 0.0861 0.100 16000 0.05 1531000 113000 1447000 117000 608000 761000 1722000 1857000 STRATEGIC ARRANGEMENTS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Effective December 1, 2007, we entered into a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzNmZhN2Q3MjdhZDQ1ODViNTY5ZjljNDg3NjYwOWU1L3NlYzplMzZmYTdkNzI3YWQ0NTg1YjU2OWY5YzQ4NzY2MDllNV8yNDUvZnJhZzpmM2ViODdiYzA3ZDY0NmE5YjJjYTI2YTEyOTc5OGM3Yy90ZXh0cmVnaW9uOmYzZWI4N2JjMDdkNjQ2YTliMmNhMjZhMTI5Nzk4YzdjXzg1_39aef9a7-2bc6-435d-985b-6a1b689f6d40">ten</span>-year agreement with Case Western Reserve University (“CASE”) to assist in certain aspects of our research and development. Effective August 2, 2017, we entered into an Amended and Restated License Agreement to account for additional licensed product and extend the agreement for another <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzNmZhN2Q3MjdhZDQ1ODViNTY5ZjljNDg3NjYwOWU1L3NlYzplMzZmYTdkNzI3YWQ0NTg1YjU2OWY5YzQ4NzY2MDllNV8yNDUvZnJhZzpmM2ViODdiYzA3ZDY0NmE5YjJjYTI2YTEyOTc5OGM3Yy90ZXh0cmVnaW9uOmYzZWI4N2JjMDdkNjQ2YTliMmNhMjZhMTI5Nzk4YzdjXzM3NQ_37d2b38b-d8fd-4cc2-818a-f4386aef8c0a">ten</span> years. The main focus of this research and development involves leveraging our exclusive rights to the Hamann-Todd Collection of the Cleveland National History Museum, the world's largest pediatric osteological collection, to assist in the design of implants which match pediatric bone curvature and structure.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In exchange for services, CASE receives certain royalties and up-front fees. The royalties and certain fees are contingent upon our obtaining FDA approval and the launch of our products into the marketplace. CASE receives a minimum annual royalty of $10 or a royalty of 3% of net sales on products, whichever is</span></div> greater. Additionally, for each new product developed, CASE will receive milestone payments of $5 for FDA approval to sell our products within the United States and $10 for general product launch. Additionally, CASE receives a royalty of 3% of net sales on products fully developed and being sold in the marketplace.<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The royalty expense recognized related to the CASE agreement is recorded as a component of cost of revenue and was $37 and $38 for the three months ended September 30, 2018 and 2017, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span>and $108 and $111 for the nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018 and December 31, 2017, $37 and $37, respectively, was due to CASE. 10000 0.03 5000 10000 0.03 37000 38000 108000 111000 37000 37000 INCOME TAXES <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">For the three and nine month periods ended September 30, 2018 and 2017, we calculated the provision of income taxes by applying an estimate of the annual effective tax rate for the full fiscal year to the ordinary loss for the reporting period resulting in a zero tax provision consistent with prior periods. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The deferred tax assets were fully offset by a valuation allowance at September 30, 2018 and December 31, 2017, and no income tax benefit has been recognized in our condensed consolidated statements of operations for any of the periods presented. At December 31, 2017, we had available federal and state tax loss carryforwards of $70,335 and tax credits for federal and state tax purposes of $335 which begin to expire in 2028. Any losses incurred in 2018 and beyond do not expire. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $16,200 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062, which is increased by $2,302 over the first five years as a result of an unrealized built in gain. The Section 382 ownership change analysis will be re–evaluated prior to release of the year-ending December 31, 2018 financial statements to account for equity ownership changes that occur during 2018.</span></div>Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2017 and through September 30, 2018. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. 0 0 70335000 335000 16200000 1062000 2302000 STOCKHOLDERS’ EQUITY<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our stock option activity and related information are summarized as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:42.212219%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.845659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.845659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.684887%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Terms </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Options </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(in Years) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">176,959 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29.42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,533)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29.29 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,652)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">114,774 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">30.33 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Options generally include a time-based vesting schedule permitting the options to vest ratably over no years. At September 30, 2018 and December 31, 2017, all options were fully vested. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">There was no stock-based compensation expense on stock options for the three and nine month periods ended September 30, 2018 and 2017, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our restricted stock activity and related information are summarized as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:56.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.032051%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.032051%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Terms </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(in Years) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">548,005 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">175,541 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,335)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(547,670)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock exercisable at September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">At September 30, 2018, there was $2,951 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 2.4 years or earlier upon an elimination of the restriction period as a result of a change in control event. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Stock-based compensation expense on restricted stock amounted to $267 and $354 for the three months ended September 30, 2018 and 2017, respectively, and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively. Due to our limited operating history and lack of marketability before the IPO, a discount of 15% was applied when estimating the stock-based compensation expense on restricted stock granted in 2017. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Total stock-based compensation expense is included as a component of general and administrative expenses in our condensed consolidated statement of operations and was $267 and $354 for the three months ended September 30, 2018 and 2017, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Warrants</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our warrant activity and related information are summarized as follows: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.198718%;"><tr><td style="width:1.0%;"/><td style="width:54.058158%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607754%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.163166%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607754%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.163166%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">44,101 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.03 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,535)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">26.55 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.69 </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">For all periods presented, the warrants were issued at exercise prices ranging from $26.27 to $30.97 per share. The warrants generally have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzNmZhN2Q3MjdhZDQ1ODViNTY5ZjljNDg3NjYwOWU1L3NlYzplMzZmYTdkNzI3YWQ0NTg1YjU2OWY5YzQ4NzY2MDllNV8yOTcvZnJhZzoyZTA5YmRiYWI2Mzg0ZGYzOWRlNTg2NGUyOGM1NGU2MC90ZXh0cmVnaW9uOjJlMDliZGJhYjYzODRkZjM5ZGU1ODY0ZTI4YzU0ZTYwXzU0OTc1NTgxNDE2MzQ_41009a8d-a699-478a-9d83-8a998cd107c3">ten</span>-year term. At September 30, 2018, no warrants had been exercised. At inception, no fair value was assigned to the warrants.</span></div> 0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our stock option activity and related information are summarized as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:42.212219%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.845659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.845659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.684887%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Terms </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Options </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(in Years) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">176,959 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29.42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,533)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29.29 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,652)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">114,774 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">30.33 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td></tr></table></div> 176959 29.42 P2Y 11533 29.29 50652 27.61 114774 30.33 P2Y1M6D <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our restricted stock activity and related information are summarized as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:56.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.032051%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.032051%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Terms </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(in Years) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">548,005 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">175,541 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,335)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(547,670)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock exercisable at September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr></table></div> 548005 P0Y3M18D 175541 1335 547670 174541 P2Y4M24D 0 2951000 P2Y4M24D 267000 354000 2899000 1081000 0.15 267000 354000 2899000 1081000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our warrant activity and related information are summarized as follows: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.198718%;"><tr><td style="width:1.0%;"/><td style="width:54.058158%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607754%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.163166%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607754%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.163166%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">44,101 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.03 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,535)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">26.55 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">27.69 </span></td></tr></table></div> 44101 27.03 25535 26.55 18566 27.69 26.27 30.97 0 NET LOSS PER SHARE<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The following is a reconciliation of basic and diluted net loss per share attributable to common stockholders:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:54.752412%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.967846%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,865)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,537)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,557)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,087)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of cumulative dividends of redeemable preferred stock to redemption value </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,484)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,364)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders - basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,865)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,021)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,557)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,451)</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares - basic and diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,624,858 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,773,385 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,417,972 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,754,576 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share attributable to common stockholders - basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.15)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.70)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.77)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.82)</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Prior to the completion of our IPO on October 12, 2017, we had authorized 7,000,000 shares of redeemable convertible preferred stock, of which 3,649,475 were outstanding as of September 30, 2017, designated in series, with the rights and preferences of each series determined by the Board of Directors. Upon completion of our IPO, all of our previously outstanding shares of Series A and B Preferred Stock were converted into common stock on a 1:1 conversion ratio. As of September 30, 2018 and December 31, 2017, there are no redeemable convertible preferred shares outstanding. Series A and B preferred stock include rights to participate in dividends and distributions to common stockholders on an if-converted basis, and accordingly are also considered participating securities.  During periods of undistributed losses however, no effect is given to our participating securities since they are not contractually obligated to share in the losses.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We have incurred a net loss for all periods presented, such that diluted net loss per common stock is the same as basic net loss per common stock. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented (shares for the redeemable convertible preferred shares for the nine months ended September 30, 2017 were determined based on the applicable conversion ratio of 1:1):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:42.230769%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:25.564103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:25.564103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock - Series A </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">670,000 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock - Series B </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2,979,475 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">174,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">704,770 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">114,774 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">177,763 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">44,101 </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">307,881 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">4,576,109 </span></td></tr></table></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">The following is a reconciliation of basic and diluted net loss per share attributable to common stockholders:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:54.752412%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.967846%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.289389%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,865)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,537)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,557)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,087)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of cumulative dividends of redeemable preferred stock to redemption value </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,484)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,364)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders - basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,865)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,021)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,557)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,451)</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares - basic and diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,624,858 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,773,385 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,417,972 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">1,754,576 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share attributable to common stockholders - basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.15)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.70)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.77)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.82)</span></td></tr></table></div> -1865000 -1537000 -9557000 -4087000 0 1484000 0 4364000 -1865000 -3021000 -9557000 -8451000 12624858 1773385 12417972 1754576 -0.15 -1.70 -0.77 -4.82 7000000 3649475 1 0 The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented (shares for the redeemable convertible preferred shares for the nine months ended September 30, 2017 were determined based on the applicable conversion ratio of 1:1):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:42.230769%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:25.564103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:25.564103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock - Series A </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">670,000 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock - Series B </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2,979,475 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">174,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">704,770 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">114,774 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">177,763 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">18,566 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">44,101 </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">307,881 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">4,576,109 </span></td></tr></table> 0 670000 0 2979475 174541 704770 114774 177763 18566 44101 307881 4576109 BUSINESS SEGMENT <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We disaggregate revenue from contracts with customers by operating segment. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three and nine months ended September 30, 2018 or 2017. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2018 and December 31, 2017. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Product sales by source were as follows: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:37.710611%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Product sales by geographic location: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,421 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">9,556 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">32,532 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">26,085 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">International </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,399 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2,819 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">10,459 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">7,854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">15,820 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,375 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">42,991 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">33,939 </span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:37.710611%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Product sales by category: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Trauma and deformity </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">10,562 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">8,730 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29,545 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">24,339 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Scoliosis </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5,027 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,299 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,609 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">8,652 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Sports medicine/other </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">231 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">346 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">837 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">948 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">15,820 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,375 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">42,991 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">33,939 </span></td></tr></table></div>No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2018 and 2017. 1 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Product sales by source were as follows: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:37.710611%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Product sales by geographic location: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,421 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">9,556 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">32,532 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">26,085 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">International </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,399 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2,819 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">10,459 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">7,854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">15,820 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,375 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">42,991 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">33,939 </span></td></tr></table></div> 12421000 9556000 32532000 26085000 3399000 2819000 10459000 7854000 15820000 12375000 42991000 33939000 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679487%;"><tr><td style="width:1.0%;"/><td style="width:37.710611%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603859%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.469453%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Product sales by category: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Trauma and deformity </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">10,562 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">8,730 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">29,545 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">24,339 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Scoliosis </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">5,027 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">3,299 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,609 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">8,652 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Sports medicine/other </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">231 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">346 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">837 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">948 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">15,820 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">12,375 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">42,991 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">33,939 </span></td></tr></table> 10562000 8730000 29545000 24339000 5027000 3299000 12609000 8652000 231000 346000 837000 948000 15820000 12375000 42991000 33939000 RELATED PARTY TRANSACTIONSIn addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 3), we currently use FMI Hansa Medical Products, LLC (“FMI”) and Structure Medical, LLC (“Structure Medical”) as two of our suppliers. Each of these entities is affiliated with Squadron. In 2017, FMI merged with and into Structure Medical. We do not have long-term contracts with either supplier. We made aggregate payments to Structure and FMI of $738 and $757 for the three months ended September 30, 2018 and 2017, respectively, and $3,004 and $1,862 for the nine months ended September 30, 2018 and 2017, respectively. 2 738000 757000 3004000 1862000 EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. Effective January 1, 2018, we have elected to match our employees' 401(k) contributions up to 3% of employees' salary. 0.03 COMMITMENTS AND CONTINGENCIES<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:115%;">We are involved with various legal actions arising in the ordinary course of our activities. We accrue for those cases where the potential liability is estimable and probable. From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. On January 20, 2017, K2M, Inc. filed suit against us in the United States District Court for the District of Delaware (K2M, Inc. v. OrthoPediatrics Corp. et al., Case No. 1:17-cv-0061) seeking unspecified damages for alleged infringement of U.S. Patent No. 9,532,816. The complaint was amended on August 21, 2017 to add, among other things, a claim of patent infringement regarding U.S. Patent No. 9,655,664. These patents relate to certain instruments used in our RESPONSE spine systems, which represent a portion of our total scoliosis portfolio. We have denied these claims and responded with counterclaims seeking declaratory relief that the patents in question are both invalid and not infringed. The parties attended a court-ordered mediation on October 24, 2017, which did not resolve the dispute, but as we move forward with this matter we welcome constructive discussions on a negotiated settlement. Nevertheless, we view our case as particularly strong and will continue to vigorously defend this matter. On January 8 and 22, 2018, we filed our first and second petitions for inter partes review ("IPR") with the United States Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB") to challenge the patentability of U.S. Patent No. 9,532,816 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-00429 and IPR2018-00521). On June 28, 2018, the PTAB instituted the subject IPRs and set a trial date of February 20, 2019 for both IPRs. Additionally, the parties have agreed to stay the above-referenced district court proceedings pending the outcome of the subject IPR proceedings. The Court ordered the stay on July 10, 2018. Moreover, on August 21, 2018, we filed three petitions with PTAB to challenge the patentability of the above-referenced U.S. Patent No. 9,655,664 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-01546, IPR2018-01547, and IPR2018-01548). Although we believe that the K2M lawsuit is without merit and we will vigorously defend the claims asserted against us, intellectual property litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">As of September 30, 2018, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. Additionally, we have minimum royalty commitments of $500 annually through 2026. </span></div>We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2018, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results. 0.005 0.20 500000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Oct. 29, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name ORTHOPEDIATRICS CORP  
Entity Central Index Key 0001425450  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   12,811,450
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash $ 24,463 $ 42,582
Accounts receivable - trade, less allowance for doubtful accounts of $131 and $143, respectively 9,456 5,603
Prepaid expenses and other current assets 1,045 831
Total current assets 61,844 69,561
Property and equipment, net 12,774 10,391
Other assets:    
Amortizable intangible assets, net 2,000 2,089
Other intangible assets 260 260
Total other assets 2,260 2,349
Total assets 76,878 82,301
Current liabilities:    
Accounts payable - trade 5,903 5,495
Accrued compensation and benefits 3,302 2,905
Current portion of long-term debt with affiliate 117 113
Other current liabilities 1,594 954
Total current liabilities 10,916 9,467
Long-term liabilities:    
Long-term debt with affiliate, net of current portion 21,330 21,418
Revolving credit facility with affiliate 3,947 3,921
Total long-term liabilities 25,277 25,339
Total liabilities 36,193 34,806
Commitments and contingencies (Note 11)
Stockholders' equity:    
Common stock, $0.00025 par value; 50,000,000 shares authorized; 12,807,520 shares and 12,621,781 shares issued and outstanding as of September 30, 2018 and December 31, 2017 2 2
Additional paid-in capital 153,649 150,424
Accumulated deficit (112,623) (103,066)
Accumulated other comprehensive (loss) income (343) 135
Total stockholders' equity 40,685 47,495
Total liabilities and stockholders' equity 76,878 82,301
U.S.    
Current assets:    
Inventories 26,646 19,498
International    
Current assets:    
Inventories $ 234 $ 1,047
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 131 $ 143
Common stock, par value (in dollars per share) $ 0.00025 $ 0.00025
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,807,520 12,621,781
Common stock, shares outstanding 12,807,520 12,621,781
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Net revenue $ 15,820 $ 12,375 $ 42,991 $ 33,939
Cost of revenue 3,843 2,884 10,825 8,321
Gross profit 11,977 9,491 32,166 25,618
Operating expenses:        
Sales and marketing 7,150 5,633 20,005 15,122
General and administrative 4,877 3,487 16,393 10,282
Research and development 1,122 1,127 3,455 2,482
Total operating expenses 13,149 10,247 39,853 27,886
Operating loss (1,172) (756) (7,687) (2,268)
Other expenses:        
Interest expense, net 608 761 1,722 1,857
Other expense (income) 85 20 148 (38)
Total other expenses 693 781 1,870 1,819
Net loss (1,865) (1,537) (9,557) (4,087)
Net loss attributable to common stockholders $ (1,865) $ (3,021) $ (9,557) $ (8,451)
Weighted average common shares - basic and diluted (in shares) 12,624,858 1,773,385 12,417,972 1,754,576
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) $ (0.15) $ (1.70) $ (0.77) $ (4.82)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net loss $ (1,865) $ (1,537) $ (9,557) $ (4,087)
Other comprehensive (loss) income:        
Foreign currency translation adjustment (100) 121 (478) 193
Other comprehensive (loss) income (100) 121 (478) 193
Comprehensive loss $ (1,965) $ (1,416) $ (10,035) $ (3,894)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Balance (in shares) at Dec. 31, 2017 12,621,781 12,621,781      
Balance at Dec. 31, 2017 $ 47,495 $ 2 $ 150,424 $ (103,066) $ 135
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (9,557)     (9,557)  
Other comprehensive loss $ (478)       (478)
Stock option exercise (in shares) 11,533 11,533      
Stock option exercise $ 326   326    
Restricted stock (in shares)   174,206      
Restricted stock $ 2,899   2,899    
Balance (in shares) at Sep. 30, 2018 12,807,520 12,807,520      
Balance at Sep. 30, 2018 $ 40,685 $ 2 $ 153,649 $ (112,623) $ (343)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
OPERATING ACTIVITIES    
Net loss $ (9,557) $ (4,087)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,177 1,748
Stock-based compensation 2,899 1,081
Changes in certain current assets and liabilities:    
Accounts receivable - trade (4,077) (1,588)
Prepaid expenses and other current assets (214) (382)
Accounts payable - trade 408 1,559
Accrued expenses and other liabilities 798 513
Other (15) 193
Net cash used in operating activities (12,855) (3,894)
INVESTING ACTIVITIES    
Purchases of licenses (195) (1,337)
Purchases of property and equipment (5,311) (3,949)
Net cash used in investing activities (5,506) (5,286)
FINANCING ACTIVITIES    
Proceeds from issuance of debt with affiliate 0 10,139
Payments on mortgage notes (84) (80)
Proceeds from exercise of stock options 326 0
Payments of deferred offering costs 0 (250)
Net cash (used in) provided by financing activities 242 9,809
NET (DECREASE) INCREASE IN CASH (18,119) 629
Cash, beginning of year 42,582 1,609
Cash, end of period 24,463 2,238
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 1,722 1,856
Accretion of redeemable convertible preferred stock 0 4,364
Transfer of instruments from property and equipment to inventory 1,061 1,196
U.S.    
Changes in certain current assets and liabilities:    
Inventories (6,087) (3,276)
International    
Changes in certain current assets and liabilities:    
Inventories $ 813 $ 345
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform | Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. In September 2018, we further expanded operations in Canada selling direct to local hospitals.

On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold 4,600,000 shares of common stock at a public offering price of $13.00 per share for aggregate gross proceeds of $59,800. We received approximately $46,900 in net proceeds after deducting $4,200 of underwriting discounts and commissions, paying approximately $2,700 of offering costs and paying approximately $6,000 of Series B dividends.
Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD and OrthoPediatrics NZ Limited (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017, the condensed consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statement of stockholders’ equity for the nine months ended September 30, 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2017 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and
Exchange Commission ("SEC") on March 15, 2018. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2017 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $112,623 and $103,066 as of September 30, 2018 and December 31, 2017, respectively. Effective December 31, 2017, we entered into an amended loan agreement with Squadron to consolidate a majority of our term note into a $20,000 term loan, reestablished a $15,000 revolving credit facility, changed the interest rate and extended the loan period through January 31, 2023. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance at September 30, 2018, expected cash flows from operations for the next twelve months subsequent to the issuance of the condensed consolidated financial statements and the availability under the revolving credit facility are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months subsequent to the issuance of the condensed consolidated financial statements.

Use of Estimates

Preparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.  

Foreign Currency Transactions

We currently bill our international distributors in United States ("U.S.") dollars, resulting in minimal foreign exchange transaction expense.

Beginning in the second quarter of 2017, we began selling direct within the United Kingdom, Ireland, Australia and New Zealand and billing using the local currency for each country. In September 2018, we began selling direct in Canada. The financial statements of our foreign subsidiaries are accounted for and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the condensed consolidated statements of comprehensive loss.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent
sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as, discounted cash flows, and are based on the best information available, including our own data.   

We do not have any assets or liabilities that are measured on a recurring basis under the presented fair value hierarchy.

Revenue from Contracts with Customers
The Company adopted ASC 606, "Revenue From Contracts With Customers (ASC 606)", on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have any impact on the Company’s consolidated historical financial statements. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of "ASC 605, Revenue Recognition (ASC 605)." In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.
 
Revenue Recognition – International

Outside of the United States, we primarily sell our products through independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on our history of collections and returns from international customers, we have concluded that collectability is not reasonably assured at the time of delivery for certain customers who have not evidenced a consistent pattern of timely payment. Accordingly, we do not recognize international revenue and associated cost of revenue at the time title transfers for these customers for whom collectibility has not been deemed probable based on the customer’s history and ability to pay, but rather when cash has been received. Until such payment, cost of revenue is recorded as inventories held by international distributors, net of adjustment for estimated unreturnable inventory, on our condensed consolidated balance sheets.
For international independent stocking distributors for whom we have determined collectability is probable, based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment.
In early 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Additionally, in September 2018 we began selling in Canada utilizing the subject agency model. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract.. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.

Cash and Cash Equivalents

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheet for cash are valued at cost, which approximates fair value.

Accounts Receivable

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods and are purchased from third parties.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.
In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.

Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand and Canada are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements 25 to 30 years 
Furniture and fixtures 5 to 7 years 
Computer equipment 3 to 5 years 
Business software 3 years 
Office and other equipment 5 to 7 years 
Instruments 5 years 
Sample inventory 2 years 

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses. Amortization is calculated on a straight-line basis over the estimated useful life of the patents and licenses. Amortization for patents and licenses commences at the time of patent approval and market launch, respectively. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.

Other Intangible Assets

We have indefinite lived tradename assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.

Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.  

Research and development costs were $1,122 and $1,127 for the three months ended September 30, 2018 and 2017, respectively, and $3,455 and $2,482 for the nine months ended September 30, 2018 and 2017, respectively.

Stock-Based Compensation

Prior to our IPO, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,789,647 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.
Restricted stock may not be transferred prior to the expiration of the restricted period. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally last until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We estimate the fair value of stock options and restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the vesting period for stock options and the restriction period for restricted stock.

Calculating the fair value of stock-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock options. Use of the valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options and the risk free rate of return for a period that approximates the expected term of our stock options. Because we were a privately-held company with a limited operating history, we utilized the historical stock price volatility from a representative group of comparable industry competitors to estimate expected stock price volatility.

Prior to the IPO, in determining the fair value of our common stock at the grant date, which is the basis for the fair value of stock based awards, we used the market approach, which was based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. In using the market approach, we consider both the guideline public company method and the precedent transaction method. Given the absence of a public trading market for our common stock prior to our IPO, we exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: the preferences and dividends of our redeemable convertible preferred stock relative to those of our common stock; our operating results and financial conditions, including our level of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. Prior to our IPO, for restricted stock awards we applied a discount for lack of marketability to the fair value of common stock to estimate the impact of valuing a minority interest in our Company as a closely held, non-public company with no liquid market for its shares. Following the IPO, we value restricted stock awards using the market value on the grant date.  

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.
We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 and our disclosure obligations regarding executive compensation may be reduced. We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering, or December 31, 2022. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

Following the recent SEC amendment raising the financial thresholds for a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we qualify as a smaller reporting company effective with the filing of this quarterly report. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” on the recognition of revenue for all contracts with customers designed to improve comparability and enhance financial statement disclosures. The underlying principle of this comprehensive model is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the payment to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These standards became effective for us on January 1, 2018. We elected to apply the modified retrospective approach, and we have not identified any accounting changes that would materially impact the amount of reported revenues and did not record any adjustments on January 1, 2018, related to this new guidance.

In February 2016, the FASB issued ASU 2016-02 “Leases,” which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new standard requires lessees to
recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB issued ASU No. 2018-11 "Leases (Topic 842): Targeted Improvements," which provides an alternative modified retrospective transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is reocognized on the date of adoption.  The new standard will be effective starting in the first quarter of 2019. Early adoption is permitted. We are currently evaluating the impact of this standard, but we do not believe this guidance will have a material effect on our financial position, results of operations or cash flows.

In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments" which provides guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted ASU 2016-15 effective January 1, 2018. The adoption did not have any impact on our consolidated financial position, results of operations and cash flows.
In March 2018, the FASB issued ASU 2018-05 "Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118”), to state the income tax accounting implications of the Tax Cuts and Jobs Act (“New Tax Act”)" which clarifies the measurement period time frame, changes in subsequent reporting periods and reporting requirements as a result of the New Tax Act of 2017. In accordance with SAB No. 118, a company must reflect the income tax effects of those aspects of the New Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the New Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the New Tax Act. SAB No. 118 provides a measurement period that should not extend beyond one year and it begins in the period that includes the enactment date which was December 22, 2017. We have not completed the accounting for the income tax effects of certain elements of the New Tax Act. When additional guidance and regulations enable us to finalize certain tax positions, we will reflect the impact of this ASU 2018-05 on the tax provision and deferred tax calculation as of December 31, 2018.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT AND CREDIT ARRANGEMENTS
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
DEBT AND CREDIT ARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS
Long-term debt consisted of the following:
September 30, December 31, 
20182017
Note payable to Squadron $20,000 $20,000 
Revolving credit facility with Squadron 3,947 3,921 
Mortgage payable to affiliate 1,447 1,531 
Total debt 25,394 25,452 
Less: current maturities 117 113 
Long-term debt, net of current maturities $25,277 $25,339 

In May 2014, we entered into the Second Amended and Restated Loan and Security Agreement with Squadron in connection with a restructuring of our debt and equity. The terms of this agreement required monthly interest only payments computed at 10% per annum with all principal and unpaid interest due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement. The note payable was secured by substantially all of our assets. In November 2015, this agreement was amended to provide a revolving loan commitment of an additional $7,000. The revolving loan commitment was structured under the same terms and conditions with interest payable monthly computed at 10% per
annum and principal due at maturity in May 2017 or earlier upon a change of control event, as defined in the agreement.

In April 2017, we entered into the Third Amended and Restated Loan and Security Agreement with Squadron to provide an additional $16,000 revolving loan commitment and extend the maturity date on the note payable and revolving credit facility to May 31, 2019 with an automatic extension to May 31, 2020 if we meet certain revenue goals. The agreement was structured similarly to previous amendments with interest payable monthly computed at 11.0% per annum and included a $1,000 extension fee payable in three installments on the anniversary date of the agreement. The extension fee was recorded in full upon closing as a deferred financing cost within long-term debt with affiliate, net of current portion, and was to be recognized ratably over the term of the agreement as deferred financing charges within interest expense on the consolidated statements of operations assuming an IPO did not happen.

Effective December 31, 2017, we entered into a Fourth Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Squadron. Pursuant to the Loan Agreement, we have consolidated a majority of the term loan amounts into a $20,000 term note and reestablished a $15,000 revolving credit facility. Also, $667 of the extension fee was cancelled as of the completion of our IPO in October 2017. Both facilities include interest only payments and will have an interest rate equal to the greater of (a) three month LIBOR plus 8.61%, or (b) 10.0%. The Loan Agreement also extended the maturity date to January 31, 2023. Borrowings under the Loan Agreement are secured by substantially all of our assets and are unconditionally guaranteed by each of our subsidiaries.

The fair value of our note payable to Squadron was estimated based on prices for the same or similar issues and the current interest rates offered for the debt of the same remaining maturities, which are considered level 2 inputs in accordance with ASC Topic 820, “Fair Value Measurements and Disclosures.” At September 30, 2018, the fair value approximated the carrying value.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At December 31, 2017, the mortgage balance was $1,531 of which current principal due of $113 was included in current portion of long-term debt. At September 30, 2018, the mortgage balance was $1,447 of which current principal due of $117 was included in current portion of long-term debt.
Interest expense relating to notes payable to Squadron and Tawani was $608 and $761 for the three months ended September 30, 2018 and 2017, respectively, and $1,722 and $1,857 for the nine months ended September 30, 2018 and 2017, respectively.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
STRATEGIC ARRANGEMENTS
 9 Months Ended
Sep. 30, 2018
Research and Development [Abstract]  
STRATEGIC ARRANGEMENTS STRATEGIC ARRANGEMENTS
Effective December 1, 2007, we entered into a ten-year agreement with Case Western Reserve University (“CASE”) to assist in certain aspects of our research and development. Effective August 2, 2017, we entered into an Amended and Restated License Agreement to account for additional licensed product and extend the agreement for another ten years. The main focus of this research and development involves leveraging our exclusive rights to the Hamann-Todd Collection of the Cleveland National History Museum, the world's largest pediatric osteological collection, to assist in the design of implants which match pediatric bone curvature and structure.

In exchange for services, CASE receives certain royalties and up-front fees. The royalties and certain fees are contingent upon our obtaining FDA approval and the launch of our products into the marketplace. CASE receives a minimum annual royalty of $10 or a royalty of 3% of net sales on products, whichever is
greater. Additionally, for each new product developed, CASE will receive milestone payments of $5 for FDA approval to sell our products within the United States and $10 for general product launch. Additionally, CASE receives a royalty of 3% of net sales on products fully developed and being sold in the marketplace.The royalty expense recognized related to the CASE agreement is recorded as a component of cost of revenue and was $37 and $38 for the three months ended September 30, 2018 and 2017, respectively, and $108 and $111 for the nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018 and December 31, 2017, $37 and $37, respectively, was due to CASE.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
For the three and nine month periods ended September 30, 2018 and 2017, we calculated the provision of income taxes by applying an estimate of the annual effective tax rate for the full fiscal year to the ordinary loss for the reporting period resulting in a zero tax provision consistent with prior periods.

The deferred tax assets were fully offset by a valuation allowance at September 30, 2018 and December 31, 2017, and no income tax benefit has been recognized in our condensed consolidated statements of operations for any of the periods presented. At December 31, 2017, we had available federal and state tax loss carryforwards of $70,335 and tax credits for federal and state tax purposes of $335 which begin to expire in 2028. Any losses incurred in 2018 and beyond do not expire. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $16,200 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062, which is increased by $2,302 over the first five years as a result of an unrealized built in gain. The Section 382 ownership change analysis will be re–evaluated prior to release of the year-ending December 31, 2018 financial statements to account for equity ownership changes that occur during 2018.
Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2017 and through September 30, 2018. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.

Our stock option activity and related information are summarized as follows:
Weighted-Average Contractual Terms 
Options Exercise Price (in Years) 
Outstanding at January 1, 2018176,959 $29.42 2.0
Exercised (11,533)29.29 
Forfeited or expired (50,652)27.61 
Outstanding at September 30, 2018114,774 $30.33 2.1
Options generally include a time-based vesting schedule permitting the options to vest ratably over no years. At September 30, 2018 and December 31, 2017, all options were fully vested.

There was no stock-based compensation expense on stock options for the three and nine month periods ended September 30, 2018 and 2017, respectively.

Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-Average 
Remaining 
Restricted Contractual Terms 
Stock (in Years) 
Outstanding at January 1, 2018548,005 0.3
Granted175,541 
Forfeited(1,335)
Vested(547,670)
Outstanding at September 30, 2018174,541 2.4
Restricted stock exercisable at September 30, 2018— 

At September 30, 2018, there was $2,951 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 2.4 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $267 and $354 for the three months ended September 30, 2018 and 2017, respectively, and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively. Due to our limited operating history and lack of marketability before the IPO, a discount of 15% was applied when estimating the stock-based compensation expense on restricted stock granted in 2017.

Total stock-based compensation expense is included as a component of general and administrative expenses in our condensed consolidated statement of operations and was $267 and $354 for the three months ended September 30, 2018 and 2017, respectively, and $2,899 and $1,081 for the nine months ended September 30, 2018 and 2017, respectively.

Warrants

Our warrant activity and related information are summarized as follows:
Weighted-Average 
Warrants Exercise Price 
Outstanding at January 1, 201844,101 $27.03 
Forfeited or expired (25,535)26.55 
Outstanding at September 30, 201818,566 $27.69 

For all periods presented, the warrants were issued at exercise prices ranging from $26.27 to $30.97 per share. The warrants generally have a ten-year term. At September 30, 2018, no warrants had been exercised. At inception, no fair value was assigned to the warrants.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
NET LOSS PER SHARE
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The following is a reconciliation of basic and diluted net loss per share attributable to common stockholders: 
Three Months Ended Nine Months Ended 
September 30, September 30, 
2018201720182017
Net loss $(1,865)$(1,537)$(9,557)$(4,087)
Accretion of cumulative dividends of redeemable preferred stock to redemption value — (1,484)— (4,364)
Net loss attributable to common stockholders - basic and diluted $(1,865)$(3,021)$(9,557)$(8,451)
Weighted average number of shares - basic and diluted 12,624,858 1,773,385 12,417,972 1,754,576 
Net loss per share attributable to common stockholders - basic and diluted $(0.15)$(1.70)$(0.77)$(4.82)

Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 

Prior to the completion of our IPO on October 12, 2017, we had authorized 7,000,000 shares of redeemable convertible preferred stock, of which 3,649,475 were outstanding as of September 30, 2017, designated in series, with the rights and preferences of each series determined by the Board of Directors. Upon completion of our IPO, all of our previously outstanding shares of Series A and B Preferred Stock were converted into common stock on a 1:1 conversion ratio. As of September 30, 2018 and December 31, 2017, there are no redeemable convertible preferred shares outstanding. Series A and B preferred stock include rights to participate in dividends and distributions to common stockholders on an if-converted basis, and accordingly are also considered participating securities.  During periods of undistributed losses however, no effect is given to our participating securities since they are not contractually obligated to share in the losses.

We have incurred a net loss for all periods presented, such that diluted net loss per common stock is the same as basic net loss per common stock. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented (shares for the redeemable convertible preferred shares for the nine months ended September 30, 2017 were determined based on the applicable conversion ratio of 1:1):
As of September 30, 
20182017
Redeemable convertible preferred stock - Series A — 670,000 
Redeemable convertible preferred stock - Series B — 2,979,475 
Restricted stock 174,541 704,770 
Stock options 114,774 177,763 
Warrants 18,566 44,101 
307,881 4,576,109 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS SEGMENT
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
BUSINESS SEGMENT BUSINESS SEGMENT
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We disaggregate revenue from contracts with customers by operating segment. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three and nine months ended September 30, 2018 or 2017. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2018 and December 31, 2017.

Product sales by source were as follows:  
Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by geographic location: 2018201720182017
U.S. $12,421 $9,556 $32,532 $26,085 
International 3,399 2,819 10,459 7,854 
Total $15,820 $12,375 $42,991 $33,939 

Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by category: 2018201720182017
Trauma and deformity $10,562 $8,730 $29,545 $24,339 
Scoliosis 5,027 3,299 12,609 8,652 
Sports medicine/other 231 346 837 948 
Total $15,820 $12,375 $42,991 $33,939 
No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2018 and 2017.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONSIn addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 3), we currently use FMI Hansa Medical Products, LLC (“FMI”) and Structure Medical, LLC (“Structure Medical”) as two of our suppliers. Each of these entities is affiliated with Squadron. In 2017, FMI merged with and into Structure Medical. We do not have long-term contracts with either supplier. We made aggregate payments to Structure and FMI of $738 and $757 for the three months ended September 30, 2018 and 2017, respectively, and $3,004 and $1,862 for the nine months ended September 30, 2018 and 2017, respectively.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
EMPLOYEE BENEFIT PLAN
 9 Months Ended
Sep. 30, 2018
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. Effective January 1, 2018, we have elected to match our employees' 401(k) contributions up to 3% of employees' salary.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
We are involved with various legal actions arising in the ordinary course of our activities. We accrue for those cases where the potential liability is estimable and probable. From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. On January 20, 2017, K2M, Inc. filed suit against us in the United States District Court for the District of Delaware (K2M, Inc. v. OrthoPediatrics Corp. et al., Case No. 1:17-cv-0061) seeking unspecified damages for alleged infringement of U.S. Patent No. 9,532,816. The complaint was amended on August 21, 2017 to add, among other things, a claim of patent infringement regarding U.S. Patent No. 9,655,664. These patents relate to certain instruments used in our RESPONSE spine systems, which represent a portion of our total scoliosis portfolio. We have denied these claims and responded with counterclaims seeking declaratory relief that the patents in question are both invalid and not infringed. The parties attended a court-ordered mediation on October 24, 2017, which did not resolve the dispute, but as we move forward with this matter we welcome constructive discussions on a negotiated settlement. Nevertheless, we view our case as particularly strong and will continue to vigorously defend this matter. On January 8 and 22, 2018, we filed our first and second petitions for inter partes review ("IPR") with the United States Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB") to challenge the patentability of U.S. Patent No. 9,532,816 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-00429 and IPR2018-00521). On June 28, 2018, the PTAB instituted the subject IPRs and set a trial date of February 20, 2019 for both IPRs. Additionally, the parties have agreed to stay the above-referenced district court proceedings pending the outcome of the subject IPR proceedings. The Court ordered the stay on July 10, 2018. Moreover, on August 21, 2018, we filed three petitions with PTAB to challenge the patentability of the above-referenced U.S. Patent No. 9,655,664 (OrthoPediatrics Corp., v. K2M, Inc., Inter Partes Case Nos. IPR2018-01546, IPR2018-01547, and IPR2018-01548). Although we believe that the K2M lawsuit is without merit and we will vigorously defend the claims asserted against us, intellectual property litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have a material adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

As of September 30, 2018, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. Additionally, we have minimum royalty commitments of $500 annually through 2026.
We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2018, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Consolidated Financial Statements
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD and OrthoPediatrics NZ Limited (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017, the condensed consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2018 and 2017, the condensed consolidated statement of stockholders’ equity for the nine months ended September 30, 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2017 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and
Exchange Commission ("SEC") on March 15, 2018. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2017 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.
The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern.
Use of Estimates Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
Foreign Currency Transactions
Foreign Currency Transactions

We currently bill our international distributors in United States ("U.S.") dollars, resulting in minimal foreign exchange transaction expense.
Beginning in the second quarter of 2017, we began selling direct within the United Kingdom, Ireland, Australia and New Zealand and billing using the local currency for each country. In September 2018, we began selling direct in Canada. The financial statements of our foreign subsidiaries are accounted for and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the condensed consolidated statements of comprehensive loss.
Fair Value of Financial Instruments
Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent
sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as, discounted cash flows, and are based on the best information available, including our own data.   
We do not have any assets or liabilities that are measured on a recurring basis under the presented fair value hierarchy.
Revenue Recognition - United States and International
Revenue from Contracts with Customers
The Company adopted ASC 606, "Revenue From Contracts With Customers (ASC 606)", on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have any impact on the Company’s consolidated historical financial statements. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of "ASC 605, Revenue Recognition (ASC 605)." In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.
 
Revenue Recognition – International

Outside of the United States, we primarily sell our products through independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on our history of collections and returns from international customers, we have concluded that collectability is not reasonably assured at the time of delivery for certain customers who have not evidenced a consistent pattern of timely payment. Accordingly, we do not recognize international revenue and associated cost of revenue at the time title transfers for these customers for whom collectibility has not been deemed probable based on the customer’s history and ability to pay, but rather when cash has been received. Until such payment, cost of revenue is recorded as inventories held by international distributors, net of adjustment for estimated unreturnable inventory, on our condensed consolidated balance sheets.
For international independent stocking distributors for whom we have determined collectability is probable, based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally upon implantation or when title passes upon shipment. In early 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Additionally, in September 2018 we began selling in Canada utilizing the subject agency model. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when the hospital obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract.. Pricing for each customer is dictated by a unique pricing agreement, which does not generally include rebates or discounts.
Cash and Cash Equivalents Cash and Cash EquivalentsWe maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheet for cash are valued at cost, which approximates fair value.
Accounts Receivable
Accounts Receivable

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.
The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.
Inventories, net
Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods and are purchased from third parties.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.
In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.
Property and Equipment, net
Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand and Canada are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements 25 to 30 years 
Furniture and fixtures 5 to 7 years 
Computer equipment 3 to 5 years 
Business software 3 years 
Office and other equipment 5 to 7 years 
Instruments 5 years 
Sample inventory 2 years 
Amortizable Intangible Assets, net
Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses. Amortization is calculated on a straight-line basis over the estimated useful life of the patents and licenses. Amortization for patents and licenses commences at the time of patent approval and market launch, respectively. Intangible assets are amortized over a 3 to 20 year period.
Amortizable intangible assets are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets.
Other Intangible Assets
Other Intangible Assets

We have indefinite lived tradename assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount exceeds the fair market value of the assets.
Cost of Revenue Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.
Sales and Marketing Expenses Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.
Advertising Costs Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.
Research and Development Costs Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.
Stock-Based Compensation
Stock-Based Compensation

Prior to our IPO, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,789,647 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.
Restricted stock may not be transferred prior to the expiration of the restricted period. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally last until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We estimate the fair value of stock options and restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the vesting period for stock options and the restriction period for restricted stock.

Calculating the fair value of stock-based awards requires that we make highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock options. Use of the valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options and the risk free rate of return for a period that approximates the expected term of our stock options. Because we were a privately-held company with a limited operating history, we utilized the historical stock price volatility from a representative group of comparable industry competitors to estimate expected stock price volatility.
Prior to the IPO, in determining the fair value of our common stock at the grant date, which is the basis for the fair value of stock based awards, we used the market approach, which was based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. In using the market approach, we consider both the guideline public company method and the precedent transaction method. Given the absence of a public trading market for our common stock prior to our IPO, we exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: the preferences and dividends of our redeemable convertible preferred stock relative to those of our common stock; our operating results and financial conditions, including our level of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. Prior to our IPO, for restricted stock awards we applied a discount for lack of marketability to the fair value of common stock to estimate the impact of valuing a minority interest in our Company as a closely held, non-public company with no liquid market for its shares. Following the IPO, we value restricted stock awards using the market value on the grant date.
Comprehensive Income (Loss) Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments.
Income Taxes
Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.
We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.
"Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements
“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 and our disclosure obligations regarding executive compensation may be reduced. We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering, or December 31, 2022. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

Following the recent SEC amendment raising the financial thresholds for a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we qualify as a smaller reporting company effective with the filing of this quarterly report. As a result, many of the same exemptions from reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, those exemptions may continue to be available to us.
Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” on the recognition of revenue for all contracts with customers designed to improve comparability and enhance financial statement disclosures. The underlying principle of this comprehensive model is that revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects the payment to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date. These standards became effective for us on January 1, 2018. We elected to apply the modified retrospective approach, and we have not identified any accounting changes that would materially impact the amount of reported revenues and did not record any adjustments on January 1, 2018, related to this new guidance.

In February 2016, the FASB issued ASU 2016-02 “Leases,” which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new standard requires lessees to
recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB issued ASU No. 2018-11 "Leases (Topic 842): Targeted Improvements," which provides an alternative modified retrospective transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is reocognized on the date of adoption.  The new standard will be effective starting in the first quarter of 2019. Early adoption is permitted. We are currently evaluating the impact of this standard, but we do not believe this guidance will have a material effect on our financial position, results of operations or cash flows.

In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments" which provides guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted ASU 2016-15 effective January 1, 2018. The adoption did not have any impact on our consolidated financial position, results of operations and cash flows.
In March 2018, the FASB issued ASU 2018-05 "Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118”), to state the income tax accounting implications of the Tax Cuts and Jobs Act (“New Tax Act”)" which clarifies the measurement period time frame, changes in subsequent reporting periods and reporting requirements as a result of the New Tax Act of 2017. In accordance with SAB No. 118, a company must reflect the income tax effects of those aspects of the New Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the New Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the New Tax Act. SAB No. 118 provides a measurement period that should not extend beyond one year and it begins in the period that includes the enactment date which was December 22, 2017. We have not completed the accounting for the income tax effects of certain elements of the New Tax Act. When additional guidance and regulations enable us to finalize certain tax positions, we will reflect the impact of this ASU 2018-05 on the tax provision and deferred tax calculation as of December 31, 2018.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Property and equipment, depreciable lives Sample inventory is carried at cost less accumulated depreciation.
Depreciable lives are generally as follows:
Building and building improvements 25 to 30 years 
Furniture and fixtures 5 to 7 years 
Computer equipment 3 to 5 years 
Business software 3 years 
Office and other equipment 5 to 7 years 
Instruments 5 years 
Sample inventory 2 years 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT AND CREDIT ARRANGEMENTS (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule of long-term debt instruments
Long-term debt consisted of the following:
September 30, December 31, 
20182017
Note payable to Squadron $20,000 $20,000 
Revolving credit facility with Squadron 3,947 3,921 
Mortgage payable to affiliate 1,447 1,531 
Total debt 25,394 25,452 
Less: current maturities 117 113 
Long-term debt, net of current maturities $25,277 $25,339 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of stock option activity
Our stock option activity and related information are summarized as follows:
Weighted-Average Contractual Terms 
Options Exercise Price (in Years) 
Outstanding at January 1, 2018176,959 $29.42 2.0
Exercised (11,533)29.29 
Forfeited or expired (50,652)27.61 
Outstanding at September 30, 2018114,774 $30.33 2.1
Schedule of restricted stock activity
Our restricted stock activity and related information are summarized as follows:
Weighted-Average 
Remaining 
Restricted Contractual Terms 
Stock (in Years) 
Outstanding at January 1, 2018548,005 0.3
Granted175,541 
Forfeited(1,335)
Vested(547,670)
Outstanding at September 30, 2018174,541 2.4
Restricted stock exercisable at September 30, 2018— 
Schedule of Warrants
Our warrant activity and related information are summarized as follows:
Weighted-Average 
Warrants Exercise Price 
Outstanding at January 1, 201844,101 $27.03 
Forfeited or expired (25,535)26.55 
Outstanding at September 30, 201818,566 $27.69 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
NET LOSS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Reconciliation of basic and diluted net loss per share attributable to common stockholders
The following is a reconciliation of basic and diluted net loss per share attributable to common stockholders: 
Three Months Ended Nine Months Ended 
September 30, September 30, 
2018201720182017
Net loss $(1,865)$(1,537)$(9,557)$(4,087)
Accretion of cumulative dividends of redeemable preferred stock to redemption value — (1,484)— (4,364)
Net loss attributable to common stockholders - basic and diluted $(1,865)$(3,021)$(9,557)$(8,451)
Weighted average number of shares - basic and diluted 12,624,858 1,773,385 12,417,972 1,754,576 
Net loss per share attributable to common stockholders - basic and diluted $(0.15)$(1.70)$(0.77)$(4.82)
Schedule of antidilutive securities excluded from computation of net loss per share The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented (shares for the redeemable convertible preferred shares for the nine months ended September 30, 2017 were determined based on the applicable conversion ratio of 1:1):
As of September 30, 
20182017
Redeemable convertible preferred stock - Series A — 670,000 
Redeemable convertible preferred stock - Series B — 2,979,475 
Restricted stock 174,541 704,770 
Stock options 114,774 177,763 
Warrants 18,566 44,101 
307,881 4,576,109 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS SEGMENT (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Schedule of product sales by geographic location
Product sales by source were as follows:  
Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by geographic location: 2018201720182017
U.S. $12,421 $9,556 $32,532 $26,085 
International 3,399 2,819 10,459 7,854 
Total $15,820 $12,375 $42,991 $33,939 
Schedule of product sales by category
Three Months Ended September 30, Nine Months Ended September 30, 
Product sales by category: 2018201720182017
Trauma and deformity $10,562 $8,730 $29,545 $24,339 
Scoliosis 5,027 3,299 12,609 8,652 
Sports medicine/other 231 346 837 948 
Total $15,820 $12,375 $42,991 $33,939 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS - Narrative (Details) - IPO
$ / shares in Units, $ in Thousands
Oct. 12, 2017
USD ($)
$ / shares
shares
Common Stock  
Class of Stock [Line Items]  
Stock issued during period, shares, new issues (in shares) | shares 4,600,000
Public offering price (usd per share) | $ / shares $ 13.00
Gross proceeds on sale of stock $ 59,800
Net proceeds on sale of stock 46,900
Underwriting discounts and commissions on sale of stock 4,200
Offering costs 2,700
Series B Preferred Stock  
Class of Stock [Line Items]  
Dividend payments $ 6,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Jun. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Accounting Policies [Abstract]                
Accumulated deficit $ 112,623,000         $ 112,623,000   $ 103,066,000
Impairment charges, finite-lived 0 $ 0   $ 0 $ 0      
Impairment charges, indefinite-lived 0 $ 0   $ 0 $ 0      
Research and development costs $ 1,122,000   $ 1,127,000     $ 3,455,000 $ 2,482,000  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Long-term debt $ 25,394,000 $ 25,452,000
Revolving Credit Facility    
Debt Instrument [Line Items]    
Revolving credit facility   15,000,000
Note payable to Squadron    
Debt Instrument [Line Items]    
Long-term debt $ 20,000,000 $ 20,000,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)
 6 Months Ended 9 Months Ended
Jun. 30, 2018
Sep. 30, 2018
Minimum    
Property, Plant and Equipment [Line Items]    
Intangible asset, useful life   3 years
Maximum    
Property, Plant and Equipment [Line Items]    
Intangible asset, useful life   20 years
Building and building improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 25 years  
Building and building improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 30 years  
Furniture and fixtures | Minimum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 5 years  
Furniture and fixtures | Maximum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 7 years  
Computer equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 3 years  
Computer equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 5 years  
Business software    
Property, Plant and Equipment [Line Items]    
Depreciable lives 3 years  
Office and other equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 5 years  
Office and other equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Depreciable lives 7 years  
Instruments    
Property, Plant and Equipment [Line Items]    
Depreciable lives 5 years  
Sample inventory    
Property, Plant and Equipment [Line Items]    
Depreciable lives 2 years  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) - shares
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options granted (in shares) 0 0 0 0 0 0
Stock Option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period (in years)           3 years
Restricted stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period (in years)           6 years
2007 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for award (in shares) 1,585,000         1,585,000
Vesting period (in years)           6 months
2017 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for award (in shares) 1,789,647         1,789,647
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Long-term debt $ 25,394,000 $ 25,452,000
Less: current maturities 117,000 113,000
Total long-term debt, net of current maturities 25,277,000 25,339,000
Note payable to Squadron    
Debt Instrument [Line Items]    
Long-term debt 20,000,000 20,000,000
Revolving credit facility with Squadron | Revolving Credit Facility    
Debt Instrument [Line Items]    
Long-term debt 3,947,000 3,921,000
Mortgage payable to affiliate    
Debt Instrument [Line Items]    
Long-term debt 1,447,000 1,531,000
Less: current maturities $ 117,000 $ 113,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2017
Apr. 30, 2017
Oct. 31, 2017
Aug. 31, 2013
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Nov. 30, 2015
May 31, 2014
Debt Instrument [Line Items]                    
Mortgage balance $ 25,452,000       $ 25,394,000   $ 25,394,000      
Current portion of long-term debt with affiliate 113,000       117,000   117,000      
Note payable to Squadron                    
Debt Instrument [Line Items]                    
Interest rate   11.00%             10.00% 10.00%
Additional revolving loan commitment   $ 16,000,000             $ 7,000,000  
Deferred financing cost   $ 1,000,000                
Extension fee payable period   3 years                
Mortgage balance 20,000,000       20,000,000   20,000,000      
Debt instrument, extension fee cancelled     $ 667,000              
Interest expense         608,000 $ 761,000 1,722,000 $ 1,857,000    
Mortgage payable to affiliate                    
Debt Instrument [Line Items]                    
Interest rate       5.00%            
Mortgage balance 1,531,000       1,447,000   1,447,000      
Monthly interest and principal installments       $ 16,000            
Current portion of long-term debt with affiliate 113,000       $ 117,000   $ 117,000      
Revolving Credit Facility                    
Debt Instrument [Line Items]                    
Revolving credit facility $ 15,000,000                  
Three month LIBOR | Revolving Credit Facility                    
Debt Instrument [Line Items]                    
Debt instrument, basis spread on variable rate 8.61%                  
Debt instrument, interest rate, effective percentage 10.00%                  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
STRATEGIC ARRANGEMENTS (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 02, 2017
Dec. 01, 2007
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Minimum annual royalty payment         $ 500,000      
Royalty expense           $ 108,000 $ 111,000  
CASE                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Royalty expense     $ 37,000 $ 38,000        
Royalty payable     $ 37,000     $ 37,000   $ 37,000
Royalty Agreement Terms | CASE                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Royalty agreement period 10 years 10 years            
Minimum annual royalty payment   $ 10,000            
Royalty agreement percentage   3.00%            
Milestone payments for FDA approval to sell our products within the United States   $ 5,000            
Milestone payment for general product launch   $ 10,000            
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2017
Sep. 30, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]          
Tax provision $ 0 $ 0 $ 0 $ 0 $ 0
Loss carryforwards         70,335,000
Tax credit carryforward         $ 335,000
Estimated limitation on losses generated prior to ownership change date       16,200,000  
Estimated annual limitation of losses       1,062,000  
Increase of estimated annual limitation of first five years       $ 2,302,000  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' EQUITY - Stock Options (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Sep. 30, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Granted (in shares) 0 0 0 0 0 0  
Options              
Outstanding at period start (in shares)       176,959   176,959  
Exercised (in shares)           (11,533)  
Forfeited or expired (in shares)           (50,652)  
Outstanding at period end (in shares) 114,774         114,774 176,959
Weighted-Average Exercise Price              
Outstanding at period start, Weighted-Average Exercise Price (in dollars per share)       $ 29.42   $ 29.42  
Exercised, Weighted-Average Exercise Price (in dollars per share)           29.29  
Forfeited or expired, Weighted-Average Exercise Price (in dollars per share)           27.61  
Outstanding at period end, Weighted-Average Exercise Price (in dollars per share) $ 30.33         $ 30.33 $ 29.42
Contractual Terms (in years)           2 years 1 month 6 days 2 years
Stock Option              
Weighted-Average Exercise Price              
Vesting period (in years)           3 years  
Stock-based compensation expense     $ 0 $ 0 $ 0    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' EQUITY - Restricted Stock (Details) - Restricted stock - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Restricted Stock          
Outstanding at period start (in shares)     548,005    
Granted (in shares)     175,541    
Forfeited (in shares)     (1,335)    
Vested (in shares)     (547,670)    
Outstanding at period end (in shares) 174,541   174,541   548,005
Weighted-Average Remaining Contractual Terms (in years)     2 years 4 months 24 days   3 months 18 days
Restricted stock exercisable (in shares) 0   0    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]          
Unrecognized compensation expense $ 2,951   $ 2,951    
Unrecognized compensation expense, weighted average period of recognition (in years)     2 years 4 months 24 days    
Stock-based compensation expense, discount rate         15.00%
General and Administrative Expense          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]          
Stock-based compensation expense $ 267 $ 354 $ 2,899 $ 1,081  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' EQUITY - Warrants (Details)
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Class of Warrant or Right Outstanding [Roll Forward]  
Outstanding at January 1, 2018 (in shares) | shares 44,101
Beginning weighted-average exercise price (in dollars per share) $ 27.03
Forfeited or expired (in shares) | shares (25,535)
Forfeited or expired, weighted average exercise price (in dollars per share) $ 26.55
Outstanding at September 30. 2018 (in shares) | shares 18,566
Ending weighted-average exercise price (in dollars per share) $ 27.69
Term of warrants (in years) 10 years
Number of warrants exercised (in shares) | shares 0
Minimum  
Class of Warrant or Right Outstanding [Roll Forward]  
Ending weighted-average exercise price (in dollars per share) $ 26.27
Maximum  
Class of Warrant or Right Outstanding [Roll Forward]  
Ending weighted-average exercise price (in dollars per share) $ 30.97
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]                
Net loss $ (1,865) $ (1,865) $ (1,537) $ (1,537) $ (9,557) $ (4,087) $ (9,557) $ (4,087)
Accretion of cumulative dividends of redeemable preferred stock to redemption value 0 0 (1,484) (1,484) 0 (4,364) 0 (4,364)
Net loss attributable to common stockholders - basic $ (1,865)   $ (3,021)       $ (9,557) $ (8,451)
Net loss attributable to common stockholders - diluted   $ (1,865)   $ (3,021) $ (9,557) $ (8,451)    
Weighted average number of shares - basic and diluted 12,624,858   1,773,385       12,417,972 1,754,576
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) $ (0.15)   $ (1.70)       $ (0.77) $ (4.82)
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
NET LOSS PER SHARE - Narrative (Details) - shares
Sep. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
Oct. 12, 2017
Sep. 30, 2017
Temporary Equity [Line Items]          
Redeemable convertible preferred stock, outstanding (in shares)   0 0    
Redeemable Convertible Preferred Stock          
Temporary Equity [Line Items]          
Redeemable convertible preferred stock, authorized (in shares)       7,000,000  
Redeemable convertible preferred stock, outstanding (in shares)         3,649,475
Conversion ratio 1        
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
NET LOSS PER SHARE - Antidilutive Securities (Details) - shares
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 307,881 4,576,109
Restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 174,541 704,770
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 114,774 177,763
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 18,566 44,101
Redeemable convertible preferred stock - Series A | Redeemable convertible preferred stock - Series A and Series B    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 0 670,000
Redeemable convertible preferred stock - Series B | Redeemable convertible preferred stock - Series A and Series B    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 0 2,979,475
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS SEGMENT - Narrative (Details) - segment
 6 Months Ended 9 Months Ended
Jun. 30, 2018
Sep. 30, 2018
Segment Reporting [Abstract]    
Number of operating segments   1
Number of reportable segments 1  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenues $ 15,820 $ 12,375 $ 42,991 $ 33,939
U.S.        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenues 12,421 9,556 32,532 26,085
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenues $ 3,399 $ 2,819 $ 10,459 $ 7,854
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS SEGMENT - Schedule of Revenue by Category (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]        
Revenues $ 15,820 $ 12,375 $ 42,991 $ 33,939
Scoliosis        
Segment Reporting Information [Line Items]        
Revenues 5,027 3,299 12,609 8,652
Sports medicine/other        
Segment Reporting Information [Line Items]        
Revenues 231 346 837 948
Trauma and deformity        
Segment Reporting Information [Line Items]        
Revenues $ 10,562 $ 8,730 $ 29,545 $ 24,339
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
RELATED PARTY TRANSACTIONS (Details) - Affiliated Entity
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
supplier
Sep. 30, 2017
USD ($)
Related Party Transaction [Line Items]        
Number of related party suppliers | supplier     2  
FMI        
Related Party Transaction [Line Items]        
Payments to related party | $ $ 738 $ 757 $ 3,004 $ 1,862
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
EMPLOYEE BENEFIT PLAN - Narrative (Details)
Jan. 01, 2018
Retirement Benefits [Abstract]  
Employer contribution as a percentage of employees' salary 3.00%
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
 6 Months Ended 9 Months Ended
Jun. 30, 2018
Sep. 30, 2018
Long-term Purchase Commitment [Line Items]    
Minimum annual royalty payment $ 500,000  
Minimum    
Long-term Purchase Commitment [Line Items]    
Royalty agreement percentage   0.50%
Maximum    
Long-term Purchase Commitment [Line Items]    
Royalty agreement percentage 20.00%  
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 130 196 1 false 40 0 false 6 false false R1.htm 0001001 - Document - Document And Entity Information Sheet http://www.orthopediatrics.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - BUSINESS Sheet http://www.orthopediatrics.com/role/BUSINESS BUSINESS Notes 8 false false R9.htm 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2110103 - Disclosure - DEBT AND CREDIT ARRANGEMENTS Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS Notes 10 false false R11.htm 2114104 - Disclosure - STRATEGIC ARRANGEMENTS Sheet http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTS STRATEGIC ARRANGEMENTS Notes 11 false false R12.htm 2116105 - Disclosure - INCOME TAXES Sheet http://www.orthopediatrics.com/role/INCOMETAXES INCOME TAXES Notes 12 false false R13.htm 2118106 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2123107 - Disclosure - NET LOSS PER SHARE Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 14 false false R15.htm 2128108 - Disclosure - BUSINESS SEGMENT Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENT BUSINESS SEGMENT Notes 15 false false R16.htm 2133109 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 2135110 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 17 false false R18.htm 2137111 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES 20 false false R21.htm 2311302 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables DEBT AND CREDIT ARRANGEMENTS (Tables) Tables http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS 21 false false R22.htm 2319303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY 22 false false R23.htm 2324304 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.orthopediatrics.com/role/NETLOSSPERSHARE 23 false false R24.htm 2329305 - Disclosure - BUSINESS SEGMENT (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables BUSINESS SEGMENT (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSSEGMENT 24 false false R25.htm 2402401 - Disclosure - BUSINESS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails BUSINESS - Narrative (Details) Details 25 false false R26.htm 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 26 false false R27.htm 2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details) Details 27 false false R28.htm 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Details 28 false false R29.htm 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Details 29 false false R30.htm 2412406 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Details 30 false false R31.htm 2413407 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Details 31 false false R32.htm 2415408 - Disclosure - STRATEGIC ARRANGEMENTS (Details) Sheet http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails STRATEGIC ARRANGEMENTS (Details) Details http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTS 32 false false R33.htm 2417409 - Disclosure - INCOME TAXES (Details) Sheet http://www.orthopediatrics.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.orthopediatrics.com/role/INCOMETAXES 33 false false R34.htm 2420410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails STOCKHOLDERS' EQUITY - Stock Options (Details) Details 34 false false R35.htm 2421411 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails STOCKHOLDERS' EQUITY - Restricted Stock (Details) Details 35 false false R36.htm 2422412 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails STOCKHOLDERS' EQUITY - Warrants (Details) Details 36 false false R37.htm 2425413 - Disclosure - NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details) Details 37 false false R38.htm 2426414 - Disclosure - NET LOSS PER SHARE - Narrative (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails NET LOSS PER SHARE - Narrative (Details) Details 38 false false R39.htm 2427415 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails NET LOSS PER SHARE - Antidilutive Securities (Details) Details 39 false false R40.htm 2430416 - Disclosure - BUSINESS SEGMENT - Narrative (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails BUSINESS SEGMENT - Narrative (Details) Details 40 false false R41.htm 2431417 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Details 41 false false R42.htm 2432418 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Details 42 false false R43.htm 2434419 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS 43 false false R44.htm 2436420 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails EMPLOYEE BENEFIT PLAN - Narrative (Details) Details 44 false false R45.htm 2438421 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES 45 false false All Reports Book All Reports kids-20180930.htm exhbit322-cfocertifica.htm exhibit311-ceocertific.htm exhibit312-cfocertific.htm exhibit321-ceocertific.htm kids-20180930.xsd kids-20180930_cal.xml kids-20180930_def.xml kids-20180930_lab.xml kids-20180930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2017-01-31 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kids-20180930.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 130, "dts": { "calculationLink": { "local": [ "kids-20180930_cal.xml" ] }, "definitionLink": { "local": [ "kids-20180930_def.xml" ] }, "inline": { "local": [ "kids-20180930.htm" ] }, "labelLink": { "local": [ "kids-20180930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "kids-20180930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "kids-20180930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" ] } }, "elementCount": 335, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2017-01-31": 56, "http://www.orthopediatrics.com/20180930": 7, "http://xbrl.sec.gov/dei/2014-01-31": 10, "total": 73 }, "keyCustom": 26, "keyStandard": 170, "memberCustom": 8, "memberStandard": 29, "nsprefix": "kids", "nsuri": "http://www.orthopediatrics.com/20180930", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document And Entity Information", "role": "http://www.orthopediatrics.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - DEBT AND CREDIT ARRANGEMENTS", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS", "shortName": "DEBT AND CREDIT ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - STRATEGIC ARRANGEMENTS", "role": "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTS", "shortName": "STRATEGIC ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - INCOME TAXES", "role": "http://www.orthopediatrics.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - NET LOSS PER SHARE", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128108 - Disclosure - BUSINESS SEGMENT", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENT", "shortName": "BUSINESS SEGMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - EMPLOYEE BENEFIT PLAN", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137111 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia0970a3727f14663806dcdb7e71083b2_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia0970a3727f14663806dcdb7e71083b2_I20180930", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables", "shortName": "DEBT AND CREDIT ARRANGEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324304 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329305 - Disclosure - BUSINESS SEGMENT (Tables)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables", "shortName": "BUSINESS SEGMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i3b696a2d41a54f5f82a204c7a08ecb35_D20171012-20171012", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - BUSINESS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "shortName": "BUSINESS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i3b696a2d41a54f5f82a204c7a08ecb35_D20171012-20171012", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ia0970a3727f14663806dcdb7e71083b2_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "INF", "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia0970a3727f14663806dcdb7e71083b2_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "contextRef": "i1eb51db7e90f4c5d899876d0e23d57dc_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "contextRef": "i1eb51db7e90f4c5d899876d0e23d57dc_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "ib3ed30322faa4ec28e5281f6ac4ac060_D20180101-20180930", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia0970a3727f14663806dcdb7e71083b2_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "icbce06b6e7fe444d97ac1f2947400bb8_I20180930", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i7becec568a5e4815825d113923bb87ee_I20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i520eb942a76c487b9b1282a0322132ec_I20170430", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i789dd944031c449ba7ed3aae9fa8817d_D20180101-20180630", "decimals": "INF", "first": true, "lang": null, "name": "kids:ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - STRATEGIC ARRANGEMENTS (Details)", "role": "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails", "shortName": "STRATEGIC ARRANGEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - INCOME TAXES (Details)", "role": "http://www.orthopediatrics.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i6b1d88ad61a94d5f937386f42b73baf1_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ib3ed30322faa4ec28e5281f6ac4ac060_D20180101-20180930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i7becec568a5e4815825d113923bb87ee_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i7becec568a5e4815825d113923bb87ee_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails", "shortName": "NET LOSS PER SHARE - Reconciliation of basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ie2d7c65f245c4fabbbea7f0f8230e969_I20180630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - NET LOSS PER SHARE - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails", "shortName": "NET LOSS PER SHARE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ie2d7c65f245c4fabbbea7f0f8230e969_I20180630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "i789dd944031c449ba7ed3aae9fa8817d_D20180101-20180630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "shortName": "NET LOSS PER SHARE - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "i789dd944031c449ba7ed3aae9fa8817d_D20180101-20180630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - BUSINESS SEGMENT - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails", "shortName": "BUSINESS SEGMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i96370e0684f0494eb4866ab71511e5a2_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "i6734a8f539744fa5a7629950d85394bc_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "iefc342c7f6464e1c8a1e48c0b71caaf6_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "iefc342c7f6464e1c8a1e48c0b71caaf6_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i6078c5ec11234076b3ff3f365c7756be_D20180101-20180101", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLAN - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i6078c5ec11234076b3ff3f365c7756be_D20180101-20180101", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i789dd944031c449ba7ed3aae9fa8817d_D20180101-20180630", "decimals": "INF", "first": true, "lang": null, "name": "kids:ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i1eb51db7e90f4c5d899876d0e23d57dc_D20180101-20180930", "decimals": "INF", "lang": null, "name": "kids:ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "if606fd3f9bce43caa4a73e9be4f4c34f_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i15fa23ececa845b5a48e8783974f947e_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i15fa23ececa845b5a48e8783974f947e_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BUSINESS", "role": "http://www.orthopediatrics.com/role/BUSINESS", "shortName": "BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ib504c8fa26364673b5cb1afb245db8ad_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 40, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "kids_A2007EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "A2007EquityIncentivePlanMember", "terseLabel": "2007 Plan" } } }, "localname": "A2007EquityIncentivePlanMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "kids_CaseWesternReserveUniversityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CaseWesternReserveUniversityMember", "terseLabel": "CASE" } } }, "localname": "CaseWesternReserveUniversityMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "domainItemType" }, "kids_ClassOfWarrantOrRightForfeitedOrExpired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class of Warrant or Right, Forfeited or Expired", "label": "Class of Warrant or Right, Forfeited or Expired", "negatedLabel": "Forfeited or expired (in shares)" } } }, "localname": "ClassOfWarrantOrRightForfeitedOrExpired", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "sharesItemType" }, "kids_ClassOfWarrantOrRightForfeitedOrExpiredWeightedAverageExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class of Warrant or Right, Forfeited or Expired, Weighted Average Exercise Price", "label": "Class of Warrant or Right, Forfeited or Expired, Weighted Average Exercise Price of Warrants or Rights", "terseLabel": "Forfeited or expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightForfeitedOrExpiredWeightedAverageExercisePriceOfWarrantsOrRights", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "perShareItemType" }, "kids_ClassOfWarrantOrRightOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class of Warrant or Right Outstanding", "label": "Class of Warrant or Right Outstanding [Roll Forward]", "terseLabel": "Class of Warrant or Right Outstanding [Roll Forward]" } } }, "localname": "ClassOfWarrantOrRightOutstandingRollForward", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "stringItemType" }, "kids_ClassofWarrantorRightExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ClassofWarrantorRightExercised", "terseLabel": "Number of warrants exercised (in shares)" } } }, "localname": "ClassofWarrantorRightExercised", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "sharesItemType" }, "kids_ClassofWarrantorRightTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ClassofWarrantorRightTerm", "terseLabel": "Term of warrants (in years)" } } }, "localname": "ClassofWarrantorRightTerm", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "durationItemType" }, "kids_CostOfGoodsAndServicesSoldPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost of Goods and Services Sold, Policy", "label": "Cost of Goods and Services Sold, Policy [Policy Text Block]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfGoodsAndServicesSoldPolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_DebtInstrumentExtensionFeeCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "DebtInstrumentExtensionFeeCancelled", "terseLabel": "Debt instrument, extension fee cancelled" } } }, "localname": "DebtInstrumentExtensionFeeCancelled", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "kids_DebtInstrumentExtensionFeeTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Instrument, Extension Fee, Term", "terseLabel": "Extension fee payable period" } } }, "localname": "DebtInstrumentExtensionFeeTerm", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "kids_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document And Entity Information [Abstract]", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.orthopediatrics.com/20180930", "xbrltype": "stringItemType" }, "kids_EmergingGrowthCompanyReportingRequirementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "EmergingGrowthCompanyReportingRequirementsPolicyPolicyTextBlock", "terseLabel": "\"Emerging Growth Company\" and \"Smaller Reporting Company\" Reporting Requirements" } } }, "localname": "EmergingGrowthCompanyReportingRequirementsPolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_FMIHansaMedicalProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FMIHansaMedicalProductsMember", "terseLabel": "FMI" } } }, "localname": "FMIHansaMedicalProductsMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "kids_LineofCreditFacilityIncreaseInMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "LineofCreditFacilityIncreaseInMaximumBorrowingCapacity", "verboseLabel": "Additional revolving loan commitment" } } }, "localname": "LineofCreditFacilityIncreaseInMaximumBorrowingCapacity", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "kids_New2017EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New2017EquityIncentivePlanMember", "terseLabel": "2017 Plan" } } }, "localname": "New2017EquityIncentivePlanMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "kids_NumberOfRelatedPartyEntitiesSuppliers": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NumberOfRelatedPartyEntitiesSuppliers", "terseLabel": "Number of related party suppliers" } } }, "localname": "NumberOfRelatedPartyEntitiesSuppliers", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "integerItemType" }, "kids_OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation", "terseLabel": "Estimated limitation on losses generated prior to ownership change date" } } }, "localname": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit", "terseLabel": "Estimated annual limitation of losses" } } }, "localname": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease", "terseLabel": "Increase of estimated annual limitation of first five years" } } }, "localname": "OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_PaymentsofStockIssuanceCostsOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "PaymentsofStockIssuanceCostsOfferingCosts", "terseLabel": "Offering costs" } } }, "localname": "PaymentsofStockIssuanceCostsOfferingCosts", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "kids_PaymentsofStockIssuanceCostsUnderwritingDiscountsandCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "PaymentsofStockIssuanceCostsUnderwritingDiscountsandCommissions", "verboseLabel": "Underwriting discounts and commissions on sale of stock" } } }, "localname": "PaymentsofStockIssuanceCostsUnderwritingDiscountsandCommissions", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "kids_ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment", "terseLabel": "Minimum annual royalty payment" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "kids_ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementAbilitytoSellMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementAbilitytoSellMilestonePayment", "terseLabel": "Milestone payments for FDA approval to sell our products within the United States" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementAbilitytoSellMilestonePayment", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "kids_ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementPercent", "terseLabel": "Royalty agreement percentage" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementPercent", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "percentItemType" }, "kids_ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementProductLaunchMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementProductLaunchMilestonePayment", "terseLabel": "Milestone payment for general product launch" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersRoyaltyAgreementProductLaunchMilestonePayment", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "kids_ResearchandDevelopmentArrangementContracttoPerformforOthersTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersTerm", "terseLabel": "Royalty agreement period" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersTerm", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "durationItemType" }, "kids_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition - United States and International" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_SaleofStockConsiderationReceivedonTransactionGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "SaleofStockConsiderationReceivedonTransactionGross", "verboseLabel": "Gross proceeds on sale of stock" } } }, "localname": "SaleofStockConsiderationReceivedonTransactionGross", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "kids_SalesAndMarketingExpensePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SalesAndMarketingExpensePolicyPolicyTextBlock", "terseLabel": "Sales and Marketing Expenses" } } }, "localname": "SalesAndMarketingExpensePolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_SampleInventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SampleInventoryMember", "terseLabel": "Sample inventory" } } }, "localname": "SampleInventoryMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "kids_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountRate", "terseLabel": "Stock-based compensation expense, discount rate" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountRate", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "kids_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisableNumber", "terseLabel": "Restricted stock exercisable (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisableNumber", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "kids_SpineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SpineMember", "terseLabel": "Scoliosis" } } }, "localname": "SpineMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_SportsMedicineandOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SportsMedicineandOtherMember", "terseLabel": "Sports medicine/other" } } }, "localname": "SportsMedicineandOtherMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_StructureMedicalLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "StructureMedicalLLCMember", "terseLabel": "Structure Medical" } } }, "localname": "StructureMedicalLLCMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "kids_TransferOfPropertyAndEquipmentToInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "TransferOfPropertyAndEquipmentToInventory", "terseLabel": "Transfer of instruments from property and equipment to inventory" } } }, "localname": "TransferOfPropertyAndEquipmentToInventory", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "kids_TraumaandDeformityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TraumaandDeformityMember", "terseLabel": "Trauma and deformity" } } }, "localname": "TraumaandDeformityMember", "nsuri": "http://www.orthopediatrics.com/20180930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable - trade" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r19", "r25" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable - trade, less allowance for doubtful accounts of $131 and $143, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r7", "r8", "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalty payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r49", "r50" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r47", "r50", "r195" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r78", "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.", "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AffiliatedEntityMember": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.", "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r156", "r175", "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r43", "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r217", "r227" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets [Abstract]" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r46" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r157", "r177" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Interim Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r213", "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by project.", "label": "Project [Axis]", "terseLabel": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r28", "r75" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of year", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r69", "r200" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "NET (DECREASE) INCREASE IN CASH" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r76", "r78", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodEndLabel": "Ending weighted-average exercise price (in dollars per share)", "periodStartLabel": "Beginning weighted-average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding at September 30. 2018 (in shares)", "periodStartLabel": "Outstanding at January 1, 2018 (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r79", "r145", "r146", "r155" ], "lang": { "en-US": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r126", "r221", "r233" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r125", "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r136" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00025 par value; 50,000,000 shares authorized; 12,807,520 shares and 12,621,781 shares issued and outstanding as of September 30, 2018 and December 31, 2017" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r16", "r17", "r137", "r140" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Conversion ratio" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r58" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CounterpartyNameAxis": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT AND CREDIT ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r204" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r39", "r225" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly interest and principal installments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r82", "r137", "r141", "r142", "r143", "r203", "r204", "r206", "r226" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r31", "r205" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Deferred financing cost" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution as a percentage of employees' salary" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r73" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r147", "r180" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense, weighted average period of recognition (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r78", "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r120" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r78", "r199", "r201" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "auth_ref": [ "r78", "r121" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.", "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "terseLabel": "Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r57" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r122" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment charges, indefinite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r122" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment charges, finite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r78", "r184", "r185", "r186", "r187", "r190", "r235" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.", "label": "Increase (Decrease) in Accounts and Notes Receivable", "negatedTerseLabel": "Accounts receivable - trade" } } }, "localname": "IncreaseDecreaseInAccountsAndNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable - trade" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in certain current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r121" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r78", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Amortizable Intangible Assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r117", "r118" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Total other assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r202", "r205", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r223" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r44", "r111" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r45", "r78", "r112", "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories, net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r219", "r230" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Revolving credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Revolving credit facility with Squadron" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Three month LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r218", "r228" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Long-term debt", "verboseLabel": "Mortgage balance" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt with affiliate", "verboseLabel": "Less: current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Total long-term debt, net of current maturities", "totalLabel": "Total long-term liabilities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r39", "r128", "r129" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Revolving credit facility with affiliate" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesAndLoans": { "auth_ref": [ "r39" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes and Loans, Noncurrent", "terseLabel": "Long-term debt with affiliate, net of current portion" } } }, "localname": "LongTermNotesAndLoans", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r39", "r130" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgage payable to affiliate" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69", "r71" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69", "r71" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r74" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r54", "r74", "r91", "r222", "r234" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r88" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r88", "r89" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss attributable to common stockholders - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Note payable to Squadron" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office and other equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r87", "r96", "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other assets:" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r192", "r193", "r194" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r192", "r193", "r194" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss", "totalLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r36" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other expense (income)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expenses:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "terseLabel": "Dividend payments" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r68" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payments of deferred offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r63" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of licenses" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r157", "r177" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r26", "r27" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r65" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of debt with affiliate" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r64", "r178" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r101", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]", "terseLabel": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r30", "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r124", "r232" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r29", "r78", "r124" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and equipment, depreciable lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r123" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Depreciable lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock", "verboseLabel": "Redeemable convertible preferred stock - Series A and Series B" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r67" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on mortgage notes" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r181", "r237" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r78", "r181" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "STRATEGIC ARRANGEMENTS" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r144", "r229" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r148", "r149", "r150", "r151" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyAgreementTermsMember": { "auth_ref": [ "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "Terms of the royalty agreement under research and development arrangements.", "label": "Royalty Agreement Terms [Member]", "terseLabel": "Royalty Agreement Terms" } } }, "localname": "RoyaltyAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds on sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering price (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r39", "r82", "r137", "r141", "r142", "r143", "r203", "r204", "r206", "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r30", "r124" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r80", "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STRATEGICARRANGEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r56", "r102" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of product sales by geographic location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r52", "r53", "r102" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r97", "r98", "r99", "r100", "r116" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r97", "r98", "r99", "r100", "r116" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of product sales by category" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r157", "r177" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r163", "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r41", "r81", "r132", "r134", "r135", "r137", "r138", "r139", "r141", "r142", "r143", "r144" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r79", "r145", "r146", "r155" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r0", "r102", "r236" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENT" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "verboseLabel": "Redeemable convertible preferred stock - Series A" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock", "verboseLabel": "Redeemable convertible preferred stock - Series B" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Terms (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares available for award (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r165", "r177" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at period end, Weighted-Average Exercise Price (in dollars per share)", "periodStartLabel": "Outstanding at period start, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r155", "r160" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r78", "r157", "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual Terms (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Business software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r0", "r102", "r151", "r153", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r136", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period, shares, new issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r136", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r136", "r144", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Stock option exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r136", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r42", "r136", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercise" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r109" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Instruments" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Accretion of redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedTerseLabel": "Accretion of cumulative dividends of redeemable preferred stock to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r10", "r133" ], "lang": { "en-US": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]", "terseLabel": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "verboseLabel": "Redeemable convertible preferred stock, authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "verboseLabel": "Redeemable convertible preferred stock, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r19", "r25", "r78", "r105", "r106", "r108", "r110", "r220", "r231" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.", "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r93", "r94", "r95" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of shares - basic and diluted", "verboseLabel": "Weighted average common shares - basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofbasicanddilutednetlosspershareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "32", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13279-108611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r239": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20187-122688" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m)(1)(i)(B)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" } }, "version": "2.0" } ZIP 64 0001425450-18-000115-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001425450-18-000115-xbrl.zip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�,B^-]-(7W2@P=@6L>\*BUEK:YLW"P6#2GQY']K_@1TR7 M(WH/KI/%M]3SFYWJ+3&LN2,^[I2'7!09M$X7VB4B[1P\)B, . ^\-^M:%!@H M1?:&T(H%%R53GO89XY+EMJQYQ/3Z;'R23F$42WT M-7Z/HRDCO[)>20#-:TU G,;V)3/M^,RD3=P#@#"Q30^KC@;072/>-1%='WTX M'U2*N;!0HU2T4$#K1R@L\ARYC[5+>Y.EM]MA;.IH ''GAA* MM829T>0PZ2QH?S)2,"<%))ZM][%-=^E=._;<)DN>?T2ZA+8V1JQ 1JGPB"2TA B?.='I,OH[.D#LE4$OCM4>,D46/V(=/,,:*CYCSBB MY?#@P8,X8WATEJ"1:^.9!EYK;M.J9ZR3'DHDEZA-MX3%F';B&'0IE+#(3-"$Y>4O.,UD%H8HWJLT9Q2.8]H0*Z\N[12&T]8RF M5UV**>G652BT.!;0.)/HC;VDU/P5P2_V;=X41SV+JFNIL MT;R^"YS[0[>G.B[O,]MV(D0B1Z>]LIQEG2W3M3)-4/3%@I(\"PA>-;G9W.$0 MB6Z5NW+ Q#*:V5@[;Z^U,25DQITE4 $-"\$:9KR?MFT(Z6NES3ULY]V8&NM* MO(&9=%LJND*ZKI$^ U8$9">29$E!IJ%*RVH0#PM"2)-C=6R:.(\+$>T9';J1 M?(,>*;,LO1N?-DS8!)\*)IV=;](JZQL4>Z;ZU27<(,%] M31OLX+S62>Y9\"8ZF4B3-1S=<U.;,VB71[PJ]-GPINWG- M+[1C6H38O/K]X]'QX<>/'P]__>WP^'25*)KY1W07*/,HN+E8F!"%,XX6G!JO MZXT+3L=H(*$W!K/ 7I3&N> MR]-8&*XX"\8ZYKCUQ (AK%L_VW .\>K)NP\_ MJ)EHGY.\&UU2(BKP.E8!0PT4 QE##EH9E7K*@]6"S/2405PGJ,=<(UE-))M= MI5BB[%K 7:1S/O7(9D)?*IT32Q&Y9" 7*&N;,W ?O+8I$G<-R-)3AD-6/#(O M8DWGM)J%DC@3'KPORH&5KFOQWYS2#LL'_(*#2XQ7O^+PTP@N/O<3G+VK^RH) MJSOE+/G"9JI;9^#S\XJ4:9/VMI ^(W*? TBR0*25(5J3>J0Y)3W-)NWYM+," MJ9B(P*;=@8LV5J9U@_AF@QC7[>R0X(T& M!UNE,8V%,RA5D$D6'83-Y',W#;*;1[3]Z\?VK%@45+>6=IH$47R: MAS5S\\D@<=Y#9D9I,JW)JR?'1M+ E1>)6PB&-[TE7(ALRR%VZVGP7DQ%E^+? M.7[L 2^>&W>W0[1H0(=I2[#15>_WCSWK@_;%18; .>W+ 1D@8XU]?NH7>;=UH8+B6^!K,Y^/AX/?Q[/A5&MK# MA+;,)D46EH- (\'"I(5B+>?$5&PQ@^]@>.F*75>L#>ZU;FR;G@4GK95D0$,M M;%=B8&"RIJW.E"1*\A::'$S? -A"AXMM^!HKR7N;Q\$/''.\IDWLTW!TU?1, M9_XEFSS'>72 W4U^^.U@Y:CI*7:BEJY6]4S-62^U"4X M)@,@=?"A23WJ%;!NZO2E6-4GD%T(8? E15-JK8]!&;[ARJ-"##L6!$-C.H9IFIBS%"-;V(E MK!-D39)-661FF@?# OV*64RE#EZ%;%L>HBQ$MIU#E/65]S ;.I+\SE%C#RCQ MQ/G)CC&B 1.NV[%?T&X[\P\C5\94KS!-[_],M+7W$#"0+F7K4!61GK*VYQ^Z M>5^K(SD/.Q!2]\JB#8R\^=Q/! @&^63R&4G([@\!P+T!JN%TI]Y-89!(AM8 M1T]+#M9K'ID=9"3'+CQ/MXO>L!=Z[41\#:)W;P]BA,M>B^N6IH%I6BE8T)Y^ M!(XZ@4C)-@KEW];!5W,W;R79;O20Z\/ANX/3PS?O#SZ<_N?IAX/CCP>O3X]. MCC^NUPL470US@\?.J1[>7^G(-!+5(MFE%5HLPM%%3*<(J^=MAT+1=!:E1(&6:+ U&CQ>QQ8ET%:#[YI_.KJF[]< MGS2XX&GK22SSVN$QYYH=SDVM4. BMU:3+EO'9CT;[>9"LCKDT&.A5VWTM"M' M@L\;W]2AU;HH0285PT!,DMK=2U3[KUHTAOP^1"W?WS8C"[W3)DF M:FN2J/H5S\QHMRGP3!L. UM+7EA1F]6ZQ'@!C<(%P6-H>9YX'])V#A);*?$1 MKJRA@=WAQDOFQ!,GB;M-B894."AEVN$-\^%@\M4;%X[\/=JM&1A?^YQ'A#\/91C#(>HJ:3QE<7\HM"B'6P#(<7=1!UA3=*;TS!(.V M)!:5)Q^=C#46?4)6N/?1GA= M'W(.YDWP&\B@HY LIZB95B4SSR/Q&$'; %GJT-BP>";2[=@;ZROWWC;24C-- M#(XN >\AA9XP3W:<0:WNTM[^=O3WNN9.KX'@[.8ZXJ8$#+J48^',NIK#[Q6- M7XK,M!$FB1)H_',AJ@LN7!Y]S39LCR:Z&381;.?7IY,1(;DO;PH_ M&2,P860I)2!CR62RNP7MMK4)M,A<96N>I>Z%K]A+57IC>3;^!CBSO#?SZ;$-!+_[F=Z2@J4J1# 6.,Z=&U0I% R9;EWQ0J(NDG' MAV6![@F3-J*GA2M+BWO>P]_>OSOYS\/#5X?'AV^/3M^_.SA>Y<;QH<=T=\OX M),BYF\5<>-8@DT8M: ZGX#(O5I-B%2D;=:_8DFG;!B93+>E96XA%Z15S*F'Q MVD?KUJ\#\@#J+DJQ/.>Q346_5$D6JQ1W/$6?@]50@@=N5/$BT513(NL>I*"E M0D-3 6@;E[4X2\BD&2^>UQWHG\VZ#F1"UVT#%&ZI&JJE8LD=N6MYEE:A0%[0NO@M"8;%AR) MW$7#_E][U[;:-A!$W_LO"WN_O 1"GPLA]-W,WD+ LHJCE/KO.^,H:6*:Q+&T MM@-YL PRML[.&6O.SLZLO(3*A-=)1P>V*FAI\@G.O\>O'H6 ?5Q?"B-221QU M)-=@5>#6HC"M>#X;G#DLN'&H6+EGD)1CNE8,"M9%EKVJ&)VTMBE/K&^@%KV? M9=T]1J;O?=?=#J2J_P5"_+ME9\ Q60T5,OG*?'08JIP/WD(H)3=I;-P#VU0] M]?HE'A*4/N=@$MYM?+48EF62#(0 !M%PGDQ5TC3)K;R#ZUB5"W-[QZY,FM/\ M9U.F *N;AVR3$>!0*&96,M7NV6W?8A",)VE#(0TAFA3#/"$XU6+ K+3N*NN# MS-MB*D9 'JOG:\DA"QQ+YI07P(,OPC!!#Q4-VD%LVW;T#,N)Z@,.8^5_W$XP MZ1FP_"G9?6^E_R3D-B3U!UJMN^]&,"GQXI(%%JO9EM$KO!$EQY(T5'-J4)8U MB?$O4)P@_W$H'_U;ILPG/%6>;E:W<-R'-L5;.A+"ZV$MB84)B05-OG M&8 RS -M4>M4309:^^,;^+Y\;'F5 #A1 8 %0 &MI9',M,C Q.# Y,S!?;&%B+GAM;.2]ZW+< MN)8F^G^>@J=F(KHJ0MC%"WC!GNF>D&6Y1C$NRT>6]YZ.BA,9N,K9.Y54DY1L M]=,?@)>\)Q- @A2KYT>5)27)M=:'Q,<%8%W^Q__\\;CP7GA1SO/E/_\4_,7_ MR>-+FK/Y\N&??_IZ_P%D/_W/?_DO_^5__#\ _)]W=Q^]]SE]?N3+RKLJ.*XX M\[[/JV_>WQDO_^&)(G_T_IX7_YB_8 #^I;[I*G]Z+>8/WRHO](-T]]/BKQQ3 MF/J$ I^P&,#,3T"6I0G G H$TRP@&%T\_)6%$>< ,,X!37P? M8\8"S+/ZH8OY\A]_5?\CN.2>-&Y9UK_^\T_?JNKIK[_^^OW[][_\(,7B+WGQ M\&OH^]&OW=4_M9?_V+O^>U1?'2"$?JT_75U:S@]=*!\;_/I_?O_XA7[CCQC, MEV6%EU0)*.=_+>L_?LPIKFK,3^KE';U"_0:ZRX#Z$PA"$ 5_^5&RG_[EOWA> M T>1+_@=%Y[Z]^O=S5&1Z%=UQ:]+_J!&]C,OYCG[4N&B^H@)7TCMZZ=5KT_\ MGW\JYX]/"][][5O!Q>''+HIBZZE*2Z2T#!*EY7\])NS7,]1WI&^UKZL#Y6IS M/[G2L0_33\[4O9?\P(=7>$/,V2HW7ZCK)1OKN[L2=;;JPVOLZFN15W@QPM=B M+69#Y87ZPT?Y4RM&/:B'3&LY+75OJ,I_5'S)>,.66X_VYNR??Y(_S9Y+\(#Q MT^PJ?WS,EU^JG/[C=_Y(>#%+4A9'$26 <"[?72+U 8)A!L(@9!GEOD]".JM6 M7^H97X*O7SKYM9 3$GXRL*TZ,D<+7N;/!5V_W1X7AUY9\FVEWF_9KTO\R,LG MW-X@U52.0*/YOS0*>K6&_^/7M1DVX"V&AV0Q'AK>'XUZ_]]16'*ZI7Y6O]2M?5&7W%Z#^ OR@=0[^ZW$AO^X-YF71 MJ8X+>@+W]HI?:2[]G:<*; V!\@\U;:QRS>]!@Z84^Y.7%XP7TH<]8,+>]_$] M)]6-=,N*VIF]66NL+;X6H4OS" M:U3WUKJ[8Q-SO%S2C('T4?G'')5=8K)X@AUCW_F/.RMD=?^'+9_Y!JG"5+ZL"T^KO M\^K;U7-9Y8^\^)POYO3U7BXRWDG]_C$3F"4!S:@$RX< $DX!IBD#1/A"I &* M1:HU;RUD3VY>-]I[=YSF#\NYV@KS@/=5_B1?@#5UEAY>LN8-N:RWRO!";_K; MC$P_/0R,]]#TT4)=;\]VJC?[MIWRWA^-^I[2WZL-T.1:&[!9NX=3/L+5["9SS"#OG;6/Y^AD7MT7C M&_X-+YZY=!"_?,,%GP4\HBD/ H P)@"FOB_7F9B#",.4^5F$(T(L=Y..R9S: M2Z'=42F5SA?>$RZ\%Z6N]_-\Z;%\L@\CJH>NSC!:F!.,8/)F#U.0N"2,XX+&Y4I3MJ\RP^G;[!CA4M* M\^=E57[&KY@L^-5S44@Q,YJDDA(0 WZ<, 9X0!GA( TP#YG/(8A"DPHX;"8 MJ?%!IZ7T16HUY1)5>HK,+Y M5ESC8CE?/I2=8_+N]? #+G_,RQF6+@1'&0$H08%^-F2?/'YN13.:==D&N[ "*$28(/$2 P3@$480*RB$D?DB=Q M'&'N)TEBPOR]TJ;&W8VRWDI;KU/7 SL#<& ./0,[8Q[5PL0E$_8+ M')7+M&S?92.]FRRWJ.@WSIX7_%;4&V'O7J\6N"SOE:,[BWE($Y&& $48 8C2 M&) 4RK5I%O,XC%,D$J.XK!Y94^.23E4O%VWX(7GU:G6]/VJ%3?>L>F#6W+5R M ][ /'(&;N:;6*<1<;J-U2-NW(VLTW;O;65IW'+69I;T?NKS/.7DD+(^ZS/; M?3GP@ E]K==*>IV6XOMF!ZKCVS)]-UA]W7^Q*LK M7'[[7.0O<^GIOWO]6G)VL[Q9OO!2B;NDTJ-O?/GN:\Y9&,$D2 "G20 @1AG M*0Q!A!"$\C\4<:/=%G,5IO;RO/GTM^LO]S>??O,NK^YO_G9S?W/]Q>QU:3$, M>FPS++@#LY!4WE/:>YWZZN7ZL[+ FR]_\59&>&LK!F$I>Q!=LI>%%J.RFCU* MNVQWQI-<;DY_DE_-=O&;!JD(2(0 "C.B]AEBD$4H!A&+&$^#($W#\/P=YK7 MJ3'#N0S/\+NR&S ELI>XCH+N ^R\P+_H1?U=9&>2L^YLN'>UX\JK2/61BF6!#J@RCE"8 ($T"(#T%*TX@( MG.$LB6=[N=662]?>H]Y43W@!^XM\XJ7AMD:QV#6 M8Y:S4!LK$/MIA97PE)) O@X>/:6FPZR.$T X3?$X)FOQK9OQ6M?:>@5R,3.G\B6[6=4@YE'B MIRP"D&)5IRAF ,=RSA.6$9&AS*?0Z(CSH)2IS?>UDDWHONE[_Q"0NB_],^$9 M_(V_0F:H,A&]$+A]UQ\2-/*+OL?6_;=\W\5VD_Z>/S[E!2Y>K__]>5Z]7E): M<'78>9_?<28_4S_7(?JSD"1(3G\*?.A+-@BS"&"*?)!&F$AW $=<&*5H:TN> M&CFL-%4^;R%UY8]U)*T<\A=>5'/U\Y/\FG+)TE;\H3\F>IPR"-(#\\Q*9Z]1 M^L);PU[EWEKQ)N7''?L8@^62D?2%C\I2QICL,I?Y ZRS$I^>)0T5 _"A"*K@_S"1WQ6K_-(I!D,6A7+O@*$V982;B(3E38ZI.38]W>AIG&!Z$ M4X]V'( T])*EPV>EXC!5K_I@<)PM>%#4V!F"??8>R KLO=PRS*H."\4E9^KY M?%G6$5R71:&J9-0;)>]>U]>T&WZ7WW'!ZO_=2ZF72_99?ELV#@2H@%E Q^$ MF4HB##@&A' $4D83%B6)*JME%)\U@))3HZ"&\+U:8=O\PR'&4H_"WGJ$!N8_ ML\$Q#Q@;$#VGD69#Z#ENB-J 2._%M@TIRX[MNP.;^_R2RJ]TP3\7^9-W0B^@XS'"24IP!S)]2R" M,4!Q1.N:B8*D"',8F7BB1R5-S9U<*>KQ5M._FM'2<4SU6,@)4@.3SAJD3LE! MPA)/0N&23HX+&Y4]3MJ\2Q:G;[ \K,M?\:)ZO7PH>.UTJ1/_LMV>@5G,,$(1 M0(() ",_!43^#GP8B("%:8H1-SJR.RYK:OS0JNJM=/5J90W/[WJPU3S%4(F-#G6AJ@5T:8I7FN+5QMST52: [4]WLK?'^*% MZP9;IU70S]-HW,KH3M#;JY;NYJF6N]QXE6)XE2_+.:M]#26<\OD+9[?+^P)+ MA6A=EC;! B<0,1"23)6I2>1Z04@O080Q3"G#2<+-MJ]-I$_-45"Y/4]%3CEG M=9QOB9LD6HOC>K-1T-QX'@K;@5GS"][(1;[PMG3W.N45WAOJ.]QPMD'-Z4ZR MD0+C;A';8+.W]VOU$(LR]&O*/++)3%[W6+7>7E9\K%)55;^*679 P"6 B0)@E'$#((T!XHH(C8A[%!"=AJI4'8B!S:NS9 MJKS:BZY/.>BNGCL'<<9G"K;0V^%_F0O'C=;;N"4<8CEF: )JD/8$QB0!+L M XH1PM;)VTMN>#)_%$X]3G$!TL!$LE+QPFN[ )ET M [(HL->/B-O:>D=DC5Q6K]_B_8IZ)ZZWK)NQ6.3?51_Z#WGQ/G\FE7A>=-6C MFR7I9G5RGH0^(B$%21@) $5$ (I##A -XMB')!&940\((^E3HY"5\I[("X^U MZGNXU=^PE(;1..C1S&#H#LP]V\!VFGNKFO)KW8X44;\N/3 M@&-?9(!AHDX1,@R0" *0L) 3C'$WC6A!6IMC4W9?FL MEHL[!0 #%B81CWS J0BM",&"/(Q\ 6C4488BB.C4*S3(J= W&31OQ>:NS M6AK@AV>;@-YL #I4649]>-P>G9V4.O+) MF2X*^P=GVG?:%G2K8U _XZ)ZW8C+6J5Z*L&;U\Q4<)2?,*K\$E4F!4& >207 M/A&!&&'(,DC-:KV9*3 YDMK(WBS:H.\GI:AI/3C#<="CIR'1'9BLN@CZ6J_- M6- +;YV(7!/9UI4N:\S98>>V_)RA#B-7IK-#:+]HG>5S+*)&[WC)L7KNDKWG M+WR1UUFX&Z%35_FRCKNO\L^\$'GQ*/^KPQ7*W;2;2R)=C^JURK_PQ>+W^8*7 M5;[D+2%(HDP1"5D("(M4._DL )E/,,!Q%*>9"&*:">W TK&TGAJ[KO3S5D6D MU9'9A_>7'GYZ*O(7O%#$6TI3/"E4A>NS9RJO4L[A?.E)!+RO:D^0-7WT- \M MQ_VF]%/Y9,=_,PPSA*PMD+ M+TCNK*29N98FM+6IZW#LU>KJ/2AEU2FE?!F5RJKR^.'D:&/*AYK1JW=GC;%SJ M[@Q1U@6.'_-EG;572RYOGZNRDJ[+?/DPXRCQ"<,$<*&Z-\&8 @PS"G@<^D1^ MP+ P"G#M$S8U#F]T;=*W+UH6EZO&E;[&A8^/P\SBP&V*6]3UI^H+[WZ7OL7H8?ZHC CRHB<"=@\&O)Q?/BXUSP M68Q%%C$: !SQ2+T455DT04'DAQAGJ1\*I%4#P$3HU%Z.&Z&V=3[JA?=H[/WL0]18ZHQ@<@EY6C)'95Z3)#8 MI2"C>RUWY^@WSIY7Q5&^Y0MY;]G45_^45_SON*C7 K?%W?SA6U6NDR[#,$U1 M$ 8@HQ0!R#(,L)_%P!>8$HP)BG%FM%]CJ\G42*LS1(6P=$H;;LM8#XKFYLL8 M4 ^]Q;*!\J85_]3V7?*4(1>K 9"3PFN,\?ZXK[M>#9)1>S:R3G=,K)49=U_D M7,SV=C_.?N# =2HWMUTV)F^0$-\G(@ I01S 5#I[&8U"0-*$R=\$Y6E@PJAG MZC,Y7KV_O?K?_^OVX_OKNR]REO^_7V_N_]6,5\\=(#UV'1'V@3GVW%*B@U"L M(WC?I)KH$96F64ZT'S_K>J(G'FM'O;_Q)2_PXG+)+MFC])I5E=)*^LUM<9>N MOCA$(28^5='KIT#NC !'D:RP$2YXQ H)')3,C+'8IR^QF.V*Z?GQ:Y*^K0\J:_$P)0^B6^#\3MAM!%R^3X9 M7NE1WT6CC<'N>VP\P;;I7$V@ZN5VH*H9!_4_9$($TBE:.X4;J@XR[_50<9O\ MTRMQY%0?'>OW$WNT[K(M^4GS1WZ/?^S6J(1QF+(@0R# 6 8$ ZR$&5 D(@A M'L=I&AAE3A\3-#7OJM'3DXKJYKFD35R MO<]^B_?K?9ZX_FUR(#9"3_[.U9F%?#>_R+7K@URK\H+.2_ZYD&_^NWRQ$'FA M;IP%B/ DJX=&I "2A "2B!!DB&*6I2@DF=GQ[.@F3(W).K5!J[?7*>[5FH\; M>6_QC= \&Y[T. ]]J.PP;G\#B NO@\([_-T9Q#=\NY&<4MB_A15_JJP ^U%R MG31PAB9G=Y&KG_R9%[6",QK $!.8 $AQ(/^7,M4^*091'$"8IA#Z$;%L&+:6WY^+IGWQ(LF$MLT0^P8QIIO$P?(#C8D/TB/MX-0#-3.;5O66W5N.VAQ3Y.VP]>?&^)X)Y?[R^>F=,?U#SDC MEWAQ]5Q6TN4ORLLE4R6,ZFC+IGCKN]??>/Y0X*=OC81L1.$/@Q MIAG B0]59\H(9"P50/@IC2-?,.$;G;T,I^K4J&HS?*^MCU&WLBR5>_6PLL6K MYU5?K\6QAUR3]R8QD$,SY\88MF8VM8\Z.[V5H?5F:%W/K0E#[PIGR\'>M->K M#1XI0G.HD1DFA-.YMF\4XSD4ZL>#0 >3>,X.<5WX1WG0'UN"N_PQ+V<$)6%$ M&04,JHK=29(!$F3RIXAP$2 .&3-K?G!".U>Z$I7KU-6KHVENH8GYWT@ MFVP?GPW=.#O(YJA9[AWWXN%^^_BPN#?80>ZU^_ F4,^V$20>EY)FG 0Q]Z8C&$0(X2#!->2H"')H0QS%!4V.-E9Y= MUL( R4+]/\?)D?VX.#LR M.D,%Z]X63[RH7C_+&5K)1;]2H([[^L2K&1$$0>8S$ >9Z@@?$D#\. :Q"#D* M8!@G9HF7?<*FYD%WNM8[=+Q3U*([J\)5[@-S.N=FA=>K6B-W/4:N4\] MR-GTJC@)B>,N%)DSSMZ]?BT5.7V8 M+_&2SI5 L/-%*FY1Z7JZ@RZ=DY^48<]M17*\1&=!1Y>F6!&.@:CHD=!PV ] M,"$IF)76WN<-<'_^VD&^4MZ[/ VS,4.9(^:2KPRDC\I>YJCLZ>R: MRPZ-PUE<=B:Z;\ME*^7'Y+(>Q$;@LD/2I\!E/:AHB)\ MZ'HBK#?\>4AB##.5FQ.JT'DL .8X!?7;12OZ@1-[QI[Q0+Y*;I1)8[T*^>VT_K*-W9G'F1S%C 0BS$$G7 M-9.D+B))ZDD09S1#68;,8L+-=9@:AV^54&ST]%96>!MFU'%ZW15-<)XA7]N, MF.;1TK#C,/01T2!#<$[92E,0!RI8J:W&6Y6J-,6IITBE\:/L6+-KT-MUL%0% MSN=5':&TCB."D, @AG)%K])G,I8 $OH0H!2GA&%!4K/,&0V94V/%==?I3FEO MK?49+JL._'J4YQC4@2G. 9[&?&: D$O^TA$[*E\9X+#+3R:WOGE2_*?GNL@@ M#1/"0P$!R;#T\5#( 4(B!%0NYQGA(N0D,V]PXUQ/D\DY7E><#34]7'F-8*]4 MDM^NP=S^&(>I3Z,XY:I#E"H[CPD@+*" HQ1BGL(L])%I>YT)C/#P/7D.CR]? MOF'[P/W1U?3YWW*\AEX1#%6"H+%T F%AIP9A$L%?1Y7\JK7A5(4/VC6N1EJ(/M?$!,8GI&V[]T9-[U6\SNHC]54OA/[IVP?OX/9 M4(WB=\58I\"JM%K^GC?_WBP_%_P)SZ5Z@A<%9VT%[LLEJ]5H$G-G*A#TC !& H"5(1I7[ D$7.B9TV6IPP?OI(J[K'&YV;Q/N\3AF@S](8 M%:Y:ZV^<3VLS8GKN_( #,%H6;JVX]W-GPB]U(D8[%ETK #443?;&9?\0V"3G MGH&@X[Q=&TW&3ND] ZT#V;[G/,V60:4;R,NJ235N)=2I#!QQ2J(0A%&"U09^ M $C$?F60L0E MCFD XBR.&T=3$_M>1Y[#0U/%PZCJKF*9$3 MK(8^[FF4K(%:J7FR$9_Y8NAR7-N[QR4FK]\Y!3M]AQQ$?\H+/'Y97 M]1X,?;TO\+)4B4+RK2F%U;\NZC.74 ^A'B70O6 I0 @- :IBEF7&,_.GI4- KF S-5+]PU?VW:,4H_D[-A M=4EZ]LJ,RHEG8[9+F><_T(Y15\ECS:KY8UZ6LP3&,8Y] CAB,8!I& &BRFF& M@6!!R-+0I] D/_6 #",6'"$1=9T0N9#:F='>(0CU".U,8 :FJC4FW=:64O!X M<),Q\?28[Y)2#HD9E2QZ[-RE@;Y++9=570'-)AT$0X%#GF1 ,%5Q+@T1()!P M@#$.DQ@'TA[?)MM[#073-:(#+U(T@;#?&%TT&:GBZ%M M">,N@ Y:M[?H.7R5W:Q=QXFKU[^*+)"<(!V#.2_?STLJ7U+/!3?L_6GTS E] M;S?TKAWD+J#M'^R LWE%]],@5'GA14VN]/&[B$3:R/?%->3/GS[)W5= M,.-!3#(4A""*HA3 &/H@2W@,$A10/V2'YN?"*M65UI/XKQX5IH/[(7Q_#\YO)?2E&.Q0:J,7\15L# MMB[9L '"GZ#??._8_2F:SQ^VX#]')_K>T1FM+7V_%A8)!^JL*F\:C\G7>#EG M]5(V7\KG<]48)E]N[&K]5JAM$B)2&K,@ AA! 2!.$$ ",A!@$H>$N/V+1X[7ER^OE'%U5-! S+")5VUH$+ $P$ D@2#67 M8IQ!]4$4V[1LZ!6J-8/>(CYTI>&Y<#]J91[3K8.0A@/X#)L''J MFP+?.!S]@.VGH\X/W>2*1E:;^U?X:2X]M-7^'<[\B" N%R^Q*@A+F,K+AZIH M#"<<(II!'QLVK-,4/;5%_M4WE4U5JAE">5%A]>]6PDV] [B88S)?U)4N_WHN M\QP=%%L:<@'UVW#2^L"O57V0'55SQ(9EK*/2WYB^3J%RFLM./L%R%Q472_G0 MLFLL+5>C:[J?KQ5KG8O']7"3OFTW_(%4\5 @4>4736_ ML<:R>J.2Y8L%+DKKUO.G1@N%*C*.4\ SU68A2E- (&(@S#AD:1(@Z!/#N'MW MXS7.DOM/-F*:^\+N1F'HC=Q64[7=VFSB7GCO5LBV^CK<=-4#QNDNZ0F1XVYK MZMF_MP^I>9O%QN'J/:7"7:YP4;R*O*@W,C_.'^6+JPY[RY=?2WY=5O-'M;R] M?,R?E]679_)O7"7"I"1!($88<21@ 0SH5VCQ*5F M4WM/K326[G2GH]IN5$PH/? 'OE2VRX^?BGE>*!+,O\L_E=_F3QZMW72/R<\- M-B2=CK/&5N5;C=[ ?.G2+$?;FT,@W;OQZ53@>%NB0^"TM5DZB("I]=%=G7:U MY>[B.$XQH0F(&)(NK$A\1?D)H"0B*!6,Q4$Z8L%*4_U-J.7_UD*6QM\)3A%# M, A %M>MW*$/2)IQD"9QY$=92&+HCU;@83"A(IJV S>)XIK&RO\YBF[:CLEX796/*6#;;$L=_SC_3$PUWLQ MN_V^#OQ&[93U5ON:/V\BV2KL,(U.'QVW[;Q.2AVY69S4WBJK<_!< M>'RU'8IKQ;=V184GYD59R?^_\"9UX(VV/0]] T;>"3US7/]$FZ,'+)W@?FG/ M>(RVA7I(AS_GKFH/FH-MM/;)M%M3O.>D6F?/K>NL4*1\6Q6507BF0C.0?%E M!B(&$>-QFJ+$J K.$3E3X_GWU^_NO$S6J;WK"WEV']-3E]IRPWM3X MN.J6EX;"QYA@$(2U ZDV%T1 0)K% 8PX]5.$3#GA@)S)<8+ZIJ_U/*,EX3%@ M]3GA3+C&X 13I*PXH0<'UYQP2-3HG-!C[R%.Z+ON?Y4YNGG7K>$W[MHG&Q$//%7#OX[!B2>M/W#'P&GL K MS0:8PD>L=CF)=T6,.HV/V+<[D8]==E[]F3M>[RY_7*9V;,G_A7SA]+NIG7_^@BV?&V0=IB J.>&[V(6_%;I#_>C$;^A")",<@ M8I'T.N(@ 5BU10H1I!FC F6)$3&Y4FQR_+5AE[3%FP=&Y^^ MVL[/NR\P6_?&I%2=-)=-A22U:=+T#)AE440C""5SLY@"B'D"4$PA2%F,,Q_2 MA 1&?92TI$YMYG=Z>FM%S1PL/:SUO"?G" [,![6^FRUX]\&\&*5IB1%P+ET< M/<&C^B]&6.PZ)V8W6W@>UX^\>)#^S&]%_KWZICP=O'R]XT]YH<)G[OB_/\^+ M.AZ_[6RRVQM(()$ADJ8@@JK+9D(XR.(, PZCF(1A1(-$JYR("V6FQF4_=?9X MC4%>:]%/]13]ZUVR055IS@>0QAE G,: 0(DF24.,(3+I]&2L@1&ACM ':E4*2*\ $#M1 MG,;1,.GYDH."/S!!*MRWNDQY*P,4^HT)WJ8-%^XK UD#Z-*_-%=B5%_3&J-= MO]/^09;E*.@WSIX7_%9\+O(G7E2OG^4WL)*>K\KW?%IW>>(X)'' "4BPD(MD M$D< P8" 0/K)/$A\%E"C^ I=P5/S+3MMY7I.Z5M[E"N-+?MIZ8Z!'N$-@>S M/'<>J.:)\88(.6F]SOO_S4+ XQ$D,0@C1 "$-,(9$E, M ]00!!'L8^8"4'UR)H:)^VV J-;KR^_K MHS9*Q[0A:*9/W%2ZH1TC$YU;K)>"5[C\)CGJ9_?ZM>1LHR+P):WF+_4Q MY*K>M5P"!HQ'*0@2E2#&0P@RGT> <.A#1JG\WWSZ MS;N\NK_YV\W]S;5ANIC%,&BO]08$=X3%GM+>Z]17!89^5A9X\^4O&V7(UU8, M4HG<'D3'"SY3+<9>\5FB=&#)9_LD.Q;\F"]9OKQ92K(@>/F/6R%XP=D=KOC' MFW>W=VT8.$T33IB? ASC ,BE'E-U7YA<]44!"2&/*#0*;=.2.C6NNY=?:>[) ME7?US:O5-",Z/:3UN,TY?@/36:.OMU+8:S7VE,K>S[72OPP0HF^$DTO&TA,\ M*DD98;'+2V8WG]F&_59L[FTUM<8,7_Y:SYK0!%DW'L_%UA[N/W6U X=XNQNA M-$BK\E[!;]/!7 >+HXW-M6ZV+8)7J5-[IP7(,9 ]FI>F.4?]4.M1O#/X!J;V M+=PV-/5:55U6N=- Q&V!NSZ!(]>VT[!]OZR=SDUV=%T'BWW*EWFW=&N.\E9T M@M,40A:"".,$0,@%D!0> Y_QB <^C% :6532[)>J-2O&KZ+9Q$FV+>I5E+E2 MV7"'^@3<>I3B +V12KC5B&UJN@H-:)5U6#Q3#Q67O')"XJC$HF?]+K-HWF6Y M9[-.@9R)#,=1X!.)(E$[,PR"3/X)"((R/PX#[!-J$IZT\>RI!1[5+=LW&UL: M[K]LH*:YRV*'Q=![*1H F&^4[)OJ=#MDX_'C;GKLV[6WM7'@DG/C9\Y,9VNC M;#*.8! F@$*1 IC1&&0(0A"CE& !(^3 M;X'F?M>;C>W0&V-O,*QGQ!"Y1'^82",G&KY1/))+=(]'+3F58I$-]*4JGFGU M7/#?.9M3Z59]O&H/AT244HPA WX8^0"JH<9A*@#DD0C#,$9;S>@Z M6;!XG7W],N.4Q0*I.2N@].<8"H%J*PU\#).$)EDU_N+^][PIVT)]J^C?NO_I+3OSSD+[^VUS9O M_O:7W9?^QO-&F6;[^G=3ZL GEDLK7LAW\+O/$A=>%)S5IVPMD[,P\1..(I!@ M+.<5@AAD4/@@H7[F"Q''F&M5Y]"0-;4)UZCJO?-6RC:'QX8KEAYPB5R IC"E M(/,3K$II!@#'- 0\1!%/*-U(N$-><^'G!LVAO90CW],!0GXT '&ZL.H1-^XJZ;3=>TL>C5MLUB_X M\6G!;^1L4>5;7MNOLQ\CD=*4@5!0N78), 09#WT0:>ER;+E((0Z2Y9S@1F:" [IYVJITF=[_S+EX)TC+E'Z--]>GO1>:5/T M+"^K6_%;GC.57R$9X65.>?DE7[##-2EXD+ 0TDRZ6'+RPC2* 8X8!@%.$"$0 M"9_&^J70S(1/;8(K]=46XQV7P_&L62+)"G6-F3\@E@-S0@=CK7L=)=-I[RGU MK8HEG0\YRVG=1Z+>Y7LSZ+>T>/,A<%71S@ZO_CIWAL\R[+D5?F)5S-."2248" "' *8I 3(92%4W162 M- V3**1&/5#ZQ4V-]"\?5:6:_ZB7A/.5NAZN];WPEMPPZO0$V'JK0'<0#LSU MC:*@UM1;J^I=MO!]ZH'/>"FHAXK+U> )B:,N"/6LWUT3:MYE1BR,SV?OVS?9 M9[GHS-GUDKW'%9_!A(@:G!&!EM/CAI_?'M=GFKFOU0_: F/=R8],I'B4 "A(F %+?!R3U,6 1#C*6\4Q$ M1JZ#N0I3XX,/-Y\N/UT-D$#?-PQZ3L6PX [,)B<2Z%=&O%$"O0:((R30]VDQ MA01Z#90T$^AUGF1[,OF@B'55P?)F*?+BL5ZO?USU"2'0IV$:I2!DD71NTC@$ MA),,1"B+$OE#C+%9P30-H5-CNE;GC;*Z&UJ?TJ0"4/.8,Q]&!"CF(E>:5-CHH_Y\@%4JKO)1C+)7ZVS20[ JTV MFN.M-1W$7]+"9*#4E ,"WRI9Y;CM/>DK/3=9ML9;U /&61W8_ Y+5^IJH^ED MEUR9$4H9) A03 B "8(@(Q&5/T4XA4%((F'DW>B)G1JKU-$3@"AMMUMS\A-Y MWN= KT,V?#-"8Z^=F]G=EAGV M76ZM*H]]A8OB53I1WW'!RED:<$FC'1< MU-182"GHT4T-#?/HCX.JQS5NH!J87];U$VN\KK3P,D^LOSI.VQ+)KWDBQ?YX*N"LWGU 5/E*77A=(QGD8\( S&B<@T4^1S@NJ\X M82CE+$AX8N2V]$J;&D^LE/4:;;U.7=-"/GT(ZS&&,]P&)HVCD T0Q:R%B=M2 M/GT"1R[EHV'[?BD?G9LL*\WCIWF%%_/_4%Y,696WXNORJ??:%<&_+>1/_\9I=?EC7L[B).9\/I9SA)O$00ZC';F\\, -SHN:8F%?('PXUIY7U!U!SW(K\ MP^&\5\E_0%'V'43:/DI_PXMG/HMYE'$<,>!'" ,8I-(9]!,.DEA$C,2JLU%F MVC9D4\#4&/5JHV/;A???_+_XOA_&WA,NO!>E[W_W8O]"_DW]YY5J*5]Z^+GZ MEA=J%/^[%X07F9]>Q.'ZTR53?TW"X"+-@NZO\[)\YJS^,'^NRDK^H-PH7-;5 M;N77M'Y+>Y%_X:G(WK92(FW_&M1_3( D[<0Q MP! 2P"A!C"<)":/,)L?VH#23;_0TT% MQ'V.[6%Q;Y!CVVOWX1S;_ENLO1C9;@"7H[:[VW6ZD:^Q9ZR&O[',[Q'-X7V8/2*D_/ MQD$Q LNQXZ(G>VR'Q@B1 XZ.V?V6L01U#LDJ0B9!7&0LDNZ.B%71%I8!%# & M4!QF@B$M=3IX?7JX>,>5._:M'!W1Q\STEU MLY33^7G5/'U&8IH11KB$PY<.=((I0%S5 H8P35,1AP@:1? ?D#&U>;E9"WP= MPZ\4]]::EW95VP]!K#>'SP1NZ%U!-Y@9S_<>5%S._$-B1N6 'CMWV:#O4CM> MN%DR+HX7;&A.4^?+!U4XYOM\L9AE@H2^H!#0(,SDTAO&((,^!PQG&8ZB*/01 M-"$-4P6FQBA-'Z6],BYFU&$\"GJ\,B2V Y/.6O5CE5Y4GZI6?Z\SP&'+*EOL M7%*3L0ZC\I8M0KND9OT%$O=:HZ:EB*:<[Z$[D2\2F) M0220:H8:JG*%C $2$IAAF 2%^&LV>ZCHC-__>+"]IW="A_(Q?ZP5RB".2"KE^$&D@7P4A]=4K M-@-4+B=2)C\1 ILM)TY(G-H[ME//>VKT\X!7%9@9YOJ>!EIWQ> 0OL&7"(V. MWL^=MK_(=9BW K35V.620!,B?:CD MK\/Q-$G,8BA\!-*,QP &$ .24 :B2+KX<8)B8K;GJ2=V:J13:ZU\GJT#1/4N M_[K$.F T8RK-<=*C*_?H#\Q9*^#7*H\3]&2&E$L" MTY0\*HN9H;%+989WV_'9/7]\R@M"97-5ZF_)ZJE9K(/)=P/(J[S^M#&Y27 Q M8S^;4=6CPJ$&:1Q>7&GO->I?>.NADJ"O3>BR5M96N./(,R!T29@V:HS*GF?@ MM$NEYSS*HE7-G?1VY!W?I*?SGK_P1?ZDGGA9%.J47?THG9TZXJ7*/_-"%=23 M_]4G/*6DI\=9BF*(5)EQ$A,JO4?" ?9] 9(,TR0-4Q8'6JM5%\I,S:>\RU_Q MHGKU\$/!:_6--M2<#$\_4XX-^L"4>:8ECAJQ.,*SMS'+N3+&:]3B"(VMQBVN MGNEP!Z]XYFRC:. ,P8#"-.6 U9'X/@\!88@")O\F7<\@BK!1K2P=H5.COU;# MKE1?D\>SJ[8)_QL;>&9"^V=Y>#?)'#43=;.\=@6CP';Y=N6^_ MR7<$":U]OF/WVJ8MKE)\MY,BZU*!99/0_O6I#GB6%Y:J^QJ),$D3Q-5N'P8P M"GR ZHJ=?DH)C%D,#*B* L=IL98:\T\53LM-\U@-!\$S7/08:$=^E1T(_]\ M)XWZHBE%6K8E%[QG:8.W-L)EAJ,U@FZ3'I\Z3MYAWROOP[RD>/&O<@7Y0?ZEG,FU M&4TRE@#A2T* ?AJ #$LTTR .HT#$)-"K3]4C8VJ#\SGF[#QZ]=]X1RPYUSSMVJ66'EGSYH#9Y/N45 M5^3Q,1WO.ADP\9[P!(UYZM$Q[MF\XIFS1#YN?$# MS]?+?HLMRR -\6YNG_P&98^.O7UW/K6LSMIFR=^*NV;OJ505J*]_R/?9$B^N MGLLJ?Y2OMOKEOGRH,QT;N4VA $BR,"-A!((8^4U%,YPR D+IN<,XBT5,C?(- MSU-G:B_LS1($G3V>&F:OL\A;F=0ZL7(UT"0.=[7";$HZG#FH>EPRWE -S$$C MC))YG5DGX#HM17N>1N-6JW6"WEY!6S=/M0QH^7S;.NP1820(,0:IB!( 24@! MYCX!,&4\(@&-8V@6M=(]>6KL*14SC#M98:3'8%:6#TQ&4JHT$&3U M\'&C/79MV@OIV+O TD52YZ'?\H6\HVSC?;ORCIB1C'"(0,#D-(0I"0$*XPB( M+ S2* Q$:E;+];BHJ4W.34W_R>.UKH:-I'MPU?1 G* UM'>Q!52CIG=95<6< M/%=UMD:5>Y_Q8&VE3X/DU$LX+FU<#^"DU7MO]]-W6 8\+.2R_E;\':O0U^JV MN)L_?&O+K*5)Y#/"?."G&00PPS' E(8@XC&6S!&P!)JU0CLJ:FKT46NJ'.Y6 M5XFH5VMKM^#IP5B/2MP@-S"5V(-F'@1Q$@^G01#'I8T;!''2ZKT@B--WV+%& MV^NK]6>#($0H%CY@@2HW$:,(9 S%@$8T3%@F.&1&1+'U]*EQPZJSWOO\$<^7 MAE2P#9S>[+>&8^ )KXV$\?P^:+'+*;TM8-19?-"VW8E[^"++N2H'[9, M1Q%7=1.E)PXY%"!+8A^D42PX#D(8!D;MHG:>/[696]<_>Y*Z>2*O2\'6RIJF M>FU#J+GQ9@_,T-MOK6:>4NW"D\JY3-0Z:+7;G*QM$2.G7QVT;S_3ZO!E]J&$ M*GQ.E9B^EX^H6Q P+L(@Y@*$@:J6A.,4D#B!@% HB* 0)Z'11#XD9&JS>;O$ M^86G]+3JY' 04;UY?2Y. T]N&XBL@@6/8> Z5G!/SNBA@L/3:,[;E MFP2E]\^%*F=4UVVHRV[<27XIYK1JDYDNO^-"<FC)#%[OXYPV-P!C 2 MZ&.<%'1)EHTQ7F/-JNGUQI T5]/#(PL5S[0BXCOINJV#6A3O:G\MV[RVCG! J,&"$) !FDFE)$"$0)X(S&% _ M\8TV+4_(FQI]*G57U7&KW/OR[\^8%:;)&Z= UF-)A] -3()-0D>KWH77M"GI MM!T@,D(3&9?D=4KDJ-RD:?\N]>C>=FY0ZA?^H-+/[GB=^;1\N%FJ2D%UW==W MK^V'Z^JK+(%I@)ED'!%1 !/& <$P 8J(P@2B(/.I732JD1Y38Z+- ,>G(F?/ MM/)*K.83>?7D!.$/>?%J&V%J-D*:3MWPN _MRVU WJKIK8SP-JRX4&/07=$< MXPY32?=,3(<))353Y8UB2*WP.AX\:O'[K% M=&#JQ :L.3M(:EO6>&V!X43!6W[[CRWJ$>S2&WJ4 A,HBA-"2 0 M*H0#?0HR%J%(^#A*@M"NK,>&E*GQS6[ABD;5\TI[;(+:SRG.H!J81JQ0 M.J/ QP$47)7XV'ST&Q7Y.&#=\3(?ARZV2.:_E"KW))Z'/O89IQQ@57,5XC@! M.,00L$Q Z.,PS0*M[2$-65-C *6L:2+_"33[)[UCC :>^OV*.DKAUT.C-X'_ MQ"/&2]_7LV4K>5_S%ON7O3KEFQ&6A33B'$008?E^IP*@* D!SA*, IAQEFGE MJNT^>&H3>O6R4LJ9O\-KK/1?VZ8(C/6F[C7>ZM6\:>GY;^/Z::._@#=M./3. MW?K<;IE_QRL\7W)VC0O5A[4[&^ AQ)E@$&0J=!R*. /$%QQD"4QC%@8LB8V: MAAT6,[6Y>$G;#CGJ%)6+.9T;QK0=05-OJ7X^1@//UDY!K]-P@$.5?A!Y*^\35ED>QO%+1G)^+7#6$8N]>OY:J(_G-\H67:H_QDLKW>U-W MGR6)B&/)D7& F'PERW5W1H,0("Y(E,9)"D5B4D]'7[0148Q0=SAY>*6UX6JL_#IH'MX.@._09+J^:YLJ=VFH'\.>O#"OEO\QJCLG?B:/\&Z=4O^R%=].@USPH_Q^ZVV*G_HH*!+I?L=US\@ZN7^773#>QPCVL<^#R+,0,$$01@EF4 M,2%_2B(_#(* (Z(5964N>G(<5@=1J9)P*_6]5G_-A8,%_!H[_8.!.C1;F>CM MZ!S "JO>8P&S)XYW2F!EZ=:A@=T3++"G M( ZP+UG'9P"%DHYHC$64XHQGD5%VWU%)4Z.;1E$519-WJGIEJZOA/L51<#6W M)5Q -O0NQ JME99=H*7+[8932#C=73@J;-S-A%,V[^T=G+SAG*V">_RCY:%W M?,G%O)K14&28XP@D<289@L$ 8!*%@&-($P_ONAR_ MW(X$OI;\5ER7U?P15W(AGR"!?($PX"S) /3#$&#((Q"D2>A'(4&QV=S??OS4 MIKS43KWA5OJ9S?H=Z/0FNST@ \_Q72PNO,8C]?YH_QTDK^(P'"ZG^HZ$46?X M8>MV)_:1JRQV(L[H&G^7O^)%]7KY4/#ZRL]-IM-'_+RDWWZ?RY5+E2_Y9_RJ M/IRE88 P3E6M3>D=0$HX0#[-0(I2',!8H"36BCP>5>NIL<]*/Y7G6I]EJ$I" M#Y+6"[Q8I9HM:EL,]D-&^Q)H;*5,<6@'YM&Q3':T@3/V"/7N_8RFS'C;1F/C MN[7C-+IPRY._G9R^]_.2+O+RN>#K?5O!J!_@F '(4RK?.!R#+*$^0)DJ'L]$ MR(11-)Z&S*F]+]Y]_7+SZ?K+%^_+]6^_7W^Z-SS)TP!9\QC/+71#[XKOY0^O M]?7^&"996!\@IV=W&F+'/;C3QV'OU,[@5MO=KQ5>%%[JM>$R@#2::* MK3 HV45(GD$A@C'/DB30:XQYZ.%3HY%.-^/PO"W$=+>V[' 8?#^K5H#EQS3O?*JZ85\2Q&/ J2@ *F.EE"%B- 6(9 !-,H M3 3B.$/F32S;IQM-S]%Z678MJ^U[6G;@Z4U4:T@&GJF-7A?>E>NNU <-=M_Q MLA/P!HTO=VP[W/]R]R++)BVX_':Y9.H?E13W@A?J>*H)M+E9TH+CDK_GS;\S M06(YZE$$:,A2 F.5)FA2/5E@ $/4(H3;C*;381/;;)_NK[W?GY_?75W??GE M^A?OYE/SD_S!N[K\\K\,V[B8C((>+0R%[<"L48?/J\"B^H<-S2^Z1/A.>8E^ MJ[[#@RP;U)PVA#&1/VZ+& MD]IK&V#S#T@U95G,V7SRK]-XO7+Z3ZPC]ZQ]T M\J+C]T*[JD)*E+'5YX^9@_*_)5E-;E6P:Y94KJSS>FM6TE*5KP]1A%>^2\)YXT<0W&WI* M3L97T\,:>]2&]LPV!VQMD'>]-6!7VP.VRIJ49C41U!=>8YE#S\XET$X]0B>* MC>M)NL1RSP-U^G#;I),VB>56?)@O\9+.\>)S7LZ52.-^FJ/'^=+?BNN"L[FU0S' MOER:12E(J2^7:P(F(*,\ SZ+,@S3( ZQT2;I(2%3%&G!K36SQ.8 MSA>J">WW>277&$+(W^1PF#<)V8-7CV7.!6U@5EDW"5$**FII5+SP/LF)X7H3 MIP\,U]U"]N2,WBWDF*6'NH4U/\^)5V$UR5^EER5L>#J-;JTI50]>A4 M]NB&KAXN/:PV+)3&^*%^1_+F0E[^DZHLCTW+R9\Q>'K,,\Z0#,Q0K1'>II9U M&.Y\H%WRX1G:C,J;YZ.VRZ\. MGFC'P^^>YPNFZL$L6??CS:/*2JH7?%TQM1@CB& &019@""#"2)(OC$"B)D& M8@K-5F):4J?&KIVF]4$/Z7Z9;^AMQJ)ZT.L1IG- !^;&+2Q7OVRJ/$"=.R.0 M7/*:GN!1*55*&.M)_Z@K[ M-GWJ9Q$B** 4@C04BEMP"A"!!*0X\!.?A]1G1HW)-&1.C5\ZE2_J%4M5SY>5 MVETOYD9UPS8[.@.@QSJ.81V8>9P@:LQ!!ABYY"$=L:-RD0$.NWQD2G@*[1HH M&NDQ->ZZX^I+49^3M6$@1*E?SSC6&. M>>4MU';**I+'PU6SMNXZP-+\\5'> M7C?3_I8OY' :+O!LAU7S^'_XP1HZ(F"CZ^*A0)UWJU%K+1FIXZ(5GL-T7#13 MY8TZ+EKA=;SCHMWCSFY=VXI2FW"/RM&LR6,C=;5\][J^ILU#K?MT-ZT!8QS' M&?93P(1JS!BDTF<,6 Q0Q)- KD:#(#(J9.),LZFQ\U:O5:4V($IO;],X;].Z MNN7JQH6MA5YMHEVK1W?#;LK5(P[FB.P]PCB>TT'7#>8#]=0]4[FWZK+K!M.> MOKN.!-BVZ*D[TGS&TN^_ER)+U6(B7TJ9FY]<_IB7LR3AG*FK,WNKGU0IZ?R@5#7G9 '8]XAT&S(&9U0A'BVX_ MII"X[0"D+7WDKD"FJ.QW"C)^@N,=S'>O:D>BGATB32%/(U_ZH+$DI31- &(H M <)/(A%$60R95B<_ YE38R.M_38+CM*!_\S]2SM0I[!_Z9BK#! :9?=R0^PT M=B_W<=#>O3QPZ]FQNO+Y7S:VRYJ&I3,<)D$*$P'BB 0 QG*13.(@ SA(4.)G M***^L(S;S6W#JP]S#P>C3D$LZ!.>CC#H;7 M_:B=$_;;"\5 0<"'9;Y52' O CT!POWW69<.W\JSOEGNB[C+%XL/>:&6@+,H M1#1*D0^"R(< $HD\3D(**/$YHRSPJ5Z]4$OY4_.%#E0?4!T4OVQ14&.%]X>R MPVL-,?2-3(=)CZ &!']@OAH =YLJYS;H.:Y^;J3"V%71;? Y4"W=ZC&6^U-- MMOS4V*S5SN,G K9T MD-/<1K+&8^BMHA8*Y[%KARUVNA.T+6'OK3EQ F&19[$<^R$@BUU%1EH(L##E@G"<\"T).4J.=YO-5FAHS;)Y)U>LK M+W]J$VJ,F9OS0;3M_MY(A8'* @(R!)4I5W&JIBX"$&@H<<(B&"("9. M]M0GWD:STWMW!WC94]GV/.3/W$Z?;@?-$WOJ8S3$,45ME'WV-^FZ:8N(]HZ[ MVXZ;EXS5%7CPXC.>LYOE%7Z:5UA.$X98$B<,T-!/ >0) D3ZAR#$/@M(FL49 M,TJ,.B)G:JRT5M-[DGJ"^=*CC::&)?J.P*K'00[ &IAR-G!2*JKMJ*L3.)E7 MQ.M'P6F-NR.BQJU:UV_O7AVZ$Y=;\@&EJCY=><L"K"LSXA;?@9>GA MQ2+_CN50UPVQ6/Y,*O&\D(O&]D:YFOQO0134K^?_%L#H0CZJ?.+*&^4+PS5E M[S!IDHPC\(=FF@Z^M9YU^X,ABJMK(.*4=?KDC4L]&I;O\8_./68DQ/A\=KVL MY-KLJLZ:J5=M]8*NO'VNRDK.G/GR88;E"BIB6(#83Z *2V( X]@'$20X9)&( MLU KL5)/W-2(J-'8:U1N-D,NFHCHTMM06X]/-!'O9Q3W. [,*>="J,TL9LCL M\I=?Y7,4K4#U@V(3N,$FFC)&X1,S>SM&,;QKW ZCO\^7\\?GQ\OE M\ADOVKW\KI5DYD,N,%-[.0(!B&$*,DKE_W#$$A]A/_6U:H@-J./4V*M553I! M2E>O:$^>GDYTAQQM2/N9;B(#-?1QX" &OGWG3PWTA^KSV2?Z3]'54P,[5ST\ M=439QIBN2\NVA;%8FL0D46O8S.< 9C "&!&BUK58A#XE<62TS[4O8FH,?*(V M])=_?\:LR)>F0:1[R.JM0L_#:V B_+A5#'J 6F+'K7<;&[HG9>1HT&-6[L=_ M'KW2LL77 I?EK:@]2O7PFXH_EK,P2I(H(P@$&56M>>,4$$8C( @/"8)9PO3\ MMEXI4YOWM9)UFFU]?OY'_>6N-34,SSR,J=YT/QNI@6>\#4CFC;;Z0'#:4>N@ MH'%;9_79NMS<=@$YOII\'R,"SO%%.O9;6Z@W4!/XX#BXG M^@$IHT[RXU;N3O">*RTC>$]5I#A6D&+M:N$()@F.0\"BT)=KU@""C,%8_A0% M/ TP1<@H+>E\E:9&'CJ59$X4DK%VCQT,L!YEC3ML U/<2"-F'OCK#&2G@;_G M:S5NX*\S%/<"?]T]^GESD@"D2FF$(N]VGRODO:O$],:"%1H= /"!)Q2RV&;A.MJ MJON?P\&U'!%G;K"M?+L7WM]P,5>1HG?RG5J[;RP.$Y0)'S :A?+%Q!*0X20 MJ1_3)*9(NLY&V7"[ J;V NGT\Y2"5N[P'H1Z3'\., ,SLA$FQEQYS'"7G+8G M8U3N.6;A+D<GZP\V]]_GCY2?# MS'7;,=&CC#&0'IA=6A/JE+EFB;5MA=>9L14#,4R&^YEH.LUXM]5EW SX,Q'; MRX@_]WFV12,K^96<2\?ILBQY57[BU?4/NGA6.2F_Y3G[/E\L9HB*R.<^ 2)6 MW>3C6/5MR6+@8Y^&C#'D9XE)<5H=H4:,.%J!VKR>IKC6VK3LHP;0>M3G&KZ! M:6ZMKM?H6V>X>C^O=/8ZI8]O-UI4=-3'R&T91PVY(]=NU$=BOV"CP;VV742> MGE4F1)D\\+Z63\Z1Z 7R27ZRVX:4@681\E@ ,DP1 QF) (I4BF\1$ MA"R*0F96P%%7\M2CU>&D00 XD88K+?2L3T 9;AJOQ[6PM MA&&(;"FPZ%'74."/#"# M2=6/@SM.?31;])P&W9KJ,&Y(KB5">P&[ML^Q);_J9DGS1_XQ+\O+%SQ?U%4E M\XU*!FWQ[KH!Z2R%V,<"$9!F3"X4 R1 QAD$?AHQ0DDH*"#.4/S7J^]0U M4';>-MET8 1-4*0ZRP2(^ #B5 #$,@I\E F19.!\4#3 M&GO8 =)]30T&^^!OJ/',;\6'^1(OZ1PO-N(]FM?AS/SUF,TY MH@/SF0:8X_C>1L"YY#(]P:,RF!$6N[QE=K-%F:XV__OO6,6M5;?%W?SA6_4A M+P2?5YS=%M<_GN8%9W_GZN^<7;[P C_PZQ^\H/.2?R[FE*_N+MO;RQGB HF4 MA(!R& &8X 0@&DL/G!/&E#N>I%B[2M<@*DZ.!SM[Y-"I_CC*H@OO>VN3AQNC MY">-5=Z3,JL.BF;Y8H&E1_C$BR9 6C,^>L#A[V?7:0SJT%NX756+5DIVM7FWLQJ/*U;,T7XT#CC3+:SKQ$=\2]<_S\@[ M*N(V*/R]-=R&D3Q>";=!D=NJX#:LI*DE3/V-E]*(5?H,97$$TRP&D$:!7 X% M!& 6^R# 400#)AB+P]F2/ZB.['H+HK%4UR(AU)#0I@'#<5"CWQ1SIG8&76\= M-JF!_,^6,]5^5_Y4.5.'A^W/D3.UH_M_DIRIPR,R7L[4$?D6*^)6;)DW1=%N MRO)9=9BXRDLI50CY_.5#_EPD6E MYR-;Z6(RAW8U&FXZO>,/\^52,5&W;08&V#8[;Q #GT9"OA;D^D;5ON8\ %D4 M,I"F7 ZF8#P.TG80KY>:RYR1AK#39[@!O*Z;3DQX]/16*X./Q]MM79ZU)VE; MM-<.R &*^AHJ\A9%?^VP.E(4V/)AEB_%W3XTZO7+V8Q$G&>J1P DONH\%5! MD@P!!'V6I#A&490:%0X_+&=J7O751LS/1;N)X\UK50V9[@BNFEQV/EI#L]6! MCE(7WDT_4N94U(^#4[(Y(FI<.NFW=X\P3EQN7T=\O>17@3GEEZ>"8W:[W"RL M$,QB F&JJK@M!F\" ME>OR\%JR1R\8;X+(H1+R1O>["JS9Z*UW)U"@216(< MJ%;@@!&((:&^S\X-ESDL>&K\=73EL=DBTOM#6>"U)FAF%QH/B6T(R_E O]7J M;GR,SPT>.1_KMPX)<=OZU!8I\^B-(\][XYB,?BM/1UJSB"$&*,@ $'L,\GVM9/Z;0).UE3X(1K8]7I:)34X4W MUGJ:.:#[0.IYFF?!,S 9KW3SKD]A8NPV'K7;I7^X+V141_"HC;L>W_$++=M: MYLL'Z1$]*D]2E0MK2Q(0DA',$ )4^-*1BZ4/AX3O QCY,"!(8&J69GU8S-3< M-J4E4&IZ2L^+MC2=5?6'([CJS?3ST1IXNML!9=[BLA<'IVTN#TL:M]5EK[5[ M[2[[K[9\QZM@%!714O!OJF+6"V^2S:0'P>5I6W.,?G_.B_F C$_0^_XSE8ZI9QI,P".0:$88)!= / M4X#B0 "?BY0D89CX)#8AF5&UGQIWM49ZM+72J]:&>7AEF:&K,NKW0=,-FNHH M#^UBU2&/6X9OY_S68?GU=Z##P-L H:Z#N &#M\:AJ1@F5W42"Y565S2?[R1O M-X X=.O>8AR=NHRC&C"N._H68[/GZKZ)$I;)!?0;9\\+?BON^$+%Q7]699(V M5"O?O6Y]HF3/LI#'OA_&(,&A? O&40@P1 R@+.$^HUF0$J/$:2LMIO8BZXQ0 MA-0JZ]7:;K)9>:%BQK<__J,VQ[1#E-7 Z;VI!A^.@=\X@XV$>0#^.4@ZC::W M4F3!-*ZNH;UC]':M=!"_Z3)'CUC-8FN_[*_@V/1'"#$E<"/3#1,BR MW*,=6_)*JNF=J(<,7.W<365J,U,JJW_] B3SIKP08((4:SHZ;)5,\ISS@?AX M )P+D S1G%*I96I"]_'?R1C:%ZA6*WFN]S$LDTS6V]7*A3[],5[^3+@QX\DX M.'KL$,B9QHCEA !FI 3(, E$D4(@%$GSM*"%(G#TJN=BUA/,V[(Z/ 30B\5? MZ_W&9?+DFMV/E^/0T]!#@/J?DIP!4L]')*O7\ELS3JW.28X@$?N0Y+V8WD]( MCMAYZ'CDV*4MNR#-W<'_\NV['>;EY;2D^&?'[9MJR!(SGA<<@DQ+5PA/IX## MG !!->*YR2@30:>FS2*'1KXKC< $4$!)2@#+I%3 MBQ2CU 0%L34)'-J*[^C!:'P'YG-,_[(N\R;5Y^33 Q.<] !HGUJU/,@1 N25RXTJ)VQ<9U M6%?M1I%#XYR&C9'6O.,!_IG;3$/DG@AHQMM@ZI2!/*0.8X.ID84"[CQC@TDT M>VJI-SS"Q&P%S#<8?YOLR^P1B-Y_U9% MWB/XF+&,OE_0LQG][QU\S#@=W$?X(%7B9MFY+!Z?/"E60)WFD *H<>%Z($/ M#"6 D()2B@G//D'?O!ZR]*L 0[F3*/672=D5<5S:%2<'SG>T4@D5 M3&$&"DEHE>4HM!% ,X(Q)BHGG,;(*&/;5L]T>CY7*NJ;V!5Q?S6XE%%=5GY M(YU*5J00VC%,WV/>E3VCK\EK>N7&R^93/[X_=Y+;5,9OJF76[**"4Z+Q##($7;&F>K%5ODP+F/PR<$I%:K$&FH;&LCQ 02G*@ M%$6%,%CD6H>%W7\Y;0>P=WY@Z_/J)[]7BD<]N0T$*^X1KJ_PGL]R S'9/]0-?4#,L-U1SO-" MJ]125^&RM 070*19!G#.,YT+B D+:@UP6,S0OAXEK/6.M-S2,T9$F+>P$+4S.>!1RY_3V63VXVU]:%M_+7,I[(K52)!Q1P-& MNE RET/$BYQ1@;/4KWIVHZ2A,<%6GFS8Y#^.I=_\CX)0QQ2PT7$[*B.Z7]$( M14PJ."ZL5S9HM/D](33?T(X3[.IULZ,VPJG]Y$.1@YSEA74'"@VXL3Z!-IA3 M#F4*21%ROK/S]*&=UKAMYO#]_EW &,ZQQH1:A 0"*-4<<,25I5"5PR*W6(95 MJVT/6 ]D&0,P/W9L#4/'C.@0V#FLZ/QDO;07FK,)J'F??]=S,YD]?9O/RJ'&Q53$] M%3+-7'&5E.LK,/V MRB]D95MB_Z@J9 MCA4S%Z+8T'B_,=3QK_'"Z((&T(_)/V)8.B9SC\ Z45KF$UB7_+ZR,"*CQP:] MKV"[(-T&$W77!M&0\+M6S_^8FD/V>V/T>/EBIYO+6/OU/)Z73UC<3+^7Q4Q. MU@4IJ*M#Q F0*6, :<$!3U,.,.,(I9+!3))>RC3'L&9HWY':&*U<0T?M;-%_ MDK(RY[U4YYP2#_!5^:##Z#:I9EN85 G'&U2LZY)4N/R)BM-$&>,AE:PYSZ ! M'.KW/':QR]O$4:KEEW[)EZ6.?].S'W/^_-/M#5[^&B]&A@L%L4" ,)X!I*"T M\URG &,E;?GO]E7Y:1G+$Y02 JD,"EUJD#8J@EQ/]:(B&/'W'$> MA*U+IC< TT7Y]&,B/Z24>H/]Q\JJ-]W6-M-/+#>Q@#=3^SKHQ?+>4MJU,5HN MQZ_:^C[2_IMU>$9IH5):$ 84AMIRCD6W)=H MK[5/OC>CW2*-L 5J<5,*0Q3H.;VP!3;[J89M'M(B&JIJ=K7;7.]ZNBS;@SR\ M/#]/QI8Z1I;'(,E<>K-).4#&*,"9772A(A/R4.9BI7! [)0?YAXQ5-&1[)BTO/2-%%,5A,W)V"J_)_478Q5DV4ZL5=B= M+9-+^*^KN5;CY16?S]],U5?L\FGV,EV.#"5I7D@">.HBJ91=J+$48B!39!C+ M-,(\Z 3EA*RA\8=5-9&EKHG<4C8PV>0$MG[N3B3$.N8)!U:E9K*MYT52:1HQ MY:09CJA))R?$]9MVTFSW7N*)QRWM&&/3)7WQ.+O7SH3Q1._$>S_.KOCBY_?Y M['6LM/KT]MM"JYOIG5U(\.5X^N/2.40EBZW#/Q@S-"\X!4HY/X4(#"C'$&BC ME2&"$I4'+X-IXFLY6!"5]; M&!CTT\D;X$>('SVN'3/INR%=&YCL9[#8?W9V)BM#W3GJ7WZK!OF?D[6YR<;> M3H*#NAR0F%S>B9Z]?@2Z1/K]UZ-362V6O0^N-^NBS#D83S6?JC+"J*8B$ M!2[L:E>F;HT+%1"Y0@!JJK3@>0[]6M8V2AK:!Z#2-7FJE?W7F5,U8&%[$E6/ M]6PLK+J.0CFA9J35JP\2)Q>M)Q_0WUK5QXZ=):K7#>=E VT'IT_+V(@7.[D> M9F9I75K]>;R0UM=YF>M-9T]&3$:TZZMC'4F H%*@/&I,*34<44Z106TR@((U M&1QA/-Y?/E[_[>8JN;R_O[S]V_6WZ]O'AW:).^'#XN?A]0)VQXRSLN%B.SOG MH@Q;6QF2K"Q)-J8DOW?2F_5L1+O(P@E7YD,R;UIC=BS;IOT#V['HYKQU4.-I$=OA M%I,& S7HE?O:H?.>\%H^)7(3-+LJ-2^3KV.C1[G1FF66U006UBNDF@&6:0T8 MAVG.7;@UC#:47H\*@]BW[Z,)WI^Q9?Z MQVS^9G]/H767,J"4M!0C4 HHY1F0%+.<*D4)]NK<<>3Y0Z.32L6DU#%9*>E' M*<<0/$T?$7#IF"K"(/%FA0;#]QE@H>6__)B]_JN]T4U^Y'YPU=!>J[)G%X^Q26E*8ZYOITHZBJ^%[N5CHY6)DH6)BS^ +352/H5%HO_Z"+P9[ MWH+WC2U3Y.1/K5XFVH5SM2^\4F9R&)KQ-"TRZURX39HL58!RR &!'%DGP[)3 M6/7*>*H-S4-96>9H*T;5I':9.1&'WH\C/V9 NS[&ZWLLPQ,.H\,>-4,QGG;] MIC1&1W4O!S*^A)@%$*]_N6QP_7UF':^W44&Y%+#@H"AD#A 3.>!&:" RJ#5# M1G'=ZG#SA,RAL?K1V5^V>(I1AW 7\K"#RTA ]G1$N8=AK;"K-.543GZO_^[T M:-(#L^Y+ >Z*'4"AOX,X^)7Q.WQKV_X33\^S.9^7)>R751&*Q>7+\N=L/OZ' M5B-!5%$8I%U/,PD0QP(PD1)@5]!:9#E'2*9A;;4:)(9,HR$UT[I(^-J&LA92 M6?]H$5@ J6DX_-@J(L0=,]5:TZ12]:(J%[1(-MK&;&KA!4OP"0K.<6GKB*:4M]NW\-1CH!MZ=?VAH"]3]*"GC[-YO/9'Y5,>\WR;<1ESGE!.!"(NE8U MQ'I74B.@"-$PRV268^'G79VAQ? \KDME#1C/IGR2S/7K;/+J9N%DQJ>NN'$= M>!(0"M]R<$X37T^ =\R [0R(%%A_'GHG0^Y;/KJ_8/SS;-\)TS_S46U#3U]< M(8RR\,*M?<'*VG62$4Z4]<@820N J(" J30%69$Q+5%>$)6&!9CN"QG:?M6V MCHE3LE4]P(-P^GE>YX+4,<,$X],BX/,X ''#.@_(Z3EX\[BE^R&:)ZYMO52; M/;GJXIL8S\ ,WQ-/&- K6^?BNLH'V]'*'238>N 1V0A:VL]X6MGX6==]F\^4/5[1=CI?:I5>HD10<_W,[H>*JT*54&I ^#I<\:'M6O_IPZ'=G4%):%-PLM>4(^M%?'^/2,1]V.20M MHIK.PS-NJ%-+77J.?SH/L?V@J#.?U[(THC'CR=B=Z584G]EL<[:>U>@;O35_?<[[+\XS_UP@4;5+VZLA&%1"F, M,; $(0'*F0!4% 5@6DK[ZU3D+*A!3DSEAD8UM7:N4X55KPRM?--\'AI9&77\ M_(CJHT:E8WJ+T/BQ_"M9C6QEX@"Z-Y[ ?1#-& _I]^?HK7@"V6BM$D_):%UY M1KW(Y=W\0<]?Q[(ZE4NN>JJIZH:<4H+)4D&M(!VS4<0 8PK"R,2G)#" M4$J]*,!#UM"88--[YX]*X46B5[J&I[WX@'V:'")#V#%'G%8T4EBE'QHGPR<; M'M%?F*2?+3OAD)ZWM%P%R[" MHL+7]=(J#+GPE9$W&%'7.\U2^UW%>*.PMS;QO[,=O]RZ!-/%4JM[^^=\+.U/ MI;0ZZ:[JN_!6EB/8JNM;D)Q" 0'&2 +K@VC 78TZP2G*!+2>"0XJ?ME&B<%Q MT%9!D?G:C"I5=]4<)W#3NM78^)%4UXAW3%MK]9.-_C6'K=)Y:Q/JNBS=%!PX M!\68?-=*CUX9\!RDWG/B6<]JVQFZ*G5;TJY^GNARAVCJ6J#-E^-_E+\?D=3 M#%,)BER[/7:8 :$@! 5)40%9GFGC5:\S1.C06'!;YW)?@F\I&]KPV0-S/[:+ MC63'[+:MKFOZ4"M+EL[^ ,7MY.PAM^<&SOY([/=M#KBW=0,&*^.G MGB[&K[K*4+C52^L6\E\CDZ$4%ZP F#,"$#4,,)=8H+6"LDB53%,1$A1_0E80 M[?00([^C:MFM,+B?PE%8_2@F$EA=;P?MX+33 K"L+N"<5ZOQ17*YM%]6\;(L M?2=7\,Y^6F/V7O6 *W*#A*/B^NZ&T&3W@=8'C;>TW%M:\F5YP/5U'>*7:\0+ MCAF0)+<<@@0&'&(#>)%SE:8221H4I+DO8F@>RUK#,R(J#P#IN5=T%CQ=[PV% M(1.^-W34^*A[0?M2^MW[.6KEWE[/\2O/*TQ^9SZ/75_-J5J,A&(\%;( 5'(, MD) $T"*S*Q4M,X0*2C *.TS>ES&T&;Y2+'FN=6U7:GP;1<_SX_.PZ?KX>%5. MW'[SU_K%+Q]^P/@N"H9OB_F0$N$'[#Q6%/S0I2UW;\O#45=IUG7.=,[:@_Y1 MRAB) NNTP!8SRA5 V@C D1! (,L Q!20R:#2&,=%#6V^;TZ,YVM=DT6M;. . M['%\/?=9HZ#6]6[J&K"-FLE#$V#ANZ6-6$3=$STNK=^=ST:K]_8WF^]HVV#H M7O\8NQ(&TZ4[31IIBI'*$ >:06B= )( 8T'4__0%1:M!DZ;/JY?8;>/;7G1D.';=KO-'3DNM:G MM;-5'<%J*Z NS3QR/:H1MTCI7&F 0ST"/"^C[H/&WS@=/,AAM:;N[53: OIVK=#WI3T;WL;5 GP14\188@ PQT M#>X+9KT F#&02A=&QNW_BJ"$0F_)0W,//KTLQE.]6"2+6NW 74!OQ#TW![O ML>L]PU4?^C(F?=V4_GU7C0[R$X/1BKK)Z"V\W[W'4$SVMB2#']".K+Z\S*?C MY4LIZ,OXE_MI-5>T$2A5& &!E8MNS200BD*0FDP3#5-I<%!TZW%10Z.CM:;E M9#*UKF&<= )8/Q** U?'K+.+U$K-#DBF&8V8K')"6J\TTFSU>][PN*,=4=S- M?_!I'4IQ-9LN9I.QXG68Q77M8W)Y=77WV^WCS>W?DN]W7V^N;JX?PMBM][?!CS.' M/,8=,_&VZ67+Q(WQ)3=OF^\VG-< )!L$MFO@EF[D!H1D@T*R@B'YO9/8WH\: MQ)@?D-YMZ/6S]%$C]/YC]V%ZG-LZ^-(^7XTG+\OQJW[0\F5>MIFY_B4G+THK M5^W(Q1Z]K+2_YO:C/OVQ^*[G9:CUAA:1*4R1H0(89ER&>NIJ&+M=6R5Q05G* M* TZ:XROXN ^@UO9(GS+QF2Q-C+1M955%3*YL=/=--7+,L[152FI4F#;=A&. M]A9X[FI\Z-AVO?VQ-:S;YB4;^Y+KG6&]VAW6E9&N1$F5RM)I DMW@]%-K^%H M6GY0S^'8*!_O/1Q=4LP>Q%XMD#^]/5J959L76A@NC0&44 U0QB'@6!N@N<$Y M@M*D*BBS)HI60_NDQ.AB?I$XZUK568DSTG[?D-['K^//1G]#%ZFGW;&RR:59Y]3)W&2/K=CU$4T4R0H" D D[6*!4IH! MK0O-2(X+K&!0FY.CHH;&R[5ZR62C\5\#6U$4X876 M&N 44X"*' (*%0-%03DCDFK!LZ"*QV'RAT8H6^K7D4YR)ZWO+VY?P/45=H8$ MEDD.'!D_^ND0[XXY:1OJJDFS9P9EQ+K+[<"+6I Y4(5^*S6WPV>OA'/+QX1' M8E]:9TPYA^S+A/\8(8HUYD0#D>O,W#JGK2DNS4LMU-<[P8IQGC G-(&4Z]X7*[;%T8]8RP\SWTZ?>N[/M<_+;HK2?L]_Z26=OL;F 2?AYVQB[U]<_[^7\?)M MO3,D"R(UTSG &'* &,X!S[ $.90(*4DAXUZ.9:C@H7VKOMYO-X<_V0 M7-Y^3AX>[Z[^X]_OOGZ^OG_XI^3Z?_UV\_A?K;?C3@]!\.9<-&#[VZHKCRPJ M1;O>K/-"IZ.MN].R/VHCSPN1$]MZ?O>W*&?OFN+>3.US7MPGT/5,L^OHV?2+ MUJYE[DAQG&'K.EMNQUGNLA:VATM-8O,5J[BB1E M<,?S:3<@&.#3S!,9MH[)QBF:;#2]2#806F4O$J=NI$+V?IB<+&3?\(C^"MG[ MV;)3R-[SEI:1^VY7K6J0>&O5?W>.90K$%982Z"S7 "G-W0X8 3++(-RDQKA*WCD!7(]3[%EB;R%&0\"A,<*#G$W&L\78,]MO#R>/[W]+Z[O>:-EH%>F;?L#.DQ_P[>O[^UH? MT'+GTWSHW]M]AV^F I)R#3.64T)X6$>%U5Q/_K'*)#BUW6QWX.X4N%D_E:TP0DENQ4 MX)%[T'CX?="CP]O/W%^IG?QEI;@+8DC62+N=AE+[9*-^O ]^&]!B?O^#Y/?J M#K1!YKUWT.H9;4/.RV[M58A[%?+X]_'RYZIA>Q4"/Y[^<+Z*_;]R<2Q8*5C8 M)08@B&&[_' MM-*46]ICJ58F8S@/2F!JH\?G\SSZ6\+?;U8CI_<&NKRR7EG5IO_ MH^5R.=M<=SF=OO!)^=\CJB'5Q"X/9>&B<%AN )<* L.$%)I8O+!78':72@Z- MB=;*V_6,4S*9K+5V4\_%;OL6>>IT;#VVD 8P8EUO.7=C8:2MK8[Q/[E-UI7L M_K;<.D9O9_NN:UDMFXG-M1HOOW#IP@'>ZB;'E-"\D"0'F:((((P9H"F&+NY5 M4,)2I420BWA(R- XN=(Q62G9LH/T03C]G,-S0>J8!H/Q">\'=@* J(W #LGI MMP/8"4OW6G^=NK;E,;PQ8ZE=I$^9'UR?%^$LU;(@!F3,SG,P,PZSP6J:P>HPFBM8 /F_0XM0GH34^\ N"E#=']"Y;%>K MYW:)QF[*+_I $OGX[;B\OH_;&BT_<+S6?$_;ID%7VNU:3VZF2O_Z#_TV8H7K M,FP9(A]!_(T M.42!IV-&"$:F1?.@(]:?VSWH_6-[;A]TQ*K]_D''+FP32>>RDLKDM.TE]U+QO!0J!<8 $*EMD5128E MH$APH PF JI<,^AUHMZWXD/CGGMM=1]+MU^\*$]E]$;C\"S/WE\#CUWD@0YN MUT=M_5D=*Y"R_W$Z':C9HSX]!H+VC_)NH.D'R&\9Y>#4^'1"TT]OFTNV-:WU M^3*;&UTVJ7 Q:->_GL?S:A_^9EHE\8X8RC.8&@J*+,L 2E$*N!8","84UXSF M6) 6T:^=*^Y%<_V'S-9ZNZI597.^\?RL0@6=#[]G7,<@1O//5P9AR^XJAWAC M>2>%$?H:IJA!+)TKW6\P3%]CL!=4TYO@EI^RJK]SU?#9A0*&)? =NWU(S%&I MF*QU["1IKPF(J'/SF*Q^IU2#Q7LSH>GZ=B]P/6<6=;R:*XC"K?YE@\"1$DHA M820H=,$!(K \5L@ SR#)(,N81%E8K:93XEHX/QW[/2MM77B7TD;/G=\S,_8' M-P^D4SK,]3F)MA]EG(U@/[2Q#5T5E+K2M.HC&H\Z? ")21\GY?5*(3Z6OZ<1 MKWO:GE NM7V%EJNNVU#D.>:2 (P,MNPA,*!,8@!SK>Q"S*[,PD+6WSU_:/M] M*_56WM&__X/#P M96V+:]9MS>[,%5_\_#*9_;$(]65//&) +^9:3?=E+4>D,2MWG=" M7L]U^IHMWZ_(YW%/9W7KZ^ OJ-,\%X*"+,T(0#H3@ O[$V&Y,0JGQF 1N6+] M,&/L_ JH1R]2'Q2#UPFX'?//Y=W537*Y7,['XF59G@6ZID!\WDV(7C!"/5>? M_XA0OF!,6E2 :\ARDQGK7 M*"4IH#B7+C\T(YI#^PH&%;ANE#@XEGIRNR'_*.?11OEUJ:FI#HP(;H;S1 MXYQ/%T;/[\SW^>Q9SY=O;B=]%=O\.+N9OMJ_9_.W$[6%^/-H7I5/>*YMJ4\.%MG+3@78+RR)R > MR']H3K-6=X!W3%W>.D>*I G&Z&0S?G\ MK8I=J8JVW[TL%Y8'746.$2TR)K#K]Y$7Q 6 N/QV#H$BJL@9ED>^"+QWCKSO:T=%?]?C M'S]=UK>=8/Q''2!W9THQ6U(^\<58N@ZOKK.W5B,NE"2Y42 O6 Z0D0B(7!I0 MZ-SR%,:$XT"":J?(\&AK94?"*T-#7AB\5VC36I,RF4$0 ;G+LH &:Y4F) )%=&,9AE+*QPW3%)0Z/# M4K\S*]<=137P2/815+KGJR53U;:QVRE&8Y9W':: ?)[;JD9CLQ^6\T6SXC:6O/* MA>!/)EJ-F%9:%A@!CEV9]QQ2P 2FH,"09"F76 NO@!Y?@4/CK;)EY'BK9:3> MZ;HI5WI':;BY@=WC>#PRF!W3E8>VG7?>W,.E9?O-S7.&T(-SSRK/1IS[][4, M95;E2>["D9)+VJD"?#9UZPSD1G-*@9"N0R\A&G!(.5 B*]*<,L91D!?4(&]H M!+*E;D.B62MT_7R<)4-1@Y :1_88@^]F_%WCL>5N[*+^7 M)V[7;Y^UF)KBBG*,@QR#.VJ*BTRP+*T 1F N+"X!RBD*"^@U*& MQB*5GM4YY4K3L+B\PV!Z^!DQ(.J8-(ZI&"_([B0"33%UAV_N-83NI/[O(^9. M7]RVE5Z9GO"=S]?U[-,4$\,4J>(54,X)X$)P@%&FJ50DYYD*ZY3W7L309G&M M85*JV+(UP $@_7R \^#I> 8'(M.B6=TQX^/VHMN3TG.KN6-6[G>2.WIERP8@ M94Q4>4Y7A79?GDP"S_8[J>@J MT56O3,L'$KET2[BSX@+*@1X?5C]$^ M=+ ZIL(( 29[,<1=> :=C<$@8DJ.*OGG""=IPCA:)$FCH)8E#NU"MYGJLBQY0!QEV6H+"43P4EH*"2%HRD'**@/(ZCDH;&WRM%RQW. ME:HM=TB.P^O'OU% ZYA'6^(57LNP"8NHA0R/"NNWBF&3S7LE#!MOZ,BO7#2$ MP-5U\O6ZN/"[5(S5OW^?6YU'A!A%.=5 (B0!HC2UY*,U*&!A.,IP2F!1Q[SQ]:-^D6KFP+\LN M7G[$WQJ%CGFYUJN#NH8'+8[)8KL">B69@[:]YX##%[4\3*RR_O[.'8,L[^;W MC@R^CJ?Z9JF?%B-(E$BS- =)V? M6NOK6B"5&B>_.YV34NG )7,#X)Z'B]%@[/I\\3P$PX\9O8")>M)X6F*_AXU> MUN^=-_K=U3I88>.E3-6]7H[GI9^RZ7D<> H9\,0!382-FLDG/=5FO.RF['@+ M="*?NWN+[_LG8+$)1LS/PGMLQ M4>'L>@ME"\FO:R3+=*PMS9/?'\OCWDZ2 OSQBKI=T2RUWRT&;Q3VM@7\[VR9 M>E06%[YZF;MB]>LO-L48TQQ"D/(< 50H"6BF,D"E$@(QF?$L:!_[H)2A$4^M M7L)+9?\:F&1T$$<_4CD;G8YY9%5!? 50%_[-20RBY@P=%-1OIM I6_?R@TY> MW&[2_R>?CQWGW_.EKL]ULP+GFA<:, H-0)A:OZ,HW/$5U&DFB%!,ALSX?1%# MF^XK#1.G8LMS\@- ^DWY\^#I>+X'(A,\UX\;'W.B'Y#2ZRP_;N7[*7[BRI:+ M\YVZ!V5Q.:OL'R5/#L5&4A6WX[8D8VOQ^5]6C5;&^ M T!Z;F:CEJYM\%P_,J6\YLO?EY.E?O+ M%4:!984DK+X1=AZ002$:XR2$3.*P, M^[D*#8W/JK:->^V]PMCL[%'R([H^L>^8 U>FE#QXH+G:P5^M3.JSYUHLS&,2 MZ=DZ]Q='ID;6890* MB11@FJ< 94(!1CFSZT:C#4PAIH2'57D/U&!HW%M5,Y^56B:ZUC*T^GOH*'B> M2W6);=?'5"6LE?))I?TZ1K\H=':U>7#=4 A+ ] 3W-6!S!UOP)N4#92F2Q_5$X6 MS/)X3'^EL_QMVBFB%7!;RSKDL^F/1SU_<@?KM]:.ZH1M!(5BBC(&."2N$45J M>4!9,L@,01HIS>U_C9:S)9_X>3V'Q01QP%I8=V_XHY.Q%6XS&7/A=BO'.G!I M>015GLN""XH!RS-C?4G79TTI^Q'$ FJJ4PMM'E3'_7Q4^R@Y^ Y5%\14-C!W M$3FUSLD37]J/8#2D_?S%\_'KF')WXY5Y_JGJ[+\JNO?A@74!#YU M0*_]6O.R+\&VRDFE8)2>J+8UR[U=:!K"3_;L= MP/KT;90J3I$0=M%!N+3N,42 I4P R@M($,UX5H1MM8;K,#3?N=P( I_V\O]C MU'0X/1B>/D:W$'?M9QRIKK"JF5"?<]4V)*41O9Q?G0%K]P4/3JLQ@*H%7CCY ME1[P>U0[BK3+A]\6]5ZAS'(%N20 9X4"J* &\,)MOF8,905FDN=>O0@./'MH ME'8S=;M9);I\$L9CVXCY\5-+'#KF':N5_;N#X@$'S(W)!]N/[W6>'[#K_?P] M=,GY'08>YW:VVU6(.XC9)$)N8MV@0+F=L@P8CMSIL,FL\X(@R'6&,T*ARE'0 MO V0/;1Y?7_]]?+Q^G/R_?+^\;^2Q_O+VX?+J\>;N]N']GT)FN#W7:ET FKG MBYGM3@;;>B<;Q9/?._$_6B#65?N#)O$?UA?!$Y=3#1-\']&Z.JC46BV^6#,. M1U48 YG)= $DMJLNE&+K<*26O8P@*3$JSXP)BHUNE#@TSEHIG+BA7@>SN%W' MQ5:42^ ^2C/N?K05%>/;3#XU*UY+G4 M+3 0>0LP/VIH"4/')% A\/TT N&QO/NV1@W+W7I\OQ&V^W;M!N.2,N->? MLXF]8^'2'I9OHUP2H@4I ,%"V*6+SNW'7V2 6 \ I0(7W.0A4W-?Q-!F:!6( ML-C2\Y\276K:(GQU%\P"%9(:HT AE0$(IBF@"DF084$II#HCLA@]EP%^#TOK M^O4!Z7MQW0'[B4]<#^"S480YH5ID&N0B+P#";C6-"0$%R54J)>2*J!K%ZZGJ M#\.5L.$CZ+EK?Q8F76_*[\S/2KWD?=!N5J/-36W/HO3GKJMX+V9FG1'A/H5E&_#?IO8A?[CXQND/MT$V>[$7 M\C)>Z&F\6+A5ZTA3J#*"=9$BG%(A*>)_,O MSI717W)&)#1V,C=B/;.=NU4FR-_.IC.[@.%.3!54>?W+139L HDI09AS(8%@ MR.5\N8@KHBA("<2<,,D"ZR'YB1V:(U95$]"5DJ$E#SV1]G/)XN/7,9M5T&UK MO(K0_DNM]#]W$JL=!E1,W\U3,R * M@0 RA@&>F@(8(WEFLASS5MT7MD0,C6C6_0*J [)VU18/(.E'+N?ATS&1A$+3 MMG?" >L[Z)>P+>4C>B075.: B@*!/#=<&8&A$6$AWAY"A\8"#[]]__[U^MOU[>/E MU^3SS0 )/9VE4/N;5/EXE"OER^SN='CI59W<^O2C.=:C4A19#FW+"08%@"Q M(@6\R"20FE(#!5<0%Z.I_N$"M3RVC#S%>DTA5DVA;>'=S:2UCJYQD:ZT#&]S M'P2]QUY/3#@_N _41;(#<:UY!["JF2P[(I1A];W#NR-]^# '5B,)P^MT21+/ M9_58ER3,NMWB)('WM@QCM>_ K7TKRKK3F:;*DC0$A"$.$*$Y8(5(@27L3",E ME0BKQK;]\*'YB4ZWQ"G7JFCW#FQ^?F!;,+K>,??%(3R,](#!42-&MY_?;W#H M 5E9;O>6[V\,S55O-AK1D1HC"6FH-!8 M <3MPE!0DH/4+A&U72OFD(?UC#]7HZ&QP4;G.C8]V$^+-UB>R\H^AZ#K->>) MZHR501?)U@A5E]?]UV^K2D=;AG5>L3$E9X;/'@EC%7 M3\^3V9O6#WK^.I;Z<(;S[6SZZ@K,J5*#11DCN_WO[L#R=K;\+[V\UW+V8SK^ MAU:;)U4WE2<(CS]YG2Z]&,D\%3FG%.386#;'3+G^C0+PG)+4Z)1F86F1'V;) MT+X"OTWG:]U=^,;:N-7Q96 (V8>](7Z?D#_%N'?\Z5EAD-0@),>K5JR1J#X] MKEG=]BMB04C>[,=H \/%SL.JFY+J3'=IP5BE<$4,L_OH 8T:QO=AQO0;)OC1 M8[87AOCA"K7['N\V+ZV<@;&L X5&+#,:9UD.($M=+(XR0&12 86YSABW X=) MR#?SI+2A?=>^S:;+GY.W9.R*@]AA*\,3GZW/),?/?%*V/.:328N>QZT$2DVM/"^R5#[UL?\]9?C>=%5NSNP][][*T M =NP8_80G$Z>L7L]J+\#]A"[=D[7@VZ, M6:3WTC'4CS(JZ]/;YI+:5RU7QE5*\,:?W5LI;Q';W[5C.KND?M5S_D/?:Q=K M:G]_99=\SH87/G$%]1>C/%40882!H9RZ\K_0.DC0 *V$PD9Q6A1!32\'9=W0 M%MPKO4&M>++6/-E2/2EU+QVR-\WGP2>-0QJ!LRH:_PG>FJY/0(_L.B=;T"3B M;6=#N89G=1!:UW+8@NC 7O..XWJ1K)!*/-[3KNLO?_!+T'UEYX\R< UHS]X M;/VJ47^TDF?DHG[=M-*J6Q>-<&'R7%$#),HU0) @P)G$0+$\)QIR+;0(3C[= MES.T+V]%>:N^5ZU;C!U#U>\K%P&KCK\W%4Q;*EZL>EY%SB(]CD+TM-$#HOK/ M$SUN[\'$T!.7MXQ**1G*T=IL:I]6IS"FF7%M[2F01KC=424 2XL""$)-IC5# M6(9%C!R2,C0JJ!VBM98M,T(/(^H987$N3EU'/P1#%!Z3< J"J/$"!P7U>Y9_ MRM:]<_:3%[>;_=_XK_'3RU/=Q $; S'-"8 :,H (=[5[$ '"D (KQ+'(@AIB M[CQ]:+.]5BYL;N_BY3>G6Z/0\5RN]>J@[\5!BV-.W5T!O4[9@[:]GZJ'+XK; M_R(PJ[CI,0-Z,4^T6N@BF=@7F3Y:*GQ,$K$O K[-$[SWP[<'\:O]Z=_^Q^HW M]@^W:?5O_^/_ U!+ P04 " #2AE]-2FS-UI9A ".7P0 %0 &MI9',M M,C Q.# Y,S!?<')E+GAM;.R]67-;R7(N^NY?T7>?UUN[:QXEL.!G_\U_87^E??DGC,(G#\>=__LL?%V^)_/[+ZVF">8J__#F_O5V?"I+^)CV:__\?O[\_ E70(9CF=S&(?R@MGP'V>+7[Z?!)@O9/XB M7;^L_4;Y$[GY&BF_(HP3P?[Z?1;_\B__\,LO2W%,)Z/T*>5?RG__^/3NAU=. MIO,ODZ\I#F$^'8;97\/D\M?RO5]O%'TRCJ?C^7!^_6Z<)]/+!='(R.+!\^NO MZ9__,AM>?AVEF]]]F:;\SW_Y^S#.D"!FJ1.TD/._GGW>KW?$?IVF&7YM\?OW M^(O58PM-71.>OL_3.*:EJ&[>/YJ$'[XT*HJ:3&_^Y0A\&BU^.R@\#IY[VXF? MS:<0Y@./P'%9!I)U\$2"9<0SX8D(UB: Y'FD+\EOX[?/L5 M'X^@9;)\*)Q)0MD*JO]KW:M_9.4^,DZFX9?)-*8IVJR;=\,T/$+)C^ME]8U? MO\(4'T3"E^$HWOSK8KQJZG4^Z5#,2UTB.W_Y!:62TW2:XONE*MHWBF,'J'2^C[OZ7K 9?2*G! ;)! 9!*).&DO+Z:%@F^'C-'V-I'^>3*\'3 G+HD$? M)]!()/Y$Q&=#9$S*>>'06Q1=F98?WKP14.3Q 65?(?>,D1O97.!W!R(H'F( MHER4: X5)59[#!5T-)H*3I7M !SW7[D1*M3QH6)GL38"AX]I.IS$&YMG@Y8N M2;1T(3HBG4$I<(@D:6VB#;A/A@[\D2??O1% ]/$"9'=!-X*4NQWR+?YF-I B M4:,$)2'Z1&2P@CAF HD9>?-& D3H#BL/WKX16LSQHF4?83>%ER7LETP(SHS5 M-!#C8B92ITB\3_A)*II!&B=-[!HQ]]Z_$6;LL6-F5X'WC)H3Y" NN!C!YX&D MP6BO/ ;V5!-IO29>:W3%@X?L<(O5(>V/E!_>N1$ZW/&A8W?!-A'4O)Y<7D[& MY_-)^/OY%Q3E[.QJ7E+#)=L^8!$)5KIDMQWZ6S%[8@V5Q B=O4A2&\_VA\G+ MA&R6=*/'!YZ.== 9HO[IUR<3WWOF[U^??7AS^N'\] U^.#][_^[-R<7IFUF2/:9C2TU&(H*#T0:H5+7$>E M\S.^3@>L+LCHYS2@&B9N3%,',N]Q4M0(CG90\SK$["7S%L"3/C]DX\WD$H;C M0?0N* #T\DU94-9QXG-0A')<86 MQ.=R.'N 9QU%C8!G/XT_Q%$GXN\11V%R M-9Y/KP=_G ^L-BH(HXCE,1"9,D:)S =B1=#X:\%DV.!<:?7 )5Y6?W@(E;N7 M]HR);K0WV4N4#1B1#Y/Q'[/?TZ5/TT%RW(!PC"2F(I'> %I5I@ACD@+H8)WQ M-L9*!8]D-RDW@).3V2S-9[<./:=*J1@]48I[% ;SN%JH M()P%H5T2'FBH@9$?R6C$Z=A1J9/.)-P,/E9U%K=, .FG4/2T0O#K9+C+ED2 MU$:+%*07BKDJN8 GJ>D7+?NH]TFD["/K!@#S&F9?3L:Q_.?TOZZ&WV"$S,Q. MYJ]A.KT>CC__.XRNT.AR$SD%2@Q$-+K.!A233R0P%JW*E"M9)4C>B+H6 +47 M"B:U5=( SD["PG6??4HA(4NXDW](\Y74!DQS[:(.)"4ID!>IB(O*$*8R>G'. MNDBKP.LYHOIU>KI'56<*: !,[\;?D.K)]!I9&%"AI-8"-_M0:+=:$B=9),E% MR0,+*O!GSB]W!\]](OHIV*P'EIT%W X/D[35QC&T^]?TWB6T)">S;^DZ0\R M&J0(V4/DY5 .H\,L44I* $:'7*H4I3%U O -:.NGI+,>E+I61P,(^Y%XJZ*7 M:#T)Y8*7NE1+P#.,.!BCD9J@6V-FLY+/BON5CN+>'=\3.8PZL@"3;ZF MZ?SZXPB6M0+HQ7TM$6JQID+1E*QB)$:5B%0 MS[-4M> &=8*C[F3? )#>#L?#>7H__);B.U3'^/,0G?\5<[@LT!(GX7 ="(DL M29L8L;'@[ UD/0\6?T&]1WJ?U)-&0U J]SYR^LY.OT>1E>E9)<:Z5P?U 0+.CQ.V4J:#6#@_1#\ M<#2<#],,XXU%W?:7R0B%/BNQQ_SZ5C1::&MMCB0''X@TF1& G E+/K.L=%:I M2JG8I@0V*D?*RN/!6&Y5 ME93F>I+Z=>'K0& ]SO;11P/(NCD>^@C7Y6SH)O,6<4MG 0VZYLF5NVR\%-DY MM.\& Q5@-.MG;OWL?S+W(SG-(&HO9:\YF-M#\@W@Y_3RZVARG=*G-"I]UQ[+ M:J!,@]'>!^% M5EK@B42:L=K;9",QS+F2X] $@EDTF]WO3VI@05"056I% M'A+2]Y7M;A3\A$G:6=H-H.4DQD6_+AA]A&%\-WX-7X>X@0YXE-ISW*8%#1S9 M4+A->TDQQ 0IG.34TBI%DVOHZ;M2I IVNI!] Q#ZE.: 864\A>D8]^/920A7 MEU>+(\ W*0\#1IKED"])D4FV%A=%UJ&,YQ D!IO :^N\KI*[?IFT?EWP2L#J M6",-8.P>!XL3'C2[2,J7-)X-OZ5WXS"Y3.\GLU+A>98OX/O <&^0C$@P!,6X M-%I'K(H2O4$5F#')1UHE);DEG?WZ[+7,6D5=-0#%QU(;>- *5(EI'0L&,&=K-0,]"$I_7KJE0"UI\0;2"6\%,(,('G@WLDR):)L^18(*!:) MIC(EF1,$G?NHU.UG:D=?&:K]==,9UOKJ@/UQH9@O:5[ZX_W(55?ML']\Q6%[ M8S_#WB$;92N5,X14K"$51")@B8]1$1X\#XX!$Z+*D=3 MZ9O)E9_GJ]'C1C W-19:6.&EI41S$XDL,VMQ0W!$&PX@??8FU+G(L@V5?6MFL8:<-?N)6AP\9]-%]*,BUS-QS1=S#L86*<\#3Z3(,I!**A ;*"R MQ-]*^1!34%5VWPUHZSOQ41EZ76NG+< MIVF<7.%V-1W^=XH#KL'I+",Q61@B M+?H3-GE#K$]4A""U-,^T8NX$: ]IZCL!G[YS&H0&U@Q9:!-/]F3_.T!08QCE&E^F% M$)$7J1FAG*642A?(7.7:S-XSF"IF-@X-JUWU<8PSF,XO\.?OIQ\NSL_>GGT\ M_71R\0[_MK/H<\WCJT>>F[#54=2Y3*O>HO06DHFB4\XU;FS&N4/J)+/*':?IM&-+L?#**@S(W+]%0#O^AM+A50" IB18\:*VM3:9.J_SU M)/4;3M9 6$?B;P!(OTTGL]G'Z20/42+9&,[X$+711G#( M58J:[]'0;V!8 RJ["KB! Z2SKVD*I=IQU=/VKOV-=R$CY8*8J%QI8L2(95(1 M%AVW+O%LGIONM,>ETG44]1O_U